Total synthesis of the antibiotic (+)-Branimycin by Marchart, Stefan
 
 
 
DISSERTATION 
Titel der Dissertation 
„Total Synthesis of the Antibiotic (+)–Branimycin“ 
 
Verfasser 
Mag. Stefan Marchart 
angestrebter akademischer Grad 
Doktor der Naturwissenschaften (Dr.rer.nat.) 
Wien, Dezember 2009  
Studienkennzahl lt. Studienblatt: A 091 419 
Dissertationsgebiet  lt. Studienblatt: Chemie 
Betreuerin / Betreuer: Univ.-Prof. Dr. Johann Mulzer 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine Eltern Josef und Edith 
und für Christa 
 
Danksagung 
Danken möchte ich an dieser Stelle allen, die in jeglicher Form an dem Entstehen dieser 
Dissertation mitgeholfen haben und mir mit ihrer Bereitschaft und Unterstützung zur Seite 
standen.  
An erster Stelle möchte ich mich bei Prof. Johann Mulzer bedanken. Sein Interesse und 
Engagement für dieses außerordentlich herausfordernde Projekt, gemeinsam mit den unzähligen 
lehrreichen Gesprächen, Vorlesungen und Seminaren waren für mich von unschätzbarem Wert. 
Es war mir außerdem stets möglich unabhängig und eigenständig an diesem Projekt zu arbeiten. 
Besonderer Dank gebührt meinen Laborkollegen Univ.-Doz. Dr. Valentin Enev und Dr. Alexey 
Gromov. Seit Beginn meiner Diplomarbeit teilten Sie stets bereitwillig ihr Wissen (und ihre 
Chemikalien) mit mir, und auch moralisch boten sie mir auf dem teilweise recht steinigen Pfad 
der Naturstoffsynthese die nötige Unterstützung. Der erfolgreiche Abschluß dieser Dissertation 
wurde in hohem Maße von ihnen beeinflußt.  
Im Laufe der Jahre beteiligten sich viele Kollegen an der Totalsynthese von Branimycin: Dr. 
Wolfgang Felzmann, Dr. Christian Pilger, Dr. Daniele Castagnolo und Dr. Daniela Rosenbeiger 
sei an dieser Stelle ebenfalls recht herzlich gedankt. Ein großes Dankeschön möchte ich Ing. 
Martina Drescher aussprechen, durch deren tatkräftige Unterstützung vor allem die Endphase 
dieses Projekts merklich verkürzt werden konnte. 
Für das nette Arbeitsklima und die schöne Zeit möchte ich mich bei all meinen Kollegen 
bedanken: Ass. Prof. Dr. Harry Martin, Dr. Uwe Rinner, Prof. Dr. Fritz Hammerschmidt, Dr. 
Konrad Tiefenbacher, Dipl. Ing. Harald Weinstabl, Dr. Roland Barth, Mag. Thomas Magauer, Dr. 
Tanja Gaich, Dr. Andreas Gollner, Dr. Kathrin Höferl-Prantz, Dr. Anna Innitzer, Dr. Marion Kögl 
(in ewiger Erinnerung), Dr. Peter Siengalewicz, Dipl. Chem. Lutz Kleemann, Dr. Anna Schweifer, 
Dr. Edyta Kuliszewska, Dr. Dagmar Kapeller, Dipl. Ing. Jürgen Ramharter, Mag. Martin 
Himmelbauer, Dr. Katja Jantos, Mag. Christian Aichinger, Mag. Rita Fürst, Mag. Christoph 
Lentsch, Mag. Christina Nowikow und Mag. Anna Wieczorek. 
Dank Dr. Hanspeter Kählig, Dr. Lothar Brecker und Ing. Susanne Felsinger war stets ein 
hervorragender und reibungsloser NMR-Betrieb gewährleistet. Danke auch für die verlässlichen 
Messungen des MS-Teams: Ing. Peter Unteregger und Josef Plangger. Ein großes Dankeschön 
spreche ich dem HPLC-Team aus, deren Dienste ich besonders oft und auch für sehr große 
Mengen in Anspruch nehmen mußte: Ing. Sabine Schneider, Fikret Nasufi und Michael Zinke. 
Bei Martin Lux-Amon, Jale Karolyi-Özgür, Sabine Brkovic und Walter Dietrich möchte ich mich 
ebenfalls für die angenehme Zusammenarbeit und deren Hilfsbereitschaft bedanken. 
Wenn das seelische Gleichgewicht mal wieder zu kippen drohte warst du immer zur Stelle. Nicht 
nur dafür danke ich dir Christa.  
Abschließend möchte ich meiner Familie meinen Dank aussprechen. Meinen Dank, für die 
jahrelangen Bemühungen und ihre immense Unterstützung. Ich hoffe, daß ich euch eines Tages 
etwas zurückgeben kann. 
   
A. Graphical Abstract 
Total Synthesis of (+)–Branimycin 
MeO
TBSO
OMOM
Li
O
OH
OH
OMe
O
OMe
O
OH
OMe
H
H
H
1
3
5
7
12
14
18
OPG
OMe
H
H
O
O
R
Nucleophilic Addition
Macrolactonization
16
Epoxide -Opening
OTBS
OMe
H
H
O
OBn
OMe
H
H
PMBO
BnO
OBn
OMe
OTES
O
PMBO
O
OH
OH
HO
CO2HHO
O
H
H
O
OH
OOTMS
O
+
(D)-quinic acid
Epoxidation
Diels-Alder SN2´-Alkylation
RCM
OBn
OMe
H
H
PMBO
BnO
Claisen-Ireland
Rearrangements
(+)-Branimycin
MeO
TIPSO
O
H
HTMS
CH3
+
Mitsunobu
Inversion
Mukaiyama-type
Condensation
asym. Propargylation
orthogonally
protected
 
 
 
   
B. Abstract 
This Ph.D. thesis describes the first total synthesis of (+)–branimycin.  
Branimycin, produced by Actinomycete GW 60/1571 is a member of a new family of macrolide 
antibiotics known as the nargenicins. It exhibits activity against Bacillus subtilis, Escherichia coli, 
Staphylococcus aureus and in particular against Streptomyces viridochromogenes. The structure 
of branimycin, which was elucidated by multidimensional NMR experiments only, is unusually 
complex, as 24 out of the 25 carbon atoms are either functionalized and/or stereogenic. 
We planned a convergent approach towards branimycin – formation of the diaxial 7,12-ether 
bridge should be accomplished via an intramolecular epoxide opening in the course of a 1,2-
addition of the polyketide side chain to the cis-decalin nucleus. In this thesis, the densely 
functionalized cis-fused decalin core was accessed by the following two synthetic strategies: 
Starting from (-)–quinic acid all chiral centers were established via purely substrate controlled 
transformations applying a high yielding Claisen-Ireland rearrangement – RCM protocol. 
Furthermore an intermolecular quinone based Diels-Alder cycloaddition was used to establish the 
cis-decalin carbon framework right at the beginning. Anti-selective SN2´-alkylation and 
regioselective allylic oxidation provided the desired substitution pattern. 
By successive coupling of the cis-decalin nucleus with the lithiated side chain, the remote 
stereochemistry of the macrolide ring and the oxa-bridge of the nucleus could be incorporated in 
only one synthetic step. After several synthetic transformations the two-carbon ester portion of the 
branimycin macrolid system was introduced via a stereoselective 1,4-addition. Further synthetic 
manipulations culminated in the closure of the highly strained nine-membered lactone ring 
containing the internal trans-double bond, followed by the final global deprotection. 
In addition, the proposed structure was validated and the absolute stereochemistry could be 
determined. 
   
C. Zusammenfassung 
Die vorliegende Dissertation beschreibt die erste Totalsynthese von (+)–Branimycin. 
Branimycin, ein Antibiotikum das aus dem Stamm Actinomycet GW 60/1571 isoliert wurde, ist 
Vertreter einer Familie neuartiger Makrolid-Antibiotika: den Nargenicinen. Es zeigt deutliche 
antimikrobielle Aktivität gegen Bacillus subtilis, Escherichia coli, Staphylococcus aureus und 
insbesondere gegen Streptomyces viridochromogenes. Die Struktur von Branimycin, welche 
ausschließlich mittels mehrdimensionaler NMR-Experimente ermittelt werden konnte, ist 
außergewöhnlich komplex, da 24 der 25 Kohlenstoffatome funktionalisiert und/oder stereogen 
sind.  
Eine konvergente Synthesestrategie wurde verfolgt – mittels intramolekularer Epoxidöffnung im 
Zuge einer 1,2-Addition der polyketidischen Seitenkette an das cis-Dekalin Kernfragment sollte 
die 7,12-Etherbrücke aufgebaut werden.  
In dieser Dissertation werden zwei verschiedene Zugänge zum Aufbau des hochfunktionalisierten 
cis-Dekalin Kerns beschrieben: Ausgehend von (-)–Chinasäure konnten alle chiralen Zentren 
ausschließlich unter Substratkontrolle in hohen Ausbeuten aufgebaut werden. Als 
Schlüsselschritte dienten hierzu zwei Claisen-Ireland Umlagerungen sowie eine ringschließende 
Metathese (RCM). Der zweite Zugang bediente sich einer intermolekularen Quinon-Diels-Alder 
Cycloaddition. Das cis-Dekalin Grundgerüst wurde hierbei bereits im ersten Syntheseschritt 
aufgebaut. Nach einer anti-selektiven SN2´-Alkylierung sowie einer regioselektiven allylischen 
Oxidation konnte das Produkt zum gewünschten vollständig funktionalisierten cis-Dekalinepoxid 
umgesetzt werden.  
Mittels 1,2-Addition der lithiierten polyketidischen Seitenkette an das cis-Dekalinepoxid konnten 
erfolgreich in nur einem Syntheseschritt die beiden Hauptfragmente verbunden, sowie die 7,12-
Etherbrücke aufgebaut werden. Nach zwei weiteren Syntheseschritten wurde stereoselektiv die 
C1,C2-Esterkomponente über eine 1,4-Addition eingeführt. Die nach wenigen weiteren 
Transformationen erhaltene Seco-Säure wurde erfolgreich in ein sehr gespanntes, eine trans-
Doppelbindung beinhaltendes neungliedriges Lakton überführt, durch darauffolgende Abspaltung 
der Schutzgruppen wurde (+)–Branimycin erhalten. 
Mit dem erfolgreichen Abschluß dieser Totalsynthese konnte die vorgeschlagene Struktur von 
Branimycin bestätigt, als auch dessen Absolutkonfiguration bestimmt werden. 
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INTRODUCTION AND BACKGROUND 
1. Branimycin and Related Natural Products 
1.1 Branimycin 
In 1998, branimycin (1) has been isolated from Actinomycete GW 60/1571 and structurally 
characterized by the Laatsch group at the University of Göttingen.1 Biological tests have 
shown that 1 is active against Bacillus subtilis, Escherichia coli, Staphylococcus aureus and in 
particular against Streptomyces viridochromogenes. The basic C-C connectivities were 
determined by extensive NMR analysis. Full structural assignment was possible by 
comparison with the NMR data available for the related compound nargenicin A1 (2) and also 
based on NOE-interactions. 
 
Figure 1: Assigned structure of branimycin (1). 
The structure of branimycin (1) is unusually complex, as 24 out of the 25 carbon atoms are 
either functionalized and/or stereogenic. It is characterized by a highly functionalized cis-
decalin core, where C7 and C12 are spanned by a transannular oxa-bridge (Figure 1). 
Annulated to the decalin is a nine-membered macrolide ring with an internal trans-double 
bond, the stereocenters on the C13-C18 polyketide chain of the macrocycle are in a syn,syn-
relationship. All in all, there are 12 stereocenters, 2 double bonds, 3 secondary OH- and 3 
CH2OMe functions. 
  
                                                   
1 a) Speitling, M. Dissertation, Universität Göttingen, 1998. (b) Speitling, M.; Grün-Wollny, I.; Hannske, F. 
G.; Laatsch, H. 12. And 13. IRSEER Naturstofftage der DECHEMA e.V. Irsee 2000, 2001, poster sessions. 
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1.2 The Nargenicins: Isolation, Biological Activity and Structure 
Elucidation 
In 1977 a novel family of antibiotics has been isolated by workers at Pfizer and Upjohn: the 
nargenicins. A stem of Nocardia, named Nocardia argentinensis nov. gen. (ATCC 31306), 
produced novel antibiotics upon aerobic submerged fermentation.2 One of these antibiotics, 
CP 47,777 was subsequently patented, although without disclosing its structure. Some years 
later the structure was published, making it the first member of a new class of antibiotics, and 
the name nargenicin A1 (2) was proposed.3 
 
Figure 2: Nargenicin A1 and its 18-Deoxy-derivative. 
In general, the nargenicin family can be described by an oxygen-bridged cis-decalin system, 
annulated to a 10-membered macrolactone ring. So far, ten members of this new family of 
antibiotics have been published (Table 1).  
Determination of the structure was based on extensive NMR-analysis which allowed initial 
assignment of all stereocenters of nargenicin A1 except positions 2, 16, 17 and 18 residing on 
the flexible macrolactone ring (Figure 2). Shortly after the publication of the structure of 
nargenicin A1 (2), scientists from Upjohn published the isolation of nodusmycin (3),4 another 
antibiotic that differs only at the C9 position lacking the 2-pyrrol-carboxylate functionality. In 
contrast to nargenicin, nodusmycin (3) could be crystallized and X-ray analysis 
unambiguously proved the relative configuration of both the polyketide macrolactone and the 
cis-decalin core. Based on this information, the structure of 2 was also successfully elucidated. 
Non empirical CD exciton chirality method of Nakanishi showed a positive Cotton effect for 
the C11 p-nitrobenzoylated analog and thus identified the absolute configuration of nargenicin 
                                                   
2 Celmer, W. D.; Cullen, W. P.; Moppett, C. E.; Jefferson, M. T.; Huang, L. H.; Shibakawa, R.; Tone, J. U.S. 
Patent 4,148,883, 1979. 
3 Celmer, W. D.; Chmurny, G. N.; Moppett, C. E.; Ware, R. S.; Watts, P. C.; Whipple, E. B. J. Am. Chem. 
Soc. 1980, 102, 4203 - 4209. 
4 Whaley, H. A.; C. G. Chidester, C. G.; Mizsak, S. A.; Wnuk, R. J. Tetrahedron Lett. 1980, 21, 3659-3662. 
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A15 which was additionally confirmed by feeding experiments (vide infra). Based on these 
results, the absolute configurations of other members of the nargenicin family were 
hypothesized. 
In 1982, the structure of 18-deoxynargenicin (4), another constituent in these fermentations,2 
could be determined by selective deoxygenation of nargenicin A1 (2) at the C18 position.6 
 
 
Name R1 R2 R3 R4 R5 R6 Ref. 
Nodusmycin (3) OMe H OH H H H 4 
Nargenicin A1 (2) OMe H OH H PC H 2, 3 
18-Deoxynargenicin (4) OMe H H H PC H 6 
Nargenicin B1 (5) H OH OH OMe PC OMe 7, 8 
Nargenicin B2 (6) H OH H OH PC OMe 7, 8 
Nargenicin B3 (7) H OH OH OMe PC H 7, 8 
Nargenicin C1 (8) OMe H OH OMe PC OMe 7, 8 
 
Table 1: The nargenicin family. 
The Pfizer group also patented the isolation of the antibiotics CP 51,467, CP 52,726, and CP 
52,748 from the species Nocardia argentinensis Huang ATCC 31438,7 without disclosure of 
its structure. However, a few years later another antibiotic was patented by the same group: 
nargenicin C1 (8).8 In this patent the structure of 8 as well as the structures of nargenicins B1-
B3 (5-7) were published.  
  
                                                   
5 (a) Cane, D. E.; Yang, C.-C. J. Antibiot. 1985, 38,423-426. (b) Cane, D. E.; Yang, C.-C. J. Am. Chem. Soc. 
1984, 106, 6633-6634. 
6 Magerlein, B. J.; Reid, R. J. J. Antibiot. 1982, 35, 254-255. 
7 Celmer, W. D.; Cullen, W. P.; Moppett, C. E.; Jefferson, M. T.; Huang, L. H.; Shibakawa, R.; Tone, J. 
United States Patent US 4,224,314, 1980. 
8 Celmer, W. D.; Cullen, W. P.; Shibakawa, R.; Tone, J. United States Patent US 4,436,747, 1984. 
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1.3 Luminamicin/Coloradocin/Lustromycin 
Luminamicin (9) was isolated by Japanese scientists from a stem of genus Nocardioides.9 It 
exhibits antibacterial activity against anaerobic bacteria, especially Clostridium. In 1987 
researchers from Abbott Laboratories isolated coloradocin from Actinoplanes coloradoensis,10 
which proved identical to luminamicin. With a combination of molecular dynamics studies 
and Mosher ester derivatization at the C11 and C18 – hydroxyl groups the absolute 
configuration of luminamicin (9) could be determined. The structure of the closely related 
lustromycin (10) was only determined by NMR-analysis.11 To date, the stereochemistry at C2 
and C3 could not be elucidated (Figure 3). 
Although the structures of 9 and 10 substantially differ from nargenicin A1 (2) they also can 
be ascribed to this family. While the oxygen bridge connects C9 – C13, it also combines a cis-
decalin core and a 10-membered lactone with a very closely related substitution pattern. 
H
H
OH
O
O
O
O
O
HO
O
O
O
O
HMeO
9
H
H
OH
O
O
O
O
O
HO
O
O
O
O
H
HO
HO
10
3
2
18 18
1111
9
1313
9
 
Figure 3: Luminamicin (9) and Lustromycin (10). 
1.4 Biosynthesis 
The biosynthetic origin of the nargenicins has been proposed on the basis of 13C incorporation 
experiments in fermentations of Norcardia argentinensis.12 These studies showed that the 
nargenicin skeleton, including the oxygens at C1, C9, C11 and C17 is apparently derived from 
5 acetate and 4 propionate units, and the Me group of the C2-OMe from methionine (Figure 
4). As none of these oxygens is derived from molecular oxygen, simple aldol and/or epoxide-
                                                   
9 Omura, S.; Iwata, R.; Iwai, Y.; Taga, S.; Tanaka, Y.; Tomoda, H. J. Antibiot. 1985, 38, 1322-1326. 
10 Jackson, M.; Karwowski, J. P.; Tehriault, R. J.; Fernandes, P. B.; Semon, R. C. J. Antibiot. 1987, 40, 
1375-1381. 
11 (a) Omura, S.; Imamura, N.; Oiwa, R.; Kuga, H.; Iwata, R.; Masuma, R.; Iwai, Y. J. Antibiot. 1986, 39, 
140. (b) Tomoda, T.; Iwata, R.; Takahashi, Y.; Iwai, Y.; Oiwa, R.; Omura, S. J. Antibiot. 1986, 39, 1205-
1210. 
12 (a) Cane, D. E.; Yang, C.-C. J. Antibiot. 1985, 38,423-426. (b) Cane, D. E.; Yang, C.-C. J. Am. Chem. 
Soc. 1984, 106, 6633-6634. c) Snyder, W. C.; Rinehart, K. L. J. Am. Chem. Soc. 1984, 106, 787-789. 
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olefin condensations can be ruled out. Late stage oxidation studies executed in an 18O2-
atmosphere proved that the oxygens at C2, C8/13 and C18 are derived from molecular 
oxygen.12a Based on these informations Cane suggested that the cis-fused decalin core of 2 
may be established via an intramolecular Diels-Alder cycloaddition mechanism in the 
polyketide chain 11, a pathway which is consistent with the distribution of functionality and 
stereochemistry in the natural product (Scheme 1). 
 
Figure 4: Biosynthetic origin of nargenicin A1. 
Diels-Alder adduct 12 is then further functionalized in late stage oxidation steps. 
This hypothesis was corroborated by successful incorporation of 13C-labelled chain elongation 
intermediate 13 into the nargenicin biosynthesis.13 
 
Scheme 1: Proposed biosynthetic intramolecular Diels-Alder pathway. 
Biosynthetic studies on luminamicin (9) proved unambiguously that the upper tricyclic ring 
system is also a polyketide whose biosynthesis generally follows the pattern established for 
nargenicin A1 (2).14 The path by which the carbons of the more unique lower bicyclic ring 
                                                   
13 Cane, D. E.; Luo, G. J. Am. Chem. Soc. 1995, 117, 6633-6634. 
14 McAlpine, J. B.; Mitscher, L. A.; Jackson, M.; Rasmussen, R. R.; Velde D.V.; Veliz, E. Tetrahedron 
1996, 52, 10327-10334. 
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system are assembled did not give an equally consistent picture. Feeding experiments with 
sodium (2,3-13C2)succinate provided direct evidence that C26 – C28 are derived from 
succinate, indicating the presence of an active citric acid cycle. It requires, however, that a 
carboxyl originally attached to C26 is lost along the sequence. Surprisingly, succinate being 
the source of C29 – C32 could be ruled out. They are synthesized in an uncommon pathway 
from acetate. The biosynthesis of this lower bicyclic ring system is definitely different from 
those few published for naturally occurring anhydrides. No 18O-labelling studies have been 
reported so far, therefore the origin of this “abnormal” C9 – C13 oxa-bridge remains unclear. 
 
Figure 5: Biosynthesis of luminamicin. 
So far no biosynthetic studies on branimycin (1) have been carried out. The similarity between 
nargenicin and branimycin from C4 upwards suggests a similar biosynthetic pathway. 
However, the C1 to C3 unit of branimycin cannot be constructed via two acetates. Also, the 
way of introducing the CH2OMe group at C2 is not clear. 
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2. Synthetic Routes to cis-Decalins 
The cis-decalin ring system is present in a wide variety of polyterpenoids and many other 
natural products with interesting biological activity. The importance of cis-decalins in natural 
products has led to the development of an immense diversity of methods for its preparation. 
Containing eleven C-C bonds, many different bond disconnections are possible, and most of 
these disconnections have appeared in numerous publications over the years.  
Among the various strategies for the synthesis of cis-fused decalin ring systems, Robinson 
annulation is one of the earliest and probably most well-known classical methods. The second 
most popular strategy involves the Diels-Alder (both intra- and intermolecular) reaction for 
the assembly of cis-decalins. As work in this area intensified, more and more new methods 
and strategies were developed. Broadly, most of these strategies for the construction of the cis-
decalin framework can be divided into four categories: (a) syntheses starting with Wieland-
Miescher type ketones, (b) Diels-Alder reactions, (c) Cope rearrangements and (d) cyclization 
strategies. 
2.1 Synthesis of cis-decalins from Wieland-Miescher type ketones 
Wieland-Miescher (WM) type ketones can of course be considered as part of a cyclization 
strategy, as they are normally made via Robinson annulation or Diels-Alder reaction. In order 
to arrange the classification of the various strategies more clearly, the syntheses of cis-decalins 
derived from WM type ketones are discussed separately. 
WM type ketones are venerable starting materials for the synthesis of cis-decalin-containing 
natural products. One of the key steps in the formation of the decalin core is saturation of the 
double bond at the ring junction (Scheme 2). Both, cis- and trans-decalins can be generated at 
this stage. Applying Birch conditions normally gives the trans-decalin skeleton whereas 
catalytic hydrogenation should give stereospecifically the cis-fused skeleton.  
 
Scheme 2: Saturation at the ring junction of WM type ketones. 
As a recent example Ando and co-workers synthesized in 1994 cis-decalin-based eudesmanes 
17a and b (Scheme 3). Santonin 14 was first transformed into 6-epi-santonin, which gave 
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carboxylic acid 15 upon reduction with Zn. Catalytic hydrogenation of 15 gave cis-fused 
decalin 16 which was then further transformed to the eudesmanes 17a,b. 
 
Scheme 3: Ando´s synthesis of eudesmanes 17a/b. 
In 1998, Mori and co-workers reported the first total synthesis of stachyflin (21). 15 
Intramolecular aldol condensation on diketone 18 gave decalenone 19, which on Rh-catalyzed  
 
Scheme 4: Mori´s synthesis of stachyflin (21). 
                                                   
15 Taishi, T.; Takechi, S.; Mori, S. Tetrahedron Lett. 1998, 39, 4347. 
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hydrogenation gave the desired cis-fused stachyflin precursor 20 as the major product 
(Scheme 4). 
2.2 Diels-Alder cycloaddition 
The Diels-Alder reaction is one of the most important and fascinating transformations in 
chemistry. Myriads of inter- and intramolecular Diels-Alder reactions have been employed to 
generate cis-decalin ring systems of any complexity. 
2.2.1 Intermolecular cycloaddition 
In general, two types of intermolecular Diels-Alder cycloadditions have been applied for the 
construction of cis-decalins (Scheme 5). 
 
Scheme 5: Types of intermolecular Diels-Alder reactions. 
In the first type an acyclic diene such as I reacts with a cyclic enone II directly to cis-fused 
decalin III, mostly in a stereo- and regioselective manner, provided both the diene and 
dienophile are appropriately activated. In the second type 1-vinylcyclohexene derivatives such 
as IV are used as Diels-Alder precursors. The resulting adduct V is unsaturated at the ring 
junction and has to be manipulated as discussed in section 2.1. 
For more than 60 years the Diels-Alder reaction subtype using quinones as dienophiles has 
provided a powerful construction for functionalized cis-fused decalin systems. Examples 
include many of the most notable achievements in complicated synthetic chemistry: steroids, 
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dendrobine, ibogamine, euonyminol, gibberellic acid, reserpine and trichodermol.16 For many 
years there were no methods available for conducting these key quinone Diels-Alder reactions 
enantioselectively. This gap in methodology has just started to be filled. A recent example was 
described by Evans and Wu (Scheme 6).17 They describe a new family of chiral Lewis acid 
complexes 25 derived from pyridyl-bis(oxazoline) ligands and gadolinium and samarium 
triflates. Reaction of quinone 22 with diene 23 gave adduct 24 in excellent yield and ee. The 
reaction was generally completed in less than 10 min; the product enantioselectivity was 
highly dependent on the choice of solvent system. The reaction is general and also gave high 
ee´s with other quinones and dienes. 
 
Scheme 6: Evans´ enantioselective quinone Diels-Alder reaction of 22 and 23. 
Corey et al. have focused on the use of 1,4-quinone monoketals 18  rather than the 
corresponding quinones as the monoketals are expected to be more Lewis basic and also the 
problem of aromatization could be avoided. Excellent results were obtained using e.g. 1,4-
quinone monoketal 26 together with pentadiene 27 in the presence of binol-TiIV based catalyst. 
The use of molecular sieves that contain water was crucial, accelerating the reaction and 
making it more efficient (Scheme 7). 
                                                   
16 a) Woodward, R. B.; Sondheimer, F. J. Am. Chem. Soc. 1952, 74, 4223. b) Salley, S. I. J. Am. Chem. Soc. 
1967, 89, 6762. c) Kende, A. S.; Bently, T. J.; Mader, A. R.; Ridge, D. J. Am. Chem. Soc. 1974, 96, 4332. d) 
Corey, E. J.; Danheiser, R. L.; Chandrasekaran, S.; Siret, P.; Keck, G. E.; Gras, J. J. Am. Chem. Soc. 1978, 
100, 8031. e) Still, W. C.; Tsai, M. Y. J. Am. Chem. Soc. 1980, 102, 3654. f) White, J. D.; Cutshall, N. S.; 
Kim, T. S.; Shin, H. J. Am. Chem. Soc. 1995, 117, 9780. 
17 Evans, D. A.; Wu, J. J. Am. Chem. Soc. 2003, 125, 10162. 
18 Breuning, M.; Corey E. J. Org. Lett. 2001, 3, 1559. 
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Scheme 7: Corey´s enantioselective Diels-Alder reaction of quinone monoketal 26. 
Barriault et al. give an example for the second type of intermolecular Diels-Alder 
cycloadditions. 19  They successfully developed a method that controls regio- and 
stereoselectivity of the Diels-Alder reaction with PhMgBr of semicyclic dienes such as 29  
 
Scheme 8: Barriault´s hydroxyl group-directed Diels-Alder reaction. 
possessing a secondary or tertiary allylic alcohol functionality in the position with activated 
dienophiles such as methyl acrylate, methacrolein and N-phenylmaleimide. Decalene 30 was 
obtained in a highly regio- and diastereoselective manner (Scheme 8). 
2.2.2 Intramolecular cycloaddition 
The intramolecular Diels-Alder cycloaddition (IMDA) has also been employed in numerous 
syntheses to construct the decalin skeleton. Depending on the transition state a triene such as  
 
Scheme 9: Intramolecular Diels-Alder reaction. 
                                                   
19 Barriault, L.; Thomas, J. D. O.; Clement, R. J. Org. Chem. 2003, 68, 2317. 
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VII can either give cis-fused decalin VIII or the trans-fused decalin such as IX (Scheme 9). 
In intramolecular Diels-Alder reactions the prediction of the stereochemistry is not always 
easy as several factors such as steric, stereoelectronic and competing conformational effects 
can strongly influence the transition state. 
 
Scheme 10: Jones´ IMDA approach. 
 In many cases, the use of Lewis acids favors an increased ratio of endo:exo products. It 
appears that secondary orbital interactions do not play a dominating role in intramolecular 
Diels-Alder reactions as quite often the stereochemical result turned out to be independent of 
the geometry of the dienophile moiety. 
 
Scheme 11: Roush´s IMDA approach to the cis-decalin core of nargenicin A1. 
The placement of a functional group can change the product distribution. In many cases the 
presence of a carbonyl group in conjugation with the diene moiety helps in the formation of 
the trans product, whereas, if a carbonyl group is in conjugation with the double bond of the 
dienophile, the cis product is predominantely formed. Also in context of approaching the 
nargenicin family three IMDA strategies were applied.20 In 1985, Jones et al. published a 
                                                   
20 Also in the Mulzer group an IMDA strategy was applied to generate the decalin core of branimycin (vide 
infra). 
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model study on the construction of the oxa-bridged cis-decalin skeleton present in the 
nargenicin family. 21  Trienone 31 underwent an exo-cycloaddition to give cis-decalin 32. 
Unfortunately, all attempts to introduce the oxa-bridge failed (Scheme 10).  
Similar to the retrosynthetic considerations by Jones, Roush et al. also envisioned to construct 
the cis-decalin core (35) of nargenicin A1 (2) via an IMDA cycloaddition.22 Interestingly, upon 
heating, 33 underwent a clean cycloaddition to yield cis-decalin 34, presumably via a boat-like 
transition state. Investigations of various diastereomeric substrates revealed that the 
involvement of a boat-like transition state in decatrienone intramolecular Diels-Alder 
reactions appears to be general (Scheme 11). 
 
Scheme 12: Roush´s transannular Diels-Alder reaction of macrolactone 36. 
In continuation of their interest in this area, the Roush group turned their attention to an 
alternative strategy to create the entire carbon framework of nargenicin A1 in one step via a 
transannular Diels-Alder reaction. 23  This strategy represents a biomimetic approach, as 
biosynthetic studies also propose a late stage intramolecular Diels-Alder reaction after full 
assembly of the polyketide chain.12a Under thermal conditions, macrolactone 36 converted 
selectively to cis-decalin 37 in high yields (85% b.r.s.m.). Also a minor amount of the C10-
epimer was obtained. Unfortunately, also this route had to be abandoned as the C8-C13 ether 
bridge could not be introduced (Scheme 12). 
Corey et al. used both inter- and intramolecular Diels-Alder reactions in the stereocontrolled 
synthesis of gibberellic acid (43).24 An initial regio- and chemoselective Diels-Alder adduct 
between quinone 39 and diene 38 forged the relative stereochemistry in 40. After a few steps 
the stage was set for a substrate-controlled intramolecular Diels-Alder reaction, which gave  
                                                   
21 Jones, R. F.; Tunnicliffe, J. H. Tetrahedron Lett. 1985, 26, 5845-5848. 
22 Coe, J. W.; Roush, W. R. J. Org. Chem. 1989, 54, 915-930. 
23 Roush, W. R.; Koyama, K.; Curtin, M. L.; Moriarty, K. J. J. Am. Chem. Soc. 1996, 118, 7502-7512. 
24 Corey, E. J.; Danheiser, R. L.; Siret, P.; Keck, G. E.; Gras, J.-L. J. Am. Chem. Soc. 1978, 100, 8031-8034. 
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Scheme 13: Corey´s total synthesis of gibberelic acid (43). 
selectively desired 42 (Scheme 13). The outcome of this IMDA reaction was exactly as 
expected, based on the stereochemical requirements of the participating functionalities. 
2.3 Cope rearrangements 
Another very elegant route to cis-decalins is the Cope rearrangement of bicyclo[2.2.2]octene-
derivatives of the types X to XI (Scheme 14). The Cope rearrangement itself is of minor 
synthetic importance as the yields are in general rather low due to the requirement of higher 
temperatures. Additionally, there are no general and flexible methods to synthesize such 
bicyclo-octenes. Oxy-Cope and oxy-anion Cope rearrangements, 25  however, have greatly 
extended their utility. They are often performed at or near room temperature and exhibit a 
considerable tolerance toward functional groups. Yields are also higher due to the 
irreversibility of these reactions. In addition X is easily accessible via addition of vinyl 
organometallics to a -unsaturated carbonyl group in the bridged bicyclic systems.  
Also enormously attractive is the enhanced structural embellishment that often develops in the 
unsaturated ketone product, whose two new functional groups can be manipulated 
                                                   
25 Paquette, L. A. Tetraehdron 1997, 53, 13971. 
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independently for synthetic purposes. 
 
Scheme 14: Cope rearrangement of bicyclo[2.2.2]octenes. 
Paquette and co-workers have extensively examined the oxy-anion Cope rearrangements. In 
1991 they published an enantioselective total synthesis of (-)-9-epi-ambrox (49) (Scheme 
15).26 Addition of lithiated 2,3-dihydrofuran to optically pure bicyclic ketone 44 gave 45 and 
its corresponding epimer in high yields (d.r. = 7:1). Heating the potassium salt of 45 induced 
the rearrangement via a boat transition state geometry for structural reasons.  
 
Scheme 15: Paquette´s synthesis of (-)-9-epi-ambrox. 
The thermal activation also caused equilibration between enolates 46 and 47, completely in 
favor of 47. Quenching of the latter enolate with phenylselenyl chloride followed by oxidative 
elimination of the corresponding phenylseleno ketone gave 48 in good overall yield (54% 
from 45), which was elaborated into 49 in four more steps. 
Liao et al. have extensively exploited the cycloaddition of cyclohexadienone ketals for the 
synthesis of eremopetasidione (54). 51 was prepared by the Diels-Alder reaction of ethyl vinyl 
ketone with masked o-benzoquinone 50 generated in situ via oxidation with iodobenzene  
 
                                                   
26 Paquette, L. A.; Guevel, R.; Sakamoto, S.; Kim, I. H.; Crawford, J. J. Org. Chem. 2003, 68, 6096. 
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Scheme 16: Liao´s synthesis of eremopetasidione (54). 
diacetate. Bicycle 51 was converted into silyl enol ether 52 which upon heating underwent 
Cope rearrangement smoothly furnishing cis-decalin 53 in high yields (Scheme 16). 
2.4 Cyclization methods 
The Robinson annulation has been extensively used for generating cis-fused decalins. 
However, various problems in efficiency, as well as in stereo- and regiocontrol made it 
necessary to develop alternative cyclization methods. Some recently developed methods are 
presented below. 
 
Scheme 17: cis-Decalins via asymmetric intramolecular Heck reaction. 
Shibasaki et al. reported their results on screening BINAP and a range of oxazoline-containing 
phosphinamine ligands in the palladium-catalyzed asymmetric intramolecular Heck 
cyclization to form cis-decalins.27 Palladium complexes derived from Pd(OAc)2 and BINAP 
proved to be the most selective catalysts in the formation of 56 from either the alkenyl triflate 
                                                   
27 Sato, Y.; Watanabe, S.; Shibasaki, M. Tetrahedron Lett. 1992, 33, 2589. 
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or the analogous alkenyl iodide 55. For the alkenyl triflate, the optimum ee achieved was 91% 
in a yield of 54% (Scheme 17). 
In 1993 Shirahama et al. reported samarium(II)iodide mediated ketone-olefin coupling 
cyclizations in a stereocontrolled manner, to give epimeric mixtures of cis-decalin diols 58 
and 59 derived from (Z)-ester 57. 28  Chelation of the samarium(III) cation with the 
incorporated hydroxyl group established the reported stereoselectivity. Exclusively cis-fused 
decalins were formed with d.r. = 6:1 (58:59) in 70% yield (Scheme 18). 
O
OH
H
MeO2C
H
OH
OH
SmI2
MeOH, THF,
-78 °C
H
OH
OH
+
CO2Me CO2Me
57 58 59  
Scheme 18: Samarium(II)iodide mediated cis-decalin formation. 
Srikrishna et al. reported enantiospecific routes to (+)-valerane 63, starting from (R)-carvone, 
using intramolecular diazoketone cyclopropanation as a key step. 29  (R)-Carvone was 
converted into diazo-ketone 60, which, on intramolecular diazo-ketone cyclopropanation (61), 
followed by reductive cleavage of the cyclopropane ring, gave ketone 62, which was 
efficiently converted into (+)-valerane 63 (Scheme 19). 
 
Scheme 19: Srikrishna´s intramolecular diazo-ketone cyclopropanation strategy. 
Tricarbonylchromium-mediated dearomatization provides an efficient access to substituted 
cyclohexadienes. In the context of an application to the asymmetric synthesis of (-)-(R,R)-
                                                   
28 Kito, M.; Sakai, T.; Yamada, K.; Matsuda, F.; Shirahama, H. Synlett 1993, 158. 
29 Srikrishna, A.; Viswajanani, R.; Dinesh, C. J. Chem. Soc., Perkin Trans. 1 2000, 4321. 
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acetoxytubipofuran (68), Kundig and co-workers reported a regio- and stereoselective one-pot 
sequence introducing up to three C-substituents (Scheme 20). 30  Nucleophilic addition of 
lithiated ethyl vinyl ether to imine complex 64 in the presence of 65 followed by 
acylation/alkylation and imine hydrolysis gave 66 in 76% ee. Hydrolysis of the vinyl ether 
followed by intramolecular aldol condensation gave 67 which was enantiomerically enriched 
via recrystallization (ee > 99%). Similarly the enantiomer of 68 was also synthesized. 
 
Scheme 20: Kundig´s tricarbonylchromium-mediated dearomatization. 
Mehta et al. have developed a new approach to assemble functionalized eudesmanes from (-)-
carvone (69) applying ring closing metathesis as key step (Scheme 21).31 Epoxidation of 69 
followed by reductive allylation under dissolving metal conditions gives ketone 70. Addition 
of the Grignard reagent in the presence of Ce(III) furnished isomeric addition products 71a/b. 
Ring-closing metathesis reaction then provided functionalized eudesmane frameworks 72a 
and b. 
In 2002, Phillips and co-workers demonstrated that ruthenium alkylidene 75 is a competent 
catalyst for ring-opening-ring-closing metathesis of bicyclo[2.2.2]octenes such as 73, 
providing a novel approach to the synthesis of functionalized decalins (74) and hydrindane 
ring systems. 32  Cyclization to give hydrindane ring systems proceeds readily at room 
temperature, whereas cyclization to give decalins requires higher temperatures - typically 
toluene at reflux. Employing carbene 76 failed to give any of the desired products (Scheme 
22). 
                                                   
30 Kundig, E. P.; Cannas, R.; Laxmisha, M.; Ronggang, L.; Tchertian, S. J. Am. Chem. Soc. 2003, 125, 5642. 
31 Mehta, G.; Kumaran, R. S. Tetrahedron Lett. 2003, 44, 7055. 
32 Minger, T. L.; Phillips, A. J. Tetrahedron Lett. 2002, 43, 5357. 
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Scheme 21: cis-Decalins via RCM. 
Overman et al. developed a ring-enlarging cyclohexane annulation method via Prins-pinacol 
rearrangement.33 Cis-fused rings of various sizes can be formed including cis-decalins. Lewis 
acid-mediated (SnCl4, TMSOTf) Prins reaction of substrates such as 77 give via kationic 
intermediates (78) decalones such as 79. 
 
Scheme 22: Ring-opening-ring-closing metathesis of bicyclo[2.2.2]octenes. 
This method provides an efficient new route to cis-bicyclo[n.4.0]alkanones having angular 
aryl or alkyl substituents (Scheme 23). In the course of their total synthesis of (-)-magellanine 
(80) it was proven that this methodology can be applied for even quite complicated systems. 
                                                   
33 Ando S.; Minor, K. P.; Overman, L. E. J. Org. Chem. 1997, 62, 6379. 
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Scheme 23: Overman´s ring-enlarging cyclohexane annulation method. 
A highly oxygenated cis-decalin core was synthesized by Kozikowski et al. in their synthesis 
towards forskolin.34 Aldehyde 81 was transformed into the corresponding nitrile oxide giving 
cis-fused isoxazol 82 in good yields via [3+2] dipolar cycloaddition (Scheme 24). 
 
Scheme 24: Kozikowski´s INOC key step in the synthesis of forskolin. 
                                                   
34 Kozikowski, A. P.; Jung, S. H.; Springer, J. P. J. Chem. Soc., Chem. Commun. 1988, 167. 
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3. Previous Synthetic Work 
3.1 Approaches towards the nargenicin family 
3.1.1 Kallmerten´s synthesis of 18-deoxynargenicin A1 
In 1984 Kallmerten et al. reported an elegant approach towards the oxa-bridged cis-decalin 
core of the nargenicins (Scheme 25). 35  The cis-decalin framework was synthesized in a 
racemic manner via intermolecular Diels-Alder cycloaddition of diene 83 and quinone 84. The 
endo adduct was reduced to triol 85 which was further acetalized to leave only one OH-group 
free. 86 could be converted to 87 by a regio- and stereoselective introduction of a methyl 
group followed by acidic hydrolysis. 
 
Scheme 25: Kallmerten´s synthesis of the “northern” fragment 89. 
Selective oxidation of the allylic alcohol followed by protection of the remaining free OH-
group as a MOM-ether gave ketone 88. Epoxidation of the more electron rich double bond 
gave a 1.8:1 diastereomeric ratio of expected epoxide 89 and its isomer. Treatment of 89 with 
methyl magnesium bromide as a test reaction furnished oxa-bridged bicycle 90.  
In 1988 the total synthesis of 18-deoxynargenicin was accomplished by the same authors.36 
Iodide 93 was obtained in analogy to a sequence published by Corey et al. (Scheme 26).37 
                                                   
35 Kallmerten, J. Tetrahedron Lett. 1984, 25, 2843-2846. 
36 Plata, D. J.; Kallmerten, J. J. Am. Chem. Soc. 1988, 110, 4041-4042. 
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Scheme 26: Synthesis of polyketide side chain 93. 
Addition of 93-Li to racemic 89 followed by direct transformation to the corresponding 
methoxymethyl ether gave a mixture of diastereomeric products 94. Both diastereomers were 
converted further, until structural assignment via X-ray analysis was possible on a crystalline 
intermediate. 
 
Scheme 27: Synthesis of seco acid 97a/b. 
Allylic oxidation of 94 gave enone 95 only in modest yield. Stereoselective conjugate addition 
of a mixed cuprate followed by immediate trapping as an enol phosphodiamidate and 
dissolving metal reduction afforded 96 again in poor yield. Selective deprotection of the  
 
Scheme 28: Completion of the synthesis of 4. 
primary alcohol, conversion to the corresponding methyl ester, oxygenation, methylation, 
saponification and global deprotection gave seco acids 97a and b as a mixture of 
                                                                                                                                                         
37 Corey, E. J.; Trybulski, E. J.; Melvin, L. S.; Nicolaou, K. C.; Secrist, J. A.; Lett, R.; Sheldrake, P. W.; 
Falck, J. R.; Brunelle, D. J.; Haslanger, M. F.; Kim, S.; Yoo, S. J. Am. Chem. Soc. 1978, 100, 4618 – 4620. 
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diastereomers (Scheme 27). Interestingly, applying Corey´s thiopyridyl ester procedure38 on 
97a/b gave only the desired macrolide product. The absence of lactonic product arising from 
the undesired diastereomer can be attributed to unfavorable steric interactions in the transition 
state. Acylation at 9-OH then gave (+)-18-deoxynargenicin, identical with an authentic 
sample. So far it was the only complete synthesis of a member of the nargenicin family 
(Scheme 28). 
3.2 Approaches towards branimycin in the Mulzer group 
In the context of an ongoing study toward the total synthesis of branimycin and its unique, 
highly functionalized cis-decalin core, five alternative routes have been investigated 
previously. 
3.2.1 Quinic acid based INOC approach 
Quinic acid was used as a chiral scaffold for elaborating the cis-decalin core of branimycin via 
an Eschenmoser-Ireland rearrangement-INOC annulations sequence (Scheme 29).39 Starting 
from known silyl-enol ether 98, stereoselective alkylation under Mukaiyama conditions gave 
ketone 99. Luche reduction, followed by Mitsunobu inversion provided allylic ester 100. 
Chelation-controlled glycolate enolate Claisen rearrangement led to 101 as a single isomer.  
 
Scheme 29: Quinic acid based INOC approach. 
Conversion to the aldehyde and Z-selective Still-Gennari olefination followed by reduction 
gave enone 102. After conversion to the corresponding cis-unsaturated oxime the stage 
for the key INOC reaction was set. Treatment of the oxime with NCS/pyridine resulted in 
                                                   
38 Corey, E. J.; Nicolaou, K. C. J. Am. Chem. Soc. 1974, 96, 5614-5616. 
39 Enev, V. S.; Drescher, M.; Mulzer, J. Tetrahedron 2007, 63, 5930-5939. 
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formation of a nitril oxide which immediately formed isoxazolidine 103 in excellent yields. 
After dihydroxylation of the double bond the cleavage of the isoxazolidine ring was possible, 
and 1,2-addition of vinylmagnesium bromide gave adduct 104 with high stereoselectiviy. 
3.2.2 Lactone based INOC approach 
Lactone 105 was converted into 106 via a copper catalyzed stereoselective Michael addition 
of vinyl Grignard, followed by an aldol reaction with acrolein and TBS-protection (Scheme 
30). Unfortunately, 106 was obtained as an epimeric mixture. Some functional group 
interconversions of this mixture furnished oxime 107 which was oxidized to the corresponding  
 
Scheme 30: Lactone based INOC approach. 
nitrile oxide. The yield of the cyclization product 108 could be dramatically increased from 
initial 30% to 79% upon increase of the temperature (80 °C).40 
3.2.3 Trans-Annular Diels-Alder approach 
The synthesis was started from known butenolide 110, which was protected as TBDPS ether 
followed by a stereoselective Michael addition of vinyl cuprate to give 111.41 Partial reduction 
and methylation gave methyl lactol 112 (Scheme 31).  
 
Scheme 31: Preparation of cis-fused decalin 116. 
                                                   
40 Gromov, A.; Enev, V. S.; Mulzer J. Tetrahedron Lett. 2009, 50, 5283-5284. 
41 Felzmann, W.; Arion, V. B.; Mieusset, J. L.; Mulzer, J. Org. Lett. 2006, 8, 3849−3851. 
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After ozonolysis of 112 the resulting aldehyde was used in a (Z)-selective, modified Julia 
olefination after which cleavage of the TBDPS group provided diene 113. Using a TPAP-
oxidation/Roush-Masamune olefination sequence seco-compound 114 was obtained in high 
yields. The key intramolecular Stille-coupling reaction under high-dilution conditions gave the 
desired macrocycle 115, which under thermal conditions was converted smoothly to 116 as a 
single diastereomer. In this sequence six new stereogenic centers were established via purely 
substrate controlled transformations. 
3.2.4 SN2´ oxa-bridge opening – RCM approach 
Starting from the readily available dibenzylether 117, opening of the oxa-bridge with a 
Grignard reagent under copper catalysis provided 118 as a single diastereomer. Separation of 
racemic 118 via chiral HPLC followed by benzyl cleavage furnished triol 119, which was 
treated with p-methoxybenzaldehyde to give alcohol 120. The remaining free primary alcohol 
was oxidized and the resulting aldehyde was used in a modified Peterson olefination to give 
olefin 121 (Scheme 32).  
 
Scheme 32: SN2´oxa-bridge opening – RCM sequence to cis-decalin core 125. 
Regioselective opening of the PMB-acetal followed by Dess-Martin oxidation furnished 
aldehyde 122, where simultaneously the second double bond required for RCM reaction as 
well as the C3-appendage were introduced to give a mixture of diastereomeric alcohols 123. 
Oxidation to the ketone, followed by regio- and stereoselective epoxidation delivered epoxide 
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124. Finally RCM of 124 with Grubbs second-generation catalyst provided epoxyketone 125 
in excellent yield.  
 
Scheme 33: Formation of the oxa-bridge. 
Ketone 125 was reacted with pre-metalated side chain 126 (derived from its corresponding 
vinyl iodide)42 where the addition to the carbonyl group was followed by transannular epoxide 
opening to give the desired alcohol 127 (Scheme 33). 
3.2.5 Diepoxynaphthalene-desymmetrization approach 
Starting from known diepoxynaphthalene 128, organometallic catalyzed successive SN2´ 
openings of the oxa-bridges were used for desymmetrization (Scheme 34).43  
 
Scheme 34: Preparation of cis-decalin 133. 
An anti SN2´ opening of exclusively one of the oxa-bridges gave compound 129 in high  
                                                   
42 Felzmann, W.; Castagnolo, D.; Rosenbeiger, D.; Mulzer, J. J. Org. Chem. 2007, 72, 2182-2186. 
43 Gromov, A.; Enev, V. S.; Mulzer J. Org. Lett. 2009, 11, 2884-2886. 
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yields. OPMB-Protection followed by oxidative cleavage of the C-Si bond gave the 
corresponding primary alcohol which was further converted to methyl ether 130. Racemic 130 
was treated with DIBAL and Ni(COD)2/(R)-BINAP and a pseudoenantiotopos selective 
hydrogen attack was achieved to give enantiomerically enriched regioisomers 131 and 132.  
 
Scheme 35: Coupling of 133 and 126 and formation of the oxa-bridge. 
Dess-Martin oxidation of 131 followed by base-catalyzed double bond isomerization and 
regioselective epoxidation gave a 3:1 mixture of diastereomeric epoxides. Finally, pursuing 
the strategy envisioned in our group, epoxyketone 133 and lithiated side chain 126 were 
coupled to give tricycle 134 with the desired oxa-bridge (Scheme 35). 
3.2.6 Synthesis of the C13-C18 side chain 
Based on the addition of chiral allenyl silane 138 to aldehyde 137 an elegant stereocontrolled 
synthesis of 140 was accomplished (Scheme 36).42 (S)-Glycidol was O-methylated and upon 
treatment with trimethylsulfonium ylide alcohol 136 was furnished.  
Scheme 36: Synthesis of the C13-C18 side chain 140. 
TIPS-protection and ozonolysis provided enantiomerically pure aldehyde 137. The TiCl4 
mediated reaction of known allenyl silane 138 with 137 gave homopropargyl adduct 139 as a 
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20:1 diastereomeric mixture in good yields. The addition is the result of an allenyl-re-
aldehyde-si face combination. Alcohol 139 was protected as its PMB ether followed by 
hydrozirconation, which, upon treatment with iodine, gave desired vinyliodide 140.  
 
Introduction and Background: Outline of the Synthetic Plan 
 
29 
 
4. Outline of the Synthetic Plan 
Structural features of branimycin (1) that merit special attention include the nine-membered 
macrolide ring with an internal trans-double bond, the chirality at C15, C16 and C17, and the 
highly functionalized oxa-bridged cis-decalin core. The construction of the nine-membered 
lactone of 1 was expected to be a highly challenging synthetic task. Molecular modeling 
showed that the desirable macrolactone should be significantly strained, which also indicates a 
certain sensitivity towards hydrolysis suggesting that this structural element should be 
introduced only at a late stage. From an entropic point of view the formation of nine-
membered rings can be regarded as an unfavourable process but on the other hand the 
connection of the macrocycle to the rigid oxa-bridged decalin nucleus should reduce the 
conformational mobility of the corresponding seco acid. In addition, the C13-C14 trans 
double bond is expected to significantly inhibit the rotational freedom of the C13-C18 side 
chain thus increasing the probability of intramolecular cyclization. 
 
Scheme 37: Key disconnections of branimycin (1) into cis-decalins D and side chain S. 
The C13-C18 substitution pattern of the branimycin macrolide offers a synthetic challenge as 
the number of methods for the selective generation of remote syn,syn-stereotriades is rather 
limited. The 7,12-oxa-bridged cis-decalin framework is unique to the nargenicin family, its 
exceptional stereochemical and structural complexity makes it also a formidable synthetic 
target.  
We planned a convergent approach towards 1 (Scheme 37) – formation of the diaxial 7,12-
ether bridge should be accomplished via a 1,2-addition of S to epoxy ketone D to give alcohol 
141, which upon warming would undergo intramolecular cyclization. Molecular modeling 
indicates that tricycle 142 features minimum torsional strain (Scheme 38). An 8,12-ether 
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bridge should not be formed as therefore an unfavourable boat-like conformation would be 
required. Application of this strategy requires a short and stereoselective synthesis of the C13-
C18 framework, which has been previously reported in our group.42 The C3-appendage was 
planned to be installed at a late stage, either via a Claisen rearrangement of an allylic 
hydroxyl-group at C5 or via conjugate addition at C3. 
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Scheme 38: Proposed formation of the branimycin 7,12-ether bridge. 
(D)-Quinic acid seemed a reasonable starting material for the synthesis of D, expecting that all 
subsequent stereocenters should be constructed based on this chirality (Scheme 39). Ring A 
would be established by a ring closing metathesis of 143, in which the required vinylic double 
bonds were to be installed via two successive chelation-controlled glycolate enolate Claisen 
rearrangements44 from precursor 144, which in turn should be arranged in stereoselective 
fashion from quinic acid. The absolute configuration would be ascertained, as quinic acid is a 
chiral pool molecule. Upon this strategy the OH-group at C5 would already be installed in the 
course of the second Claisen rearrangement. 
Following an intermolecular quinone based Diels-Alder cycloaddition strategy, known tricycle 
86 was also considered as a suitable precursor for D (Scheme 39). 45  As the cis-decalin 
skeleton is already constructed all following transformations would focus on establishing the 
functional group pattern. The enone functionality of 145 should be obtained via a 
regioselective allylic oxidation. Incorporation of a masked C9-methoxy methyl substituent  
                                                   
44 Burke, S. D.; Fobare, W. F.; Pacofsky, G. J. J. Org. Chem. 1983, 48, 5221-5228 and references cited 
therein. 
45 a) White, J. D.; Choi, Y. Helv. Chim. Acta 2002, 85, 4306-4327 b) reference 35. 
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Scheme 39: Retrosynthetic analysis of cis-decalins D. 
should be accomplished stereoselectively from the convex face by SN2´ displacement of 
mesylated 86.This strategy requires a late stage allylic oxidation at C5. 
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Introduction
The increasing resistance of bacterial pathogens against
standard antibiotics combined with an emerging threat of bi-
oterrorism has led to the urgent need for developing innova-
tive anti-infective drugs.[1] Recently, branimycin (1) has been
isolated by the Laatsch group from actinomyces GW 60/
1571[2] .
First biological tests have shown that 1 is highly active
against Streptomyces viridochromogenes. The structure of 1
is related to that of the nargenicins[3] (e.g., nargenicin A1, 2)
and has been reliably elucidated by multidimensional 1H
and 13C NMR experiments. The interesting biological activi-
ty and the complex molecular architecture make 1 an attrac-
tive target for total synthesis. Our retrosynthetic analysis
(Scheme 1) features a disconnection of the molecule into a
bicyclic cis-decalin type core (e.g., 3 or 4) and a vinyl mag-
nesium side chain (5). In this report we describe the synthe-
sis of 5 and novel approaches to cis-fused decalin deriva-
tives.
Synthesis of Side Chain 5
The synthesis started from natural (R,R)-diethyl tartrate (6),
which was converted into the protected glyceraldehyde 7
(Scheme 2). Titanium tetrachloride mediated addition of the
nonracemic allenylsilane 8[4] resulted in the selective forma-
tion (d.r. >20:1) of the all-syn diastereomer 10, presumably
via a chelate intermediate 9. Benzyl-protection led to 11
which was converted into 5 via a regio- and stereocontrolled
hydrozirconation-iodination-metalation sequence.
Abstract: A variety of highly functionalized cis-decalin
systems have been prepared by means of the stereose-
lective transannular Diels–Alder (TADA) reaction of a
(Z,E,Z,Z)-tetraene macrolide, and by means of intra-
molecular nitrile oxide olefin (INOC) or ring-closing
metathesis (RCM) annulations to quinic acid deriva-
tives.
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Synthesis of cis-Dehydrooctalin Lactone 12: The
Transannular Diels–Alder (TADA) Approach
Following the retrosynthetic suggestion in Scheme 3, we
aimed for a synthesis of 4 that should be prepared by means
of a intramolecular Diels–Alder (IMDA) reaction[5] of tet-
raene 13. In this manner, lactone 12 should be formed
through an endo-transition state. Tetraene 13, in turn, was to
be constructed by a Stille coupling[6] of vinyl iodide 14 and
vinyl stannane 15 (Scheme 4).
For the synthesis of 14, lactone 16 was subjected to a ster-
eoselective 1,4-addition of vinyl cuprate. As the lactone
function turned out to be incompatible with the transforma-
tions envisaged later, it was reduced to the lactol and con-
verted into acetal 17 with high stereocontrol. Oxidation of
the olefinic sidechain to the aldehyde followed by a cis-se-
lective Wittig olefination gave vinyl iodide 18 in good over-
all yield, which was transformed into (Z)-enoate 14 by
means of an Ando olefination[7] (Scheme 5). The synthesis
of dienyl-stannane 15 is outlined in Scheme 6. Allylic alco-
hol 19 was oxidized to aldehyde 20, which was subjected to
a Still–Gennari olefination to give ester 21 with high Z se-
lectivity. Reduction with diisobutyl aluminium hydride and
formation of the p-methoxybenzyl ether led to 15. Stille cou-
pling with 14 furnished geometrically pure tetraene 13 in
satisfactory yield. The attempted IMDA reaction[5] failed
under all conditions we tried (heating to 150 8C, addition of
Lewis acids, high pressure up to 13 kbar). Instead, extensive
E/Z isomerization was observed in the triene part of the
molecule.
To remedy this situation, we decided to inhibit such iso-
merizations by incorporating the triene into a macrolide
ring, such as 24, and switch from IMDA to TADA[8] cycliza-
tion (Scheme 7). To achieve smooth macrocyclization, an
(E)-enoate had to replace the former (Z)-enoate, and the
former endo transition state had to be converted into the
exo transition state. The synthesis of 24 (Scheme 8) was
started with a (Z)-selective Julia olefination[9] of aldehyde
25 with sulfone 26 to give (Z,E)-diene 27, which was oxi-
dized to aldehyde 28 and olefinated to ester 30. Stille mac-
rocyclization[6] gave 24 in moderate yield.
Scheme 2.
Scheme 3.
Scheme 4.
Scheme 5.
Scheme 6.
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As expected, 24 underwent smooth TADA cyclization
under thermal conditions (Scheme 9) to give the diastereo-
merically pure cis-dehydrooctalin lactone 31 according to
HPLC and NMR analysis. The relative configuration of 31
was elucidated by 1NMR spectroscopy. Specifically, the low
value of J5,10 (6 Hz) and the NOE interactions shown in the
three-dimensional representation strongly supported the
configurations assigned. Further experiments are under way
to convert 31 into octalin 32, ready for connection with side
chain 5 (Scheme 10).
Intramolecular Nitrile Oxide Olefin (INOC)
Cyclizations
In a second approach, the intramolecular nitrile oxide olefin
(INOC) cyclization[10] was attempted for generating highly
substituted cyclohexane and cis-decalin systems. Thus com-
pound 33 was envisaged as a suitable core moiety of 1
(Scheme 11).
cis-Decalin 33 was to be derived from a ring-closing meta-
thesis reaction[11] of diolefin 34, which could be prepared
from lactone 36 via nitrile oxide 35. To probe the viability of
this approach, lactone 37 was converted into 39 through the
conjugate addition of vinyl cuprate and acrolein
(Scheme 12). Unfortunately, 39 was obtained as an epimeric
mixture and all attempts to generate 39 in epimerically pure
form failed. Straightforward functional manipulation of this
mixture furnished oxime 41, which was oxidized to nitrile
oxide 42. Under the conditions in situ cyclization to diaster-
eomerically pure isoxazoline 43 occurred, the configuration
Scheme 8.
Scheme 9.
Scheme 10.
Scheme 11.
Scheme 7.
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of which was elucidated by single-crystal diffraction
(Figure 1). Only the b-OTBS diastereomer underwent the
INOC reaction, the a-diastereomer did not give defined
products. Although 43 could be converted into diol 44 with
high stereocontrol, this approach was abandoned due to the
low efficiency of the INOC step. Instead, it was decided to
use the INOC reaction for an annulation of ring B to an al-
ready existing cyclohexene ring A, which should be derived
from d-()-quinic acid (45) as an inexpensive chiral starting
material (Scheme 13).
Scheme 13.
Figure 1. Crystal structure of compound 43.
Scheme 12.
Scheme 14.
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Hence, in a model study, 46 was prepared from 45 as de-
scribed[12,13] and transformed into cyclohexene diol 51 by
means of the sequence shown in Scheme 14, with stereocon-
trolled hydroboration/oxidation (47 to 48) and Corey–Hop-
kins elimination[14] (49 to 50) as the key steps.
AWittig–Still rearrangement was used to generate alcohol
52 (Scheme 15), which was oxidized to aldehyde 53. Non-
stereocontrolled addition of alkyne 54 furnished an epimeric
mixture of alcohol 55 that was separated. The b-epimer was
used in an INOC annulation via aldehyde 57 and oxime 58,
which were both stable towards E/Z isomerization. Nitrile
oxide formation and cycloaddition occurred in situ to fur-
nish isoxazoline 59 in a diastereomerically pure form. En-
couraged by this success, we decided to prepare the fully
substituted core compound. Thus, as shown in Scheme 16,
45 was converted into silyl dienol ether 60,[15] to which dime-
thoxymethane was added under trimethylsilyl trifluorome-
thanesulfonate (TMSOTf) catalysis with high axial prefer-
Scheme 15.
Scheme 16.
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ence (indicated by vertical arrow) to give cyclohexenone de-
rivative 61. Reduction under Luche conditions furnished al-
lylic alcohol 62 stereoselectively, which was converted into
ester 63 under inversion of configuration. Claisen–Ireland
rearrangement[16] smoothly gave acid 64 as a single stereo-
isomer. After reduction to alcohol 65, the INOC annulation
sequence was performed and indeed led to isoxazoline 70 in
high overall yield (Schemes 17 and 18). However, all at-
tempts to generate the desired hydroxy ketone failed. Either
ether 71 was obtained (which demonstrated the proximity of
functional groups in cis-decalin systems such as 73) or over-
reduction to 72 occurred. To rescue the approach, the
double bond was protected as an acetonide in 75. In fact,
hydroxy ketone 76 was now formed without problems and
protected as the triethylsilyl (TES) ether 77 (Scheme 19).
However, although vinyl magnesium bromide could be
Scheme 18.
Scheme 19.
Scheme 17.
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added to give 78 stereoselectively, isopropenyl magnesium
bromide did not react at all.
To exploit the INOC approach further, the possibility of
introducing the appendage in ring B prior to annulation was
investigated (Scheme 20). Thus aldehyde 68a was converted
into adduct 80 through Crimmins aldolization[17] with oxazo-
lidinethione 79. Tesylation and reduction gave aldehyde 81
and after the usual INOC procedure, isoxazoline 83 was ob-
tained. Reductive ring opening to hydroxy ketone 84 was
successful; however, as extensive epimerization occurred,
the INOC approach was abandoned as a whole.
Ring-Closing Metathesis (RCM) Annulation
Following the general retrosynthetic concept depicted in
Scheme 21, intermediate 62 was chosen as a substrate for a
Claisen–Ireland rearrangement (Scheme 22). It turned out
that diol 86 could be acylated at the allylic alcohol position
with high regioselectivity to give ester 88. The remaining hy-
droxyl function was TES-protected and a Claisen–Ireland
rearrangement was performed to give acid 90, which was
converted to olefin 93 as shown. After desilylation to 94, an
analogous sequence was performed that furnished the de-
sired diolefin 98.
RCM of 98 with HoveydaKs catalyst[18] gave cis-dehydrooc-
talin 99 (Scheme 23), which was converted into enone 101
with high yield. Stereo- and regioselective epoxidation of
the electron-rich double bond led to epoxide 102, diastereo-
merically pure according to the 1H NMR spectrum
(Figure 2) after chromatography, which is now ready for the
addition of side chain 5. From alkoxide 103, the desired
cyclic ether 104 should be formed.
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Figure 2. 1H NMR spectrum (CDCl3, 400 MHz) of epoxide 102.
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ABSTRACT
Starting from (−)-quinic acid an efficient synthesis of highly functionalized cis-r,â-unsaturated ketone 3, an advanced precursor of branimycin,
has been accomplished via two key step reactions: a ring closing metathesis reaction to prepare the cis-decalin system, and a highly
stereoselective epoxidation reaction.
The synthesis of highly functionalized cis-decalin systems
has been a longstanding problem. In many cases Diels-
Alder-based annulations to p-quinoids have been employed,
but despite the conceptual simplicity of this approach the
subsequent elaboration of stereogenic centers and appendages
has proved problematic. Intrigued by the low price of quinic
acid we looked for possibilities to annulate a second ring to
this template. By using a non-Diels-Alder methodology, a
richly elaborated cis-decalin system should be generated. As
a target for this strategy we chose branimycin (1),1,2 an
unusual member of the nargenicin antibiotic family,3 which
has been isolated from Streptomyces by the Laatsch group
in Go¨ttingen.4 Biological tests have shown that branimycin
is active against Escherichia coli, Bacillus subtilis, Staphylo-
coccus aureus, and in particular Streptomyces Viridochro-
mogenes. Apart form the biological activity, the complex
cis-fused decalin core, the 1,4-oxygen bridge, and the
9-membered macrolide ring make 1 an attractive target for
total synthesis.
The retrosynthetic concept is shown in Figure 1. As a key
disconnection the 1,2-addition of vinyllithium subunit 2 to
bicyclic 7,8-epoxy-12-ketone 3 was envisaged. This highly
convergent approach necessitates efficient syntheses of both
2 and 3. As outlined before, (-)-quinic acid5 7 was chosen
as a starting material for 3, to explore whether the existing
chiral centers could be used to control the synthesis of an
enantiomerically and diastereomerically pure cis-decalin
system. Ring B should be constructed by a ring closing
metathesis6 (RCM) of 4, in which the required monosubsti-
tuted double bonds were to be installed via two successive
Claisen-Ireland rearrangements,7 from protected diol precur-
(1) Enev, V. S.; Drescher, M.; Kaehlig, H.; Mulzer, J. Synlett 2005, 14,
2227-2229.
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sor 5. In turn, 5 would be assembled in stereoselective
fashion from enone 6.
Our synthesis started from the known compound 8,8 which
was subjected to a Mukaiyama-type condensation with
dimethoxymethane9 (Scheme 1) to afford 6 as a single
diastereomer in moderate yield (55%, 78% after recycling).
The same stereoselectivity has been observed with use of
m-CPBA and NBS as electrophiles, which is a consequence
of the conformational rigidity due to the trans-diequatorial-
protected 1,2-diol. An axial attack on the electron-rich C9
avoids a twist boat conformation.10
Longer reaction times improved the yield remarkably, but
with a sacrifice in diastereomeric ratio. Luche reduction of
6 occurred exclusively from the less hindered side. This
newly formed stereocenter is planned to be inverted in a later
stage of the synthesis. Benzylation and removal of the BDA11
group furnished diol 9 in 80% yield over three steps.
Conversion of 9 to 5 was achieved in a two-step sequences
regioselective acylation of the C7-hydroxy group of 9 (p-
MeOC6H4OCH2COCl,12 2,6-di-tert-butylpyridine,13 82% yield)
followed by TES protection at the C8-hydroxy groupswhich
set the scene for the first Claisen-Ireland rearrangement.
Following Corey’s procedure14 ester 5 was converted to the
silylketene acetal under internal quench conditions (TMSCl/
LHMDS) and subsequently heated to give 10 (94% after one
recycling step) as a mixture of isomers (Scheme 2). The low
stereoselectivity for C12 was inconsequential as this stereo-
genic center becomes oxidized later in the synthesis.
Nevertheless, the diastereomers were separated to avoid
ambiguous spectra information for the proximate reaction
steps. The synthesis was carried on with pure main isomer
10, whose configuration was assigned by 2D NMR studies
of the corresponding iodolactone 10a.15
Acid 10 was transformed to olefin 11 in 3 steps via
reduction to the corresponding aldehyde and subsequent
(8) Murray, L. M.; O’Brien, P.; Taylor, R. J. K. Org. Lett. 2003, 5, 1943-
1946.
(9) Murata, S.; Suzuki, M.; Noyori, R. Tetrahedron 1988, 13, 4259-
4275.
(10) (a) Murray, L. M.; O’Brien, P.; Taylor, R. J. K. Org. Lett. 2003, 5,
1943-1946. (b) Mathews, R. S.; Girgenti, S. J.; Folkers, E. A. J. Chem.
Soc., Chem. Commun. 1970, 708-709. (c) House, H. O.; Umen, M. J. J.
Org. Chem. 1973, 38, 1000-1003. (d) Skaddan, M. B.; Wu¨st, F. R.;
Katzenellenbogen, J. A. J. Org. Chem. 1999, 64, 8108-8121.
(11) Ley, S. V.; Baeschlin, D. K.; Dixon, D. J.; Foster, A. C.; Ince, S.
J.; Priepke, H. W. M.; Reynolds, D. J. Chem. ReV. 2001, 101, 53-80.
(12) Piers, E.; Lemieux, R. Organometallics 1995, 14, 5011-5012.
(13) It has to be pointed out that use of pyridine or 2,6-lutidine resulted
in a 1:1 mixture of C-7/8 O-acyl regioisomers.
(14) Corey, E. J.; Gross, A. Tetrahedron Lett. 1984, 25, 495-498.
(15) Selected NOE data for 10a.
Figure 1. Retrosynthetic analysis.
Scheme 1. Synthesis of Rearrangement Precursor 5
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Wittig olefination16 in 84% overall yield. To initiate the
second Claisen-Ireland rearrangement 11 was desilylated
and the resulting allylic alcohol was acylated to give ester
12 via Mitsunobu inversion.17 In the course of this reaction
the C6-appendage was introduced simultaneously. The
conversion of 12 to di-olefin 4 followed the established four-
step sequence: rearrangement to 13, followed by esterifi-
cation, reduction to the corresponding aldehyde, and Wittig
olefination (dr 2:1, 56% overall yield). The RCM reaction
was carried out with either the Grubbs’ second generation
catalyst18 or Hoveyda-Grubbs’ second generation catalyst.19
Unfortunately it turned out that Grubbs’ second generation
catalyst underwent decomposition in the course of the
reaction at the required temperature (ca 75 °C), whereas
Grubbs-Hoveyda catalyst was stable enough to give 65%
of cis-decalin 14 with only starting material left, which could
be recycled (Scheme 3). After chromatographic separation
the pure isomer 14 was deprotected (DDQ/DCM/buffer) and
subsequently oxidized (DMP)20 to give 15 in 78% yield
(Scheme 3). 2D NMR spectra confirmed that none of the
dreaded epimerization at C11 had occurred.
Stereo- and regioselective epoxidation of the C7-C8
double bond with m-CPBA furnished diastereomerically pure
crystalline epoxyketone 16 whose relative configuration was
established by single-crystal diffraction (Figure 2).
In conclusion, we have shown that quinic acid is a suitable
substrate for stereocontrolled annulations via the Claisen-
Ireland rearrangement; RCM protocol. Quite obviously the
configurations at C6 and C11 can be manipulated at will by
acylating diol 9 under retention or inversion of configuration
so that cis- and trans-decalins with either absolute config-
uration should be available under perfect stereocontrol.
Specifically, we have described an efficient route to the cis-
decalin core of branimycin, whose further synthesis is
actively pursued in our laboratory.
(16) Cadogan, J. I. G. Orgnanophosphorus Reagents in Organic Syn-
thesis; Academic Press: New York, 1979.
(17) Mitsunobu, O. Synthesis 1981, 1, 1-28.
(18) Grubbs, R. H.; Schwab, B.; Ziller, J. W. J. Am. Chem. Soc. 1996,
118, 100-110.
(19) (a) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. J.
Am. Chem. Soc. 2000, 122, 8168-8179. (b) Gessler, S.; Randl, S.; Blechert,
S. Tetrahedron Lett. 2000, 41, 9973-9976.
(20) Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155-4156.
(21) Farrugia, L. J. J. Appl. Crystallogr. 1997, 30, 565.
Scheme 2. Preparation of RCM Precursor 4 Scheme 3. Synthesis of Epoxyketone 16
Figure 2. ORTEP-321 projection (ellipsoid: 50% probability) of
epoxyketone 3.
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cis-Decalins from Quinic Acid: Toward a Synthesis of 
Branimycin – Supporting Information 
 
Stefan Marchart, Johann Mulzer,* and Valentin S. Enev* 
Institut für Organische Chemie, Währinger Strasse 38, A – 1090 Vienna, Austria 
 
General Information 
The following general procedures were used in all reactions unless otherwise noted. Reaction 
vessels were dried by repeated heating under vacuum (heat gun) followed by purging with 
dry argon. Oxygen- and moisture sensitive reactions were carried out under a slight argon 
overpressure (balloon) and in dry solvents. Sensitive liquids and solutions were transferred 
by double tipped needle or syringe through rubber septa. All reactions were stirred 
magnetically if not stated otherwise. 
 
Solvents 
The solvents used were purified and dried according to common procedures as follows. Dry 
solvents were stored under Argon over molsieve (4 Å). 
• Acetone was distilled from phosphorpentoxide. 
• Benzene, toluene and xylene were refluxed over potassium and freshly distilled. 
• Chloroform was filtered through basic aluminium oxide (desiccant form), refluxed over 
phosphorpentoxide and freshly distilled. 
• Dichloromethane was distilled from CaH2 or phosphorpentoxide. 
• Diethyl ether was predried over NaOH, refluxed over LiAlH4 and freshly distilled. 
• Dimethylformamide was refluxed over CaH2 and distilled in vacuum. 
• Hexane and ethyl acetate for chromatography were purified by distillation using a column. 
• Methanol was treated with magnesium filings, refluxed for several hours and then distilled. 
• Pyridine was distilled from KOH. 
• Tetrahydrofuran was filtered through basic aluminium oxide (desiccant form), refluxed 
over sodium/benzophenone ketyl and freshly distilled. All other solvents were HPLC grade 
or were purified and dried by standard methods. 
 
48
SUPPORTING INFORMATION S2 
Chemicals 
All commercially available reagents were purchased in the best quality available and used 
without further purification unless stated otherwise.  
 
Chromatography 
Thin-layer chromatography (TLC) 
All reactions were monitored using Merck silica gel 60 F254 plates. The plates were usually 
developed with a mixture of hexane / ethyl acetate. Unless the compound was coloured, UV-
active spots were detected at 254 nm. Most plates were additionally treated with one of the 
following visualization reagents: Anisaldehyde [anisaldehyde (6 g) in ethanol (250 ml) + 
conc. H2SO4 (25 mL)], Ceric sulfate [H2SO4 (10 %, 100 ml), phosphormolybdic acid (4.5 g), 
Ce(IV)SO4 (0.1 g)], Vanillin [vanillin (6 g) in ethanol (250 ml) + conc. H2SO4]. 
 
Column chromatography 
Preparative column chromatography and flash chromatography was performed with silica gel 
60 from Merck (0.040-0.063 µm, 240 - 400 mesh). 
 
Analytic and preparative HPLC 
For the determination of diastereomeric ratios etc. in analytical scale module systems from 
Jasco (PU-980, UV-975 UV detector, RI-930 RI detector, 250 × 4 mm column) were used. 
The adsorbent was Supersphere Si 60 (4 µm, Merck) or Nucleosil 50 (4 µm, Macherey- 
Nagel). The semipreparative and preparative scale was covered by module systems from 
Dynamax (SD-1 pump, UV-1 UV detector) and Knauer (RI detector). Compounds separated 
by preparative HPLC were checked by analytical HPLC on homogenity.  
 
NMR spectroscopy 
NMR spectra were recorded on either a Bruker Avance DPX 250 MHz, a Bruker Avance 
DRX 400 MHz or a Bruker Avance DRX 600 MHz spectrometer. Unless otherwise stated, all 
NMR spectra were measured in CDCl3 solutions and referenced to the residual CDCl3 signal 
(1H, δ = 7.26; 13C, δ = 77.0) or the TMS signal (1H, δ = 0.0; 13C, δ = 0.0). The following 
abbreviations are used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, b = broad, dd = doublet of doublets, dt = doublet of triplets, dq = 
doublet of quartets, ddd = doublet of doublet of doublet, dddd = doublet of doublet of doublet 
49
SUPPORTING INFORMATION S3 
of doublet etc.; other combinations derive from those listed. Coupling constants J are given in 
Hz; assignments of proton resonances were confirmed, when possible, by selective 
homonuclear decoupling experiments or by correlation spectroscopy. 
 
Mass spectroscopy 
Mass spectra were measured on spectrometers from Micro Mass, Fisions Instrument and 
Trio200. Stated, is the kind of ionization (in most cases EI, Electron Impact; occasionally 
FAB, Fast Atom Bombardment) and electron activation energy (in eV). HRMS (High 
Resolution Mass Spectra) were taken with a Finnigan MAT 8230 with a resolution of 10000. 
 
Infrared spectroscopy 
IR spectra were recorded using a Perkin-Elmer 1600 Series FTIR spectrometer and are 
reported in wave numbers (cm-1). All compounds were measured as a thin film on a silicon 
single crystal plate (Si-pellet).  
 
 
 
Polarimetry 
Optical rotations were measured on a P 341 Perkin-Elmer polarimeter. The length of the 
measuring chamber is 1 dm and the solution is kept at 20.0°C. The optical rotation is 
measured with monochromatic sodium light (589 nm) and unless otherwise stated CHCl3 is 
used as solvent.  
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 (2R, 3S, 4aR, 5S, 8aS)- 2,3-Dimethoxy-5-methoxymethyl-2,3-dimethyl-2,3,4a,8a-
tetrahydro-5H-benzo[1,4]dioxin-6-one (6) 
 
O
O
OMe
OMe
OTMS
O
O
OMe
OMe
O
O
 
 
To a solution of the enol trimethylsilyl ether (13.0 g, 41.3 mmol) in DCM (80 mL) 2,6-di-
tert-butylpyridine (0.94 mL, 4.2 mmol) and dimethoxymethane (6.3 g, 82.9 mmol) were 
added and the reaction mixture was cooled to 0 °C. TMSOTf (0.756 mL, 4.2 mmol) was 
added dropwise, the reaction was stirred for 2 h at 0 °C and  quenched with a saturated 
NaHCO3 solution. The phases were separated and extracted with DCM (3 x 70 mL), dried 
over MgSO4 and the solvent was removed under reduced pressure. The crude product was 
purified by HPLC to yield 6.5 g (55 %) of the desired product and 6.0 g of starting material.
 
1H-NMR (250 MHz, CDCl3): = 6.80 (1H, dd, J = 10.1, 1.7 Hz), 5.99 (1H, dd, J = 10.2, 2.6 
Hz), 4.88 (1 H, td, J = 9.3, 2.1 Hz), 4.16 (1H, dd, J = 9.4, 6.4 Hz), 3.87 (1 H, dd, J = 9.1, 3.9 
Hz), 3.76 (1 H, dd, J =9.3, 3.9 Hz), 3.29 (3 H, s), 3.28 (3 H, s), 3.23 (3 H, s), 2.71 (1 H, m), 
1.34 (3 H, s), 1.32 (3 H, s) 
13C-NMR (100.6 MHz, CDCl3): = 198.8, 148.5, 129.8, 100.7, 99.9, 69.3, 69.1, 
 66.1, 60.4, 59.2, 50.2, 48.0, 31.6, 22.6, 17.8, 17.6, 14.2 
IR (Si, Film)  max = 3346, 2950, 2833, 1683, 1619, 1455, 1110, 1012, 931, 901, 611, 571 
MS (EI, 70 eV, 40 °C): m/z = 255, 218, 197, 176, 154, 138, 123, 101, 73, 55 
HRMS (EI, 70 eV, 60 °C) calc. for C13H19O5 (= M+ - MeOH): 255.1232;  
found: 255.1236 
[ ]D
20   + 77.8 (c = 0.65 CHCl3) 
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(2R, 3S, 4aR, 5S, 6R, 8aS)- 2,3-Dimethoxy-5-methoxymethyl-2,3-dimethyl-2,3,4a,5,6,8a-
hexahydro-benzo[1,4]dioxin-6-ol 
 
O
O
OMe
OMe
O
O
O
OMe
OMe
OO
OH
 
 
A solution of ketone 6 (3 g, 10.5 mmol) in MeOH (50 ml) was cooled to 0 °C, CeCl3 (472 
mg, 1.3 mmol) was added and the solution was stirred for 15 min. NaBH4 (472 mg, 12.5 
mmol) was added portionwise and after 15 min. the reaction was quenched with NH4Cl. The 
solvent was removed under reduced pressure and the product was hydrolysed with H2O (20 
mL) and EtOAc (100 mL). The two phases were separated and the aqueous phase was 
extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with brine, 
dried over MgSO4 and the solvent was removed under reduced pressure to give 3.1 g (100 %) 
of the desired alcohol as a viscous oil.  
 
1H-NMR (250 MHz, CDCl3): = 5.73 (1 H, dd, J = 10.3, 1.4 Hz), 5.55 (1 H, dd, J = 10.2, 
2.0 Hz), 4.59 (1 H, m), 4.14 (1 H, m), 3.81 (3 H, m), 3.65 (1 H, t, J = 9.3 Hz), 3.36 (3 H, s), 
3.25 (3 H, s), 3.23 (3 H, s), 2.59 (1 H, m), 1.30 (3 H, s), 1.29 (3 H, s) 
13C-NMR (100.6 MHz, CDCl3): = 133.1, 125.5, 100.8, 100.7, 70.9, 69.4, 68.9, 66.2, 59.3, 
48.2, 48.2, 42.5, 18.2, 18.1 
IR (Si, Film) max = 3476, 2992, 2949, 2900, 2833, 1456, 1376, 1130, 1042, 933,  
MS (EI, 70 eV, 60 °C): m/z = 257, 225, 156, 140, 101, 78, 55 
HRMS (EI, 70 eV, 60 °C) calc. for C13H21O5 (= M+ - MeOH): 257.1389; found: 257.1384 
[ ]D
20   + 47.3 (c = 1.11, CHCl3) 
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(2R, 3S, 4aR, 5S, 6R, 8aS)-6-Benzyloxy-2,3-dimethoxy-5-methoxymethyl-2,3-dimethyl-
2,3,4a,5,6,8a-hexahydro-benzo[1,4]dioxine 
 
O
O
OMe
OMe
O
OH
O
O
OMe
OMe
O
OBn
 
 
To a solution of the alcohol (1 g, 3.5 mmol) in THF (15 mL) NaH (220 mg, 5,25 mmol) was 
added and the reaction mixture was stirred until no gas evolution occurred anymore (0.5 h). 
Then DMF (15 mL), BnBr (0.623 mL, 5.25 mmol) and a catalytic amount of Bu4NI were 
added and the reaction mixture was stirred at rt. for 18 h. The reaction was quenched with 
NH4Cl, THF was removed under reduced pressure and the solution was diluted with toluene 
(100 mL). The organic layer was separated, extracted with H2O (3 x 15 mL) and washed with 
brine. Toluene was removed under reduced pressure. The crude product was purified by 
column chromatography (hex:EtOAc = 3:1) to yield 1.22 g (93 %) of the desired product as a 
viscous oil. 
 
1H-NMR (250 MHz, CDCl3): = 7.40 – 7.23 (5H, m), 5.67 (1H, d, J = 10.4 Hz), 5.60 (1H, 
d, J = 10.4 Hz, ), 4.85 (1H, d, J = 11.6 Hz, ), 4.45 (1H, d, J = 11.4 Hz), 4.33 (1H, m), 4.23 
(1H, m), 3.76 (1H, dd, J = 9.3, 4.0 Hz), 3.71 (1H, dd, J = 9.1, 2.0 Hz), 3.57 (1H, dd, J = 9.1, 
7.1 Hz), 3.34 (3H, s), 3.26 (3H, s), 3.24 (3H, s), 2.69 (1H, m), 1.31 (3H, s), 1.30 (3H, s). 
13C-NMR (100.6 MHz, CDCl3): = 139.0, 131.1, 128.7, 128.2, 127.9, 100.7, 100.6, 76.7, 
71.2, 69.1, 68.2, 66.2, 59.2, 48.3, 48.2, 42.5, 42.0, 18.3, 18.2 
IR (Si, Film) max = 2950, 1719, 1497, 1454, 1375, 1114, 1049, 902, 849, 811, 739, 698, 611, 
514 
MS (EI, 70 eV, 60 °C): m/z = 347, 270, 230, 185, 139, 91, 78 
HRMS (EI, 70 eV, 60 °C) calc. for C20H27O5 (= M+ - CH3OH): 347.1858; found: 347.1853 
[ ]D
20   + 31.2 (c = 0.65, CHCl3) 
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(1R, 2R, 5R, 6R)-5-Benzyloxy-6-methoxymethyl-cyclohex-3-ene-1,2-diol (9) 
 
O
O
OMe
OMe
O
OBn
OH
OH
O
OBn
 
 
To a solution of the dioxine (2.6 g, 7 mmol) in H2O (7 mL) was added TFA (20 mL, 261 
mmol) and the reaction mixture was stirred for 5 min at rt. It was transferred slowly to a 
stirred mixture of a saturated Na2CO3 solution (150 mL) and Et2O (200 mL). The aqueous 
layer was extracted with Et2O (5 x 60 mL). The combined organic layers were washed with 
brine and dried over MgSO4, and the solvent was removed under reduced pressure. The crude 
product was filtered off over silica gel (hex:EtOAc = 2:1) to yield 1.55 g (86 %) of the diol. 
 
1H-NMR (400 MHz, CDCl3): = 7.39 – 7.26 (5H, m), 5.90 (1H, ddd, J = 10.2, 2.8, 1.0 Hz), 
5.85 (1H, ddd, J = 10.3, 2.8, 1.3 Hz), 4.59 (2H, s), 4.28 (1H, m), 4.20 (1H, m), 3.80 (2H, m), 
3.67 (2H, m), 3.38 (3H, s), 2.72 (1H, m), 2.25 (1H, s) 
13C-NMR (100.6 MHz, CDCl3): = 138.2, 129.7, 129.3, 128.9, 128.3, 128.0, 74.7, 74.0, 71.7, 
71.5, 70.5, 59.7, 40.4 
IR (Si, Film) max = 3417, 3031, 2917, 1953, 1732, 1651, 1607, 1498, 1456, 1394, 1197, 
1107, 803, 752, 698, 667, 514 
MS (EI, 70 eV, 40 °C): m/z = 246, 176, 156, 140, 124, 107, 91, 78, 65 
HRMS (EI, 70 eV, 40 °C) calc. for C15H18O3 (= M+ - H2O): 246.1256; found: 246.1259 
[ ]D
20   - 107.2 (c = 0.53, CHCl3) 
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(1R, 4R, 5R, 6R)-(4-Methoxy-benzyloxy)-acetic acid 4-benzyloxy-6-hydroxy-5-
methoxymethyl-cyclohex-2-enyl ester 
 
OBn
O
OH
OH
OBn
O
OH
O
PMBO
O  
 
A solution of 9 (1 g, 3.78 mmol) in toluene (10 mL) was cooled down to – 18 °C. Then 2,6-
di-tert-butylpyridine (4 mL) was added, and after 5 min. p-methoxybenzoyl acetic acid 
chloride (810 mg, 3.78 mmol) was added dropwise over 15 min. After stirring at – 18 °C for 
2 h the reaction mixture was warmed to rt. After 5 h the reaction was quenched with saturated 
NaHCO3 solution and diluted with toluene (140 mL). The organic layer was separated, 
washed with H2O (2 x 10 mL), and the solvent was removed under reduced pressure. The 
crude product was purified by column chromatography (hex:EtOAc = 5:1) to yield 1.37 g (82 
%) of the desired product. 
 
1H-NMR (400 MHz, CDCl3): = 7.38 – 7.27 (7H, m), 6.88 (2H, d, J = 8.8 Hz), 6.10 (1H, 
ddd, J = 10.2, 3.8, 1.1 Hz), 5.87 (1H, dd, J = 10.1, 3.8 Hz), 5.42 (1H, dd,  J = 4.8, 3.8 Hz), 
4.63 (1H, d, J = 11.6 Hz), 4.57 (1H, d, J = 11.4 Hz), 4.56 (2H, s), 4.16 (1H, m), 4.10 (1H, d, 
J = 16.4 Hz), 4.04 (1H, d, J = 16.4 Hz), 3.85 (1H, m), 3.80 (3H, s), 3.76 (1H, dd, J = 11.5, 
9.4 Hz), 3.68 (1H, dd, J = 9.8, 9.0 Hz), 3.39 (3H, s), 2.54 (1H, m) 
13C-NMR (100.6 MHz, CDCl3): = 170.3, 160.0, 138.0, 131.4, 130.2, 130.1, 129.6, 129.0, 
128.8, 128.4, 128.1, 126.4, 114.3, 73.4, 72.4, 72.2, 72.0, 71.2, 70.6, 67.2, 67.1, 60.8, 59.7, 
55.7, 40.6 
IR (Si, Film) max = 3480, 2914, 1733, 1615, 1586, 1516, 1456, 1107, 823, 700, 514 
MS (ESI): m/z = 465, 447, 441, 425, 395, 349, 328, 310, 287 
HRMS (ESI) calc. for C25H30O7Na (= M+ + Na): 465.1889; found: 465.1902 
[ ]D
20   - 144.9 (c = 0.74, CHCl3) 
 
 
55
SUPPORTING INFORMATION S9 
(1R, 4R, 5R, 6R)-(4-Methoxy-benzyloxy)-acetic acid 4-benzyloxy-5-methoxymethyl-6-
triethylsilanyloxy-cyclohex-2-enyl ester (5) 
 
OBn
O
OH
O
PMBO
O
OBn
O
OTES
O
PMBO
O  
 
To a solution of the starting material (3.9 g, 8.8 mmol) in DCM (100 mL), 2,6-lutidine (3.08 
mL, 26.4 mmol) was added, and the mixture was cooled to – 78 °C. TESOTf (3.19 mL, 14.08 
mmol) was added dropwise over 15 min. and the reaction mixture was stirred for 30 min. at – 
78 °C. Then it was warmed to rt and after 1.5 h quenched with saturated NaHCO3 solution. 
The mixture was diluted with toluene (600 mL) and H2O (100 mL), the organic layer was 
separated and the aqueous phase was extracted with toluene (2 x 100 mL). The combined 
organic layers were washed with brine and the solvent was removed under reduced pressure. 
The crude product was filtered off over silica gel (hex:EtOAc = 5:1) to yield 5 (4.90 g, 100 
%). 
 
1H-NMR (400 MHz, CDCl3): = 7.40 – 7.25 (7H, m), 6.88 (2H, d, J = 8.8 Hz), 5.89 (1H, d, 
J = 10.4 Hz), 5.62 (1H, td, J = 10.2, 2.6 Hz), 5.28 (1H, ddd, J = 6.8, 4.6, 2.3 Hz), 4.73 (1H, d, 
J = 11.6 Hz), 4.58 (1H, d, J = 11.4 Hz), 4.54 (1H, d, J = 11.4 Hz), 4.52 (1H, d, J = 11.6 Hz), 
4.18 (1H, m), 4.05 (2H, s), 3.93 (1H, dd, J = 6.8, 3.8 Hz), 3.80 (3H, s), 3.69 (1H, dd, J = 9.3, 
3.5 Hz), 3.63 (1H, dd, J = 9.0, 6.4 Hz), 3.33 (3H, s), 2.51 (1H, m), 0.95 (9H, t, J = 8.0 Hz), 
0.60 (6H, q, J = 8.0 Hz) 
13C-NMR (100.6 MHz, CDCl3): = 170.4, 159.9, 139.0, 132.6, 130.2, 129.5, 128.7, 128.1, 
127.9, 125.5, 114.3, 74.3, 73.7, 73.3, 71.1, 70.2, 68.6, 67.2, 59.3, 55.7, 45.2, 7.1, 5.3 
IR (Si, Film) max = 2955, 2913, 1755, 1733, 1613, 1515, 1456, 1390, 1303, 1250, 1194, 
1108, 1030, 961, 822, 743, 698 
MS (ESI): m/z = 579, 521, 487, 465, 459, 415 
HRMS (ESI) calc. for C31H44O7SiNa (= M+ + Na): 579.2723; found: 579.2746 
[ ]D
20   - 74.9 (c = 0.55, CHCl3) 
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1-{[1(S),6(R)-Benzyloxy-5(R)-methoxymethyl-4(S)-triethylsilanyloxy-cyclohex-2-enyl]}-
1{[1(S)-4-methoxy-benzyloxy]}-acetic acid (10) 
 
OBn
O
OTES
O
PMBO
O
OBn
O
OTES
HO
O
PMBO OBn
O
OTES
HO
O
PMBO
+
H H
 
A solution of compound 5 (510 mg, 0.92 mmol) in THF (20 mL) was cooled to - 78 °C and 
TMSCl (0.62 mL, 6.6 mmol, dissolved in 5 mL THF) was added. After 5 min. LiHMDS (3.3 
mL, 1 M in toluene) was added quickly and the reaction was stirred for 30 min. at – 78 °C. 
Then it was allowed to warm to rt and heated at 60 – 65 °C for 3 h. The reaction mixture was 
quenched with a saturated NaHCO3 solution and diluted with toluene (40 mL) and H2O (3 
mL). The phases were separated and the pH of the aqueous phase was lowered to 3 with HCl. 
It was extracted with toluene (3 x 10 mL), the combined organic layers were washed with 
brine and the solvent was removed under reduced pressure. The crude product was filtered 
off over silica gel (hex:EtOAc = 5:1) and the diastereomeric ratio was estimated from crude 
NMR dr = 3:1. The combined yield was 418 mg (82 %). 
 
 
 
1-{[1(S),6(R)-Benzyloxy-5(R)-methoxymethyl-4(S)-triethylsilanyloxy-cyclohex-2-enyl]}-
1{[1(S)-4-methoxy-benzyloxy]}-acetic acid methyl ester 
 
OBn
O
OTES
HO
O
PMBO OBn
O
OTES
MeO
O
PMBO
H H
 
 
To a solution of acid 10 (240 mg, 0.43 mmol) in toluene:MeOH = 5:1 (1.5 ml, 0.3 mL) 
TMSCHN2 (0.216 ml, 2M in hexane) was added dropwise until no gas evolution occurred 
anymore. The reaction mixture was stirred for 10 min.  The solvents were removed under 
reduced pressure to yield a crude product (244 mg, 99 %, dr = 3:1) which after column 
chromatography gave 180 mg of the desired product. 
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1H-NMR (400 MHz, CDCl3): = 7.38 – 7.22 (7H, m), 6.86 (2H, d, J = 8.6 Hz), 5.60 (1H, d, 
J = 10.1 Hz), 5.38 (1H, td, J = 10.1, 2.4 Hz), 4.70 (1H, d, J = 11.6 Hz), 4.61 (1H, d, J = 10.9 
Hz), 4.38 (1H, m), 4.34 (1H, d, J = 11.8 Hz), 4.34 (1H, d, J = 10.4 Hz), 3.98 (1H, d, J = 3.3 
Hz), 3.86 (1H, d, J = 8.6, 3.8 Hz), 3.80 (3H, s), 3.60 (1H, dd, J = 9.3, 4.5 Hz), 3.55 ( 1H, dd, 
J = 9.3, 4.3 Hz), 3.45 (3H, s), 3.27 (3H, s), 2.81 (1H, m), 2.48 (1H, m), 0.98 (9H, t, J = 8.0 
Hz), 0.63 (6H, q, J = 7.9 Hz)  
13C-NMR (100.6 MHz, CDCl3): = 172.4, 159.8, 139.0, 133.3, 130.0, 130.0, 128.7, 128.4, 
127.7, 126.7, 114.1, 77.2, 74.3, 72.4, 70.9, 68.7, 68.4, 59.0, 55.7, 51.9, 44.1, 42.9, 7.3, 5.3 
IR (Si, Film) max = 3033, 2953, 2876, 1721, 1612, 1586, 1514, 1456, 1303, 1249, 1173, 
1108, 1036, 849, 745, 700, 514 
MS (ESI): m/z = 593, 577, 551, 503, 473, 439 
HRMS (ESI) calc. for C32H46O7SiNa (= M+ + Na): 593.2911; found: 593.2921 
[ ]D
20   + 114.0 (c = 0.35, CHCl3) 
 
 
1-{[1(S),6(R)-Benzyloxy-5(R)-methoxymethyl-4(S)-triethylsilanyloxy-cyclohex-2-enyl]}-
1{[1(R)-4-methoxy-benzyloxy]}-acetaldehyde 
 
OBn
O
OTES
MeO
O
PMBO OBn
O
OTES
H
O
PMBOH H
 
 
 A solution of the methyl ester (1.719 g, 3.02 mmol) in DCM (50 ml) was cooled to – 78 °C. 
DIBALH (6.03 mL, 1 M in toluene) was added dropwise and stirred for 3 h. The reaction 
mixture was quenched with MeOH and Na-K-tartrate at – 78 °C, allowed to warm to rt and 
stirred for 18 h. It was diluted with toluene, the phases were separated and the aqueous phase 
was extracted with toluene (2 x 10 mL). The combined organic layers were washed with 
brine and the solvent  
was removed under reduced pressure. The crude product was filtered off over silica gel 
(hex:EtOAc = 5:1) to yield 1.52 g (93 %) of the desired aldehyde. 
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1H-NMR (400 MHz, CDCl3): = 9.47 (1H, d, J = 1.0 Hz), 7.29-7.15 (7H, m), 6.81 (2H, d, J 
= 8.6 Hz), 5.53 (1H, d, J = 10.1 Hz), 5.35 (1H, td, J = 10.2, 2.2 Hz), 4.60 (1H, d, J = 11.6 
Hz), 4.56 (1H, d, J = 11.1 Hz), 4.43 (1H, d, J = 11.6 Hz), 4.34 (1H, m), 4.30 (1H, d, J = 11.4 
Hz), 3.77 (1H, d, J = 3.8 Hz), 3.76 (1H, m), 3.75 (3H, s), 3.53 (1H, dd, J = 9.6, 4.3 Hz), 3.47 
(1H, dd, J = 9.5, 4.4 Hz), 3.20 (3H, s), 2.79 (1H, td, J = 8.9, 3.0 Hz), 2.46 (1H, m), 0.92 (9H, 
t, J = 8.0 Hz), 0.57 (6H, q, J = 7.8 Hz) 
13C-NMR (100.6 MHz, CDCl3): = 202.6, 159.9, 138.4, 134.0, 130.1, 129.8, 128.7, 128.0, 
126.7, 114.2, 83.4, 74.2, 72.9, 70.8, 68.8, 68.3, 59.2, 55.7, 43.8, 42.8, 7.2, 5.2 
IR (Si, Film) max = 3034, 2954, 1742, 1739, 1733, 1729, 1616, 1520, 1516, 1467, 1248, 
1204, 1173, 1107, 1030, 744, 699, 514,  
MS (ESI): m/z = 563, 549, 533, 509, 505, 475, 445, 429, 413, 401, 393 
HRMS (ESI): calc. for C31H44O6SiNa (= M+ + Na): 563.2804; found: 563.2793 
[ ]D
20   + 97.7 (c = 0.97, CHCl3) 
 
 
 (1S)-{5(S)-Benzyloxy-4(S)-[1(R)-(4-methoxy-benzyloxy)-allyl]-6(R)-methoxymethyl-
cyclohex-2-enyloxy}-triethyl-silane (11) 
 
OBn
O
OTES
H
O
PMBO OBn
O
OTES
H
PMBO
HH
 
 
In THF (18 mL) Ph3PCH3Br (1.53 g, 4.07 mmol) and tBuOK (0.457 g, 4.07 mmol) were 
dissolved and refluxed for 5 min. The reaction mixture was cooled to rt and the aldehyde 
(1.465 g, 2.713 mmol in 10 ml THF) was added dropwise. After 10 min. the reaction was 
quenched with saturated NH4Cl solution, the phases were separated and the aqueous phase 
was extracted with Et2O (3 x 10 mL). The combined organic layers were washed with brine 
and dried over MgSO4. The solvent was removed under reduced pressure and the crude 
product was filtered off over silica gel (hex:EtOAc = 7:1) to yield 1.32 g (91 %) of the 
desired product. 
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1H-NMR (400 MHz, CDCl3): = 7.28 – 7.21 (5H, m), 7.19 (2H, d, J = 8.6 Hz), 6.82 (2H, d, 
J = 8.8 Hz), 5.65 (1H, td, J = 10.4, 2.4 Hz), 5.59 (1H, m), 5.57 (1H, m), 5.17 (1H, dd, J = 
10.4, 1.8 Hz), 4.95 (1H, dd, J = 17.1, 1.8 Hz), 4.59 (1H, d, J = 11.6 Hz), 4.45 (1H, d, J = 11.4 
Hz), 4.32 (1H, d, J = 11.6 Hz), 4.24 (1H, d, J = 11.4 Hz), 4.26 – 4.23 (1H, m), 3.91 (1H, dd, J 
= 8.6, 4.8 Hz), 3.76 (3H, s), 3.58 (1H, dd, J = 9.4, 4.7 Hz), 3.50 (1H, dd, J = 9.3, 5.0 Hz), 
3.45 (1H, dd, J = 8.1, 3.5 Hz), 3.24 (3H, s), 2.65 (1H, m), 2.40 (1H, m), 0.94 (9H, t, J = 8.0 
Hz), 0.59 (6H, q, J = 7.8 Hz) 
13C-NMR (100.6 MHz, CDCl3): = 159.4, 139.1, 136.5, 132.4, 131.2, 129.7, 128.6, 128.5, 
127.8, 126.3, 119.8, 114.1, 80.3, 75.3, 70.7, 70.2, 69.4, 68.1, 59.1, 55.7, 44.4, 42.3, 7.3, 5.3 
IR (Si, Film) max = 3033, 2954, 2876, 1613, 1586, 1514, 1497, 1455, 1417, 1388, 1302, 
1248, 1204, 1172, 1108, 1005, 849, 822, 743, 698 
MS (ESI): m/z = 561, 525, 488, 469, 429, 393, 370, 342 
HRMS (ESI): calc. for C32H46O5SiNa (= M+ + Na): 561.3012; found: 561.3010 
[ ]D
20   + 295.6 (c = 0.70, CHCl3) 
 
 
(1S)-{5(S)-Benzyloxy-4(S)-[1(R)-(4-methoxy-benzyloxy)-allyl]-6(R)-methoxymethyl}-
cyclohex-2-enol 
 
OBn
O
OTES
H
PMBO OBn
O
OH
H
PMBOH H
 
 
To a solution of compound 11 (1.27 g, 2.36 mmol) in MeOH (25 ml) NH4F (2.41 g, 65.11 
mmol) was added portionwise and the reaction mixture was stirred for 3 h at rt. Then the 
solvent was removed under reduced pressure. EtOAc (20 mL) and H2O (20 mL) were added, 
the phases were separated and the aqueous phase was extracted with EtOAc (3 x 20 mL). The 
combined organic layers were washed with brine, dried over MgSO4 and the solvent was 
removed under reduced pressure to yield 1 g (100 %) of the alcohol.  
 
1H-NMR (400 MHz, CDCl3): = 7.35 – 7.24 (5H, m), 7.21 (2H, d, J = 8.6 Hz), 6.86 (2H, d, 
J = 8.6 Hz), 6.01 (1H, ddd, J = 10.1, 4.5, 1.8 Hz), 5.73 (1H, ddd, J = 17.2, 10.3, 8.1 Hz), 5.59 
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(1H, dd, J = 10.1, 4.3 Hz), 5.32 (1H, dd, J = 10.4, 1.5 Hz), 5.16 (1H, dd, J = 17.2, 1.0 Hz), 
4.55 (1H, d, J = 11.9 Hz), 4.53 (1H, d, J = 11.4 Hz), 4.39 (1H, d, J = 11.9 Hz), 4.22 (1H, d, J 
= 11.4 Hz), 4.11 (1H, s), 4.00 (1H, m), 3.81 (3H, s), 3.70 (1H, dd, J = 9.4, 7.1 Hz), 3.50 (2H, 
dd, J = 9.1, 7.1 Hz), 3.29 (3H, s), 3.08 (1H, d, J = 10.6 Hz), 2.63 (1H, m), 2.04 (1H, m) 
13C-NMR (100.6 MHz, CDCl3): = 159.6, 138.6, 137.0, 131.7, 130.7, 129.9, 129.4, 129.0, 
128.8, 128.3, 128.1, 126.4, 119.6, 114.2, 80.6, 75.3, 71.9, 71.6, 70.1, 65.7, 59.3, 55.7, 44.3, 
39.7, 32.3, 30.1 
IR (Si, Film) max = 3522, 2923, 1613, 1514, 1455, 1247, 1060, 821, 749, 698 
MS (ESI): m/z = 447, 437, 393, 349, 327, 305 
HRMS (ESI): calc. for C26H32O5Na (=M+ + Na): 447.2147; found: 447.2142 
[ ]D
20   + 56.9 (c = 0.84, CHCl3) 
 
 
(1R)-Benzyloxy-acetic acid 5(S)-benzyloxy-4(S)-[1(R)-(4-methoxy-benzyloxy)-allyl]-
6(R)-methoxymethyl-cyclohex-2-enyl ester (12) 
 
OBn
O
OH
H
PMBO OBn
O
O
H
PMBO
OBn
O
H H
 
 
A solution of the alcohol (1.00 g, 2.36 mmol) in THF (25 ml) and DCM (25 mL) was cooled 
to 0 °C. Ph3P (2.75 g, 10.50 mmol) and 5 min. later benzyloxy acetic acid (1.38 g, 8.3 mmol) 
were added. After additional 5 min. DEAD (2.75 mL, 17.4 mmol) was added dropwise and 
the reaction mixture was stirred for 30 min. at 0 °C. Then the solution was stored at + 4 °C 
for 24 h. The reaction mixture was diluted with toluene (80 mL) and concentrated under 
reduced pressure. The crude product was purified by column chromatography (hex:EtOAc = 
4:1) to yield 1.02 g (76 %) of the desired product.  
 
1H-NMR (400 MHz, CDCl3): = 7.40 – 7.25 (10H, m), 7.23 (2H, d, J = 8.6 Hz), 6.86 (2H, 
d, J = 8.6 Hz), 5.83 (1H, dd, J = 10.2, 2.9 Hz), 5.77 (1H, ddd, J = 10.3, 3.0, 1.7 Hz), 5.66 
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(1H, ddd, J = 17.3, 10.3, 8.2 Hz), 5.50 (1H, m), 5.27 (1H, dd, J = 10.2, 1.6 Hz), 5.12 (1H, dd, 
J = 17.2, 1.3 Hz), 4.64 (2H, s), 4.52 (1H, d, J = 11.4 Hz), 4.50 (1H, d, J = 11.6 Hz), 4.46 (1H, 
d, J = 11.6 Hz), 4.27 (1H, d, J = 11.4 Hz), 4.08 (2H, s), 3.94 (1H, dd, J = 5.6, 3.3 Hz), 3.80 
(3H, s), 3.80 (1H, m), 3.53 (1H, dd, J = 9.4, 6.3 Hz), 3.29 (1H, dd, J = 9.2, 7.4 Hz), 3.23 (3H, 
s), 2.57 (1H, m), 2.30 (1H, ddd, J = 13.3, 6.7, 3.4 Hz) 
13C-NMR (100.6 MHz, CDCl3): = 170.4, 159.5, 138.8, 137.6, 136.4, 130.9, 130.5, 129.7, 
128.9, 128.7, 128.4, 128.4, 128.3, 128.0, 126.3, 119.9, 114.2, 80.6, 73.7, 73.3, 71.3, 70.7, 
70.4, 70.2, 67.7, 59.2, 55.7, 44.0, 40.4 
IR (Si, Film) max = 3033, 2920, 1750, 1732, 1615, 1586, 1515, 1498, 1455, 1422, 1393, 
1246, 1109, 823, 738, 698, 599, 515 
MS (ESI): m/z = 595, 577, 537, 495, 470, 430, 417 
HRMS (ESI): calc. for C35H40O7Na (=M+ + Na): 595.2672; found: 595.2666 
[ ]D
20   - 47.0 (c = 0.60, CHCl3) 
 
 
(1R)-Benzyloxy-1(S)-{5(S)-benzyloxy-6(S)-[1(R)-(4-methoxy-benzyloxy)-allyl]-4(R)-
methoxymethyl-cyclohex-2-enyl}-acetic acid (13) 
 
OBn
O
O
H
PMBO
OBn
O
H
OBn
O
H
PMBO
BnO
OHO
H
H
OBn
O
H
PMBO
BnO
OHO
H
H
+
 
 
A solution of compound 12 ( 1.00 g, 1.75 mmol) in THF (43 mL) was cooled to – 78 °C and 
TMSCl (1.14 mL, 12.2 mmol) was added. After 5 min. LiHMDS (6.0 mL, 1 M in toluene) 
was added quickly and the reaction was stirred for 30 min. at – 78 °C. Then it was allowed to 
warm to rt and stirred over night at ~ 65 °C. The reaction mixture was quenched with a 
saturated NaHCO3 solution and diluted with toluene (150 mL) and H2O (10 mL). The phases 
were separated and the pH of the aqueous phase was lowered to 3 with HCl. It was extracted 
with toluene (3 x 15 mL), the combined organic layers were washed with brine and the 
solvent was removed under reduced pressure. The crude product was filtered off over silica 
62
SUPPORTING INFORMATION S16 
gel (hex:EtOAc = 5:1) and the diastereomeric ratio was estimated from crude NMR dr = 2:1. 
The combined yield was 692 mg (69 %) and the product was used immediately. 
 
IR (Si, Film) max = 3031, 2926, 1731, 1613, 1586, 1514, 1497, 1454, 1303, 1248, 1093, 931, 
822, 738, 699 
 
Following the same procedures as for the synthesis of 11, compound 13 was converted to 4. 
 
 
 (1S, 2R, 4aS, 5S, 8R, 8aS)-1,5-Bis-benzyloxy-8-(4-methoxy-benzyloxy)-2-
methoxymethyl-1,2,4a,5,8,8a-hexahydro-naphthalene (14) 
 
OBn
O
H
PMBO
BnO
H
OBn
O
PMBO
BnO
H
H
H
H
 
 
To a stirred solution of 4 (55 mg, 0.10 mmol) in degassed toluene (10 mL) a solution of 
Hoveyda – Grubbs catalyst 2nd generation (13 mg, 20 mol%) in degassed toluene (3.2 mL) 
was added via a syringe pump for 3.5 h and the reaction mixture was stirred over night at 75 
°C. The reaction was cooled down to rt., air was bubbled through the solution and the solvent 
was removed under reduced pressure. The crude product was purified by column 
chromatography (hex : EtOAc = 5:1) to yield 34 mg (65 %) of the two isomers 
(Spectroscopical data from the main isomer). 
 
1H-NMR (600 MHz, CDCl3): = 7.37 – 7.27 (10H, m), 7.20 (2H, d, J = 8.7 Hz), 6.85 (2H, 
d, J = 8.7 Hz), 5.94 (1H, d, J = 10.2 Hz), 5.85 (1H, dd, J = 10.5, 2.2 Hz), 5.81 (1H, dd, J = 
10.4, 1.3 Hz), 5.61 (1H, dd, J = 10.2, 2.6 Hz), 4.67 (1H, d, J = 11.7 Hz), 4.61 (1H, d, J = 11.7 
Hz), 4.53 (1H, d, J = 11.3 Hz), 4.52 (1H, d, J = 11.7 Hz), 4.49 (1H, d, J = 11.7 Hz), 4.35 (1H, 
d, J = 11.3 Hz), 4.18 (1H, dd, J = 6.0, 2.2 Hz), 4.00 (1H, t, J = 4.3), 3.90 (1H, dd, J = 8.5, 1.3 
Hz), 3.80 (3H, s), 3.49 (1H, dd, J = 9.1, 7.2 Hz), 3.37 (1H, dd, J = 8.9, 7.4 Hz), 3.32 (3H, s), 
3.28 (1H, m), 2.54 (1H, m), 2.35 (1H, m) 
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13C-NMR (150.9 MHz, CDCl3): = 159.3, 138.8, 138.4, 130.7, 130.5, 129.5, 128.4, 128.3, 
127.9, 127.8, 127.6, 127.5, 127.4, 125.5, 113.8, 74.6, 73.4, 73.2, 72.2, 71.4, 70.4, 70.3, 58.8, 
55.3, 40.4, 38.2, 32.9 
IR (Si, Film) max = 3031, 2923, 1735, 1685, 1654, 1611, 1560, 1513, 1497, 1453, 1383, 
1303, 1249, 1173, 1072, 821, 738, 698,  
MS (ESI): m/z = 549, 507, 487, 459, 413, 393, 341, 309 
HRMS (ESI): calc. for C34H38O5Na (=M+ + Na): 549.2617; found: 549.2625 
[ ]D
20   + 28.8 (c = 0.32, CHCl3) 
 
 
(1R, 4R, 4aS, 7R, 8S, 8aR)-4,8-Bis-benzyloxy-7-methoxymethyl-1,4,4a,7,8,8a-
hexahydro-naphthalen-1-ol  
 
OBn
O
PMBO
OBn
OBn
O
HO
OBn
H H
HH  
 
To a solution of compound 14 (21 mg, 0.04 mmol) in DCM (2 mL) and buffer (2 mL, pH 7) 
on the ultrasound bath, DDQ (21 mg, 0.093 mmol) was added portionwise. After 1.5 h the 
reaction was quenched with a saturated NaHCO3 solution, the phases were separated, and the 
aqueous phase was extracted with Et2O (3 x 2 ml). The combined organic layers were dried 
over MgSO4 and the solvents were removed under reduced pressure. The crude product was 
filtered off over silica gel (hex:EtOAc = 7:1) to yield 14.6 mg (90 %) of the alcohol. 
 
1H-NMR (250 MHz, CDCl3): = 7.40 – 7.22 (10 H, m), 5.94 (1 H, d, J = 10.0 Hz), 5.88 – 
5.72 (2 H, m), 5.64 (1 H, td, J = 10.2, 2.9 Hz), 4.64 (1 H, d, J = 11.9 Hz), 4.63 (1 H, d, J = 
11.6 Hz), 4.57 (1 H, d, J = 11.6 Hz), 4.52 (1 H, d, J = 11.8 Hz), 4.24 – 4.09 (3 H, m), 3.63 (1 
H, dd, J = 8.9, 7.6 Hz), 3.43 (1 H, dd, J = 8.9, 7.1 Hz), 3.36 (3 H, s), 3.21 (1 H, m), 2.89 (1 H, 
m), 2.14 (1 H, m) 
13C-NMR (100.6 MHz, CDCl3): = 139.1, 134.6, 132.3, 130.3, 128.8, 128.5, 128.1, 128.0, 
127.7, 127.6, 127.2, 126.6, 74.9, 74.4, 73.3, 72.2, 71.6, 70.7, 67.0, 59.3, 43.8, 34.6, 34.0 
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IR (Si, Film) max = 3401, 3030, 2922, 1717, 1605, 1497, 1454, 1383, 1255, 1194, 1090, 
1068, 1028, 738, 698 
MS (ESI): m/z = 429, 393, 349, 339, 305, 232 
HRMS (ESI): calc. for C26H30O4Na (=M+ + Na): 429.2042; found: 429.2432 
[ ]D
20   + 12.1 (c = 0.15, CHCl3) 
 
 
(4R, 4aS, 7R, 8S, 8aS)-4,8-Bis-benzyloxy-7-methoxymethyl-4a,7,8,8a-tetrahydro-4H-
naphthalen-1-one (15) 
 
OBn
O
O
OBn
OBn
O
HO
OBn
H
H
H
H  
 
To a stirred solution of NaHCO3 (31 mg, 0.37 mmol) and DMP (39 mg, 0.092 mmol) in 
DCM (1.5 mL) a solution of alcohol (15 mg, 0.037 mmol), in DCM (1.5 mL) was added 
dropwise. After 20 min. the reaction mixture was filtered off over silica gel (hex:EtOAc = 
5:1) to yield 13 mg (87 %) of the desired ketone. 
 
1H-NMR (250 MHz, CDCl3): = 7.40 – 7.28 (10 H, m), 6.74 (1 H, dd, J = 10.3, 1.8 Hz), 
5.91 (1 H, m), 5.89 (1 H, dd, J = 10.3, 2.5 Hz), 5.64 (1 H, d, J = 10.4 Hz), 4.77 (1 H, d, J = 
11.7 Hz), 4.62 (1 H, d, J = 11.9 Hz), 4.61 (1 H, d, J = 11.9 Hz), 4.58 (1 H, d, J = 11.8 Hz), 
4.43 (2 H, m), 3.55 (1 H, t, J = 8.6 Hz), 3.53 (1 H, m), 3.37 (1 H, dd, J = 9.0, 7.0 Hz), 3.35 (3 
H, s), 2.76 (1 H, t, J = 4.2 Hz), 2.66 (1 H, m) 
13C-NMR (150.9 MHz, CDCl3): = 198.3, 149.4, 138.6, 137.6, 129.2, 128.6, 128.5, 128.4, 
128.0, 127.7, 127.7, 124.4, 75.0, 73.5, 72.6, 72.2, 71.8, 70.8, 58.7, 46.8, 37.4, 34.4 
IR (Si, Film) max = 3031, 2922, 1733, 1674, 1652, 1498, 1455, 1386, 1208, 1090, 813, 739, 
699, 602 
MS (ESI): m/z = 427, 393, 349, 305, 275, 235, 211 
HRMS (ESI): calc. for C26H28O4Na (= M+ + Na): 427.1885; found: 427.1896 
[ ]D
20   + 66.3 (c = 0.12, CHCl3) 
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(1aR, 2R, 3S, 3aS, 7R, 7aS, 7bS)-3,7-bis(benzyloxy)-2-(methoxymethyl)-1a, 2,3,3a,7,7a-
hexahydronaphtho[1,2-b]oxiren-4(7bH)-one (16) 
 
OBn
O
O
OBn
H
H
OBn
O
O
OBn
H
H O  
 
To a stirred solution of ketone 15 (12 mg, 0,03 mmol) in CHCl3 (0.5 mL) and buffer (0.5 mL, 
pH 7) at rt m-CPBA (30 mg, 0.12 mmol) was added portionwise over a period of 4 h. After a 
total of 6 h the reaction was quenched with Na2S2O3 and diluted with H2O and NaHCO3 
solution. The aqueous phase was extracted with EtOAc (4 x 2 mL), the combined organic 
layers were washed with brine, dried over MgSO4 and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography (hex:EtOAc = 
5:1) to yield 10.3 mg (82 %) of the desired epoxide as colourless needles (mp = 68 - 69°C). 
 
1H-NMR (600 MHz, CDCl3): = 7.42 - 7.14 (10H, m), 6.91 (1 H, td, J = 10.5, 2.0 Hz), 5.94 
(1 H, dd, J = 10.4, 2.4 Hz), 4.84 (1 H, d, J = 11.7 Hz), 4.63 (1 H, d, J = 11.7 Hz), 4.53 (1 H, 
d, J = 12.1 Hz), 4.48 (1 H, d, J = 12.1 Hz), 4.44 (1 H, m), 4.31 (1 H, t, J = 4.5 Hz), 3.67 (1 H, 
dd, J = 9.1, 7.5 Hz), 3.61 (1 H, dd, J = 9.1, 7.2 Hz), 3.41 (1 H, d, J = 4.2 Hz), 3.36 (3 H, s), 
3.11 (1 H, m), 3.07 (1 H, t, J = 3.4 Hz), 2.51 (1 H, t, J = 4.3 Hz), 2.39 (1 H, m) 
13C-NMR (150.9 MHz, CDCl3): = 197.7, 151.0, 138.7, 130.2, 129.5, 128.9, 128.8, 128.6, 
128.3, 128.2, 128.1, 74.1, 73.9, 73.3, 71.6, 71.2, 59.4, 52.7, 51.1, 46.3, 36.6, 35.4 
IR (Si, Film)  max = 2923, 1703, 1695, 1682, 1674, 1651, 1634, 1575, 1455, 1418, 1306, 
1264, 1103, 1071, 898, 748 
MS (ESI): m/z = 443.5, 421.5, 404, 390, 372, 354, 333, 317 
HRMS (ESI): calc. for C26H28O5Na (= M+ + Na): 443.1834; found: 443.1840 
[ ]D
20   + 45.0 (c = 0.10, CHCl3) 
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6.1 Additional work on the quinic acid approach 
After desilylation of 1146 we also managed to introduce a MOM-protecting group in the 
course of an acylation via Mitsunobu inversion (Scheme 40). With this substitution pattern the 
Claisen-Ireland rearrangement gave 147 in 83% yield as a diastereomeric mixture.  
 
Scheme 40: Preparation of cis-decalin 149. 
Interestingly, in the absence of the PMB-protecting group the RCM reaction proceeded 
smoothly to give 149 in 96% yield. After TES protection at the C12-hydroxy group a high 
yielding  
 
Scheme 41: Attempted allylic oxidation of 152. 
                                                   
46 Numbering of publication. 
Results and Discussion 
 
78 
 
and highly chemoselective debenzylation at C10 was conducted47 (90%) to give 150 in 81% 
yield over 2 steps (Scheme 41). Subsequent oxidation (DMP) followed by Luche reduction 
afforded alcohol 151 as a 10:1 diastereomeric mixture. Removal of the OTES-protecting 
group gave diol 152. Initial attempts to convert 152 into 153 were unsuccessful. 
This approach shows that quinic acid is a suitable substrate to generate highly functionalized 
cis-decalins via a Claisen-Ireland rearrangement - RCM protocol. The synthesis proceeded 
with a high degree of diastereoselection and excellent yields for most of the steps. TBS-
protection of enone 153 followed by regio- and stereoselective epoxidation will also furnish 
the desired cis-decalin core of branimycin with the C5 OH-group already being incorporated. 
 
 
                                                   
47 Liu, H.; Yip, J.; Shia, K. Tetrahedron Lett. 1997, 38, 2253. 
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7. Total Synthesis of the Antibiotic Branimycin 
Marchart, S.; Gromov, A.; Mulzer J. Angew. Chem., Int. Ed. 2009, accepted. 
 
 
 1
Natural Product 
Synthesis  
DOI: 10.1002/anie.200((will be filled in by the editorial staff)) 
Total Synthesis of the Antibiotic Branimycin 
 
Stefan Marchart*, Alexey Gromov and Johann Mulzer* 
 ((Dedication----optional))
The nargenicin antibiotics1 have repeatedly been the target of 
synthetic efforts over the past 20 years,2-4 although only one 
synthesis was completed so far.2 Branimycin (1), which has been 
isolated from Actinomycete GW 60/1571 by the Laatsch group,5 is 
the most complex member of this family so far. Biological tests 
have shown that branimycin is active against Escherichia coli, 
Bacillus subtilis, Staphylococus aureus and in particular against 
Streptomyces viridochromogenes. The structure of 1, which was 
elucidated by multidimensional NMR experiments only, is 
unusually complex, as 24 out of the 25 carbon atoms are either 
functionalized and/or stereogenic. All in all, there are 12 
stereocenters, 2 double bonds, 3 secondary OH- and 3 CH2OMe 
functions. Additionally, the cis-fused dehydro-decalin core, the 
7,12-ether bridge and the nine-membered macrolide ring make 1 an 
attractive target for total synthesis.6 In this communication we report 
the first total synthesis of 1, which also confirms the relative 
stereochemistry assigned by the Laatsch group. Additionally, the 
absolute configuration of 1 has been established. 
 
Figure 1 The structure of Branimycin. 
In keeping with the retrosynthetic plan outlined previously 
(Scheme 1),6c we intended to assemble the target molecule via the 
addition of the organometallic side chain 3 to the cis-decalin ketone 
2. In a recent publication6g we have described the preparation of 
enantiopure decalin 5 via desymmetrization of the known precursor 
4 (Scheme 2).  
 
Scheme 1. Retrosynthetic analysis of 1. TBS = tert-butyldimethylsilyl, 
MOM = methoxymethyl. 
The protecting group was changed from PMB in 5 to TBS in 6 to 
ensure a decent stereoselectivity in the ensuing epoxidation step (6 
2). Sidechain 8 was prepared in gram quantities from (S)-
glycidol (7) by a modified version of our earlier approach7 (Scheme 
3) (see supporting information).  
 
Scheme 2. Preparation of decalin ketone 2. Reagents and conditions: a) 
DDQ, pH 7 buffer, DCM, 0-2 °C, 30 min, ultrasonic bath; b) TBSOTf, 2,6-
di-tert-butyl-pyridine, THF, -78 °C, 1 h; c) mCPBA, DCM, 0 °C, 2 h. DDQ 
= 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone, Tf = 
trifluoromethanesulfonyl, mCPBA = 3-chloroperbenzoic acid, DCM = 
dichloromethane, THF = tetrahydrofuran. 
Vinyl iodide 8 was metallated to 3 with tert-butyllithium and the 
organolithium species was added to ketone 2 (Scheme 4). The 
primary adduct 9 could not be observed as the ether bridge was 
closed to form 10 directly, presumably under the influence of the 
lithium species as a Lewis acid catalyst. 
 
[∗] Mag. S. Marchart, Dr. A. Gromov, Prof. Dr. J. Mulzer  
 University of Vienna  
 Institute of Organic Chemistry 
 Waehringer Strasse 38 
 1090 Wien, Austria 
 Fax: (+) 431-427752189 
E-mail: johann.mulzer@univie.ac.at 
[∗∗] We thank Dr. Valentin Enev for fruitful discussions, Ing. 
Martina Drescher for experimental work, Dr. Hanspeter 
Kählig and Ing. Susanne Felsinger for NMR spectra, Prof. 
H. Laatsch for an authentic sample of 1 and the Austrian 
Science Fund for financial support (P-15929-N08). 
 Supporting information for this article is available on the 
WWW under http://www.angewandte.org or from the 
author. 
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Scheme 3. Preparation of vinyl iodide 8. 
 
Scheme 4. Preparation of intermediate 12. Reagents and conditions: a) 8 
(1.7 equiv), tert-BuLi, THF, -78 °C, 2.5 h; b) 2 (1.0 equiv.), THF, -78 °C, 5 
min, warmed to 22 °C overnight; c) TBSCl, imidazole, DMF, 22 °C, 12 h; d) 
CrO3, 3,5-dimethyl-pyrazole, DCM, -20 °C, 2 h, then 11 in DCM, -20 °C, 2 
h. DMF = dimethylformamide. 
 
OTBS-protection to 11 was followed by allylic oxidation8 to 
furnish enone 12. The introduction of the sidechain at C3 was first 
attempted via Claisen-Eschenmoser rearrangement. 9 Thus, enone 12 
was reduced to the allylic alcohol 13 with high stereocontrol and 
then treated with acetamide acetal 14 in DMF under microwave 
irradiation to obtain amide 15. Direct hydrolysis to the acid was 
avoided due to the harsh conditions required. Therefore, alcohol 16 
was prepared via reduction with Superhydride. Removal of the 
OMOM-protecting group was followed by a selective oxidation of 
the primary hydroxyl group with TEMPO10 first to the aldehyde and 
then to seco acid 17. Macrolactonization under modified Yamaguchi 
conditions11 smoothly produced the nine-membered lactone 18. 
Unfortunately all attempts to introduce the 2-CH2OMe group were 
unsuccessful. 
Therefore it was decided to install the crucial sidechain via 
Michael addition (Scheme 6). In fact, enone 12 added malonate 
anion stereoselectively from the top face. The enolate was trapped 
by vinyl triflate formation. Reduction with Bu3SnH under Pd-
catalysis gave diester 20 in good yield. Reduction furnished diol 21 
which was converted into a mixture of monomethyl ethers 22a/b. 
The ratio of 22a/b strongly depended on the conditions. Thus, MeI 
and Ag2O12 furnished a 1:1-mixture, whereas the ratio was 1:4 with 
MeI, KHMDS. 
After selective deprotection of the OMOM-group with MgBr2, 
chromatographic separation of the two epimers was possible. In 
parallel experiments, the diastereomers 22a and b were oxidized to 
seco acids 23a and b in excellent yield. Yamaguchi lactonization led 
to elimination at the 2-CH2OMe-group, presumably induced by the 
base present in the reaction mixture. Therefore we switched to the 
virtually neutral Corey-Nicolaou-Gerlach13 conditions which did 
afford the nine-membered macrolactones 19 and 24 in acceptable 
yields. On treatment with TBAF in THF the least hindered 17-
OTBS group in 19/24 was removed first, whereupon the two 
remaining TBS groups followed suit to give branimycin (1) and its 
C2-epimer 25 in high yield.14 
  
Scheme 5. Preparation of macrolactone 18. Reagents and conditions: a) 
NaBH4, CeCl3. 7 H2O, MeOH, 0 °C, 12 h; b) 14, DMF, microwave, 220 °C, 2 
min; c) LiBEt3H (10 equiv), THF, 0 °C, 5h; d) MgBr2. Et2O, Me2S, DCM, 
40 °C, 12 h (70% b.r.s.m., 80% conversion); e) TEMPO (0.3 equiv), 
PhI(OAc)2 (3 equiv), DCM, 22 °C, 2 h (87%); f) 2-methyl-2-butene, NaClO2, 
NaH2PO4. H2O, tert-BuOH, H2O, 18 °C, 40 min, (85%); g) 2,4,6,-
trichlorobenzoyl chloride, iPr2NEt, DMAP, toluene, 110 °C, 4 h. TEMPO = 
2,2,6,6-tetramethyl-1-piperidinyloxy, DMAP = 4-(dimethylamino)pyridine. 
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Scheme 6. Preparation of monomethyl ethers 22a/b. Reagents and 
conditions: a) CH2(CO2Me)2, NaOMe, MeOH, -21 °C  22 °C, 14 h 
(88%); b) PhNTf2, KHMDS, THF, -78 °C  22 °C, 30 min, (93%); c) 
Bu3SnH, Pd(PPh3)4, LiCl, 2,6-lutidine, THF, 22 °C, 14 h (78%); d) LiBEt3H, 
THF, 0 °C  22 °C, 18 h; e) Ag2O, MeI, 42 °C, 24 h, (99% b.r.s.m., 80% 
conversion); f) MgBr2.Et2O, Me2S, DCM, 40 °C, 6 h, (70% b.r.s.m., 75% 
conversion). HMDS = hexamethyldisilazane, b.r.s.m. = based on recovered 
starting material. 
According to the usual criteria (1H and 13C NMR as well as IR 
and MS spectra, Rf values in three different solvents) our synthetic 
sample of 1 was identical with authentic material. The optical 
rotation of the synthetic product ([α]D25 = + 88 (c = 0.04, CHCl3)) 
nicely matched the value of the natural product ([α]D25 = + 80 (c = 
0.045, CHCl3)) and confirmed the absolute configuration depicted in 
formula 1. 
 
Scheme 7. Completion of the synthesis. Reagents and conditions: a) 
TEMPO, PhI(OAc)2, DCM, 22 °C, 2 h (92%); b) 2-methyl-2-butene, NaClO2, 
NaH2PO4.H2O, tert-BuOH, H2O, 15 °C, 30 min, (90%); c) (PyS)2, PPh3, 
AgClO4, toluene, 85 °C, 2 h; d) TBAF, THF, 22 °C, 14 h. TBAF = tetra-n-
butylammonium fluoride, (PyS)2 = 2,2´-dithio-dipyridine. 
 
In conclusion we have developed the first synthesis of 
branimycin along a convergent route with 22 steps in the longest 
linear sequence and an overall yield of 2%. Our route is flexible 
with respect to the substituents and configurations of the individual 
stereogenic centers. More specifically, some of the hydroxyl groups 
might be inverted, removed or replaced by other functions, e.g. 
amines. This should enhance the diversity of an envisaged library 
for detailed SAR-studies. 
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Total Synthesis of the Antibiotic 
Branimycin  
The first total synthesis of branimycin (1) uses a highly convergent approach by 
adding the vinyl lithium derivative 3 to a cis-decalin ketone 2. The original structural 
assignment has been confirmed by our scaleable and flexible route, which has 22 
steps in the longest linear sequence with an overall yield of 2%.  
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General Methods 
All commercially available reagents were used as received. Thin layer chromatography (TLC) 
was performed on silica gel 60 F254
 
plates. Plates were visualized by dipping into ceric sulfate 
mixture [H2SO4 (10 vol %, 100 mL), phosphormolybdic acid (4.5 g), Ce(IV)SO4
 
(0.1 g)] 
followed by heating with a heat gun. Flash column chromatography was carried out with silica 
gel 60 (0.040-0.063 μm, 240-400 mesh). Dichloromethane was dried by storage over MS 4Å. 
THF, diethyl ether, benzene and toluene were distilled from Na/benzophenone. Dry DMF and 
NMP (over molecular sieves) were purchased from Fluka. Molecule sieves 4Å (Aldrich) in 
powder (5 µ) or in beads (Merck) 4Å or 3Å were activated by heating at 350 °C in high 
vacuum for 8 h. All reactions were performed under atmosphere of Ar with flame-dried 
glassware unless otherwise stated. Microwave experiments were carried out on a Biotage 
Initiator (Biotage, Sweden) with reaction times specified as the ramp time and hold times at 
the final temperature. Temperatures were measured at the vessel surface by IR-sensors. 
NMR spectra were recorded at 250, 400 or 600 MHz in CDCl3 or C6D6 at 300 K. Chemical 
shift values were quoted in parts per million (ppm), and coupling constants were quoted in 
hertz. Residual signal of CHCl3 (δ = 7.26 ppm) or C6H6 (δ = 7.16 ppm) were used as an 
internal reference for 1H chemical shifts; signals of CDCl3 (δ = 77.16 ppm) or C6D6 (δ = 
128.06 ppm) were used as an internal reference for 13C chemical shifts. 13C NMR spectra were 
measured J-modulated and proton decoupled unless otherwise stated. Abbreviations for 
multiplicities are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = 
broad. IR spectra were recorded with a FTIR spectrometer and are reported in wave numbers 
(cm-1). All compounds were measured as a thin film on a silicon single crystal plate (Si-
pellet). Optical rotations were measured on a P 341 Perkin-Elmer polarimeter. Mass spectra 
(HRMS) were performed with a Finnigan MAT 8230 with a resolution of 10000.  
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(4aS,7R,8R,8aS)-8-(tert-butyldimethylsilyloxy)-7-(methoxymethyl)-4,4a,8,8a-tetrahydro-
naphthalen-1(7H)-one (6). 
To a solution of enone 5 (50.0 mg, 0.151 mmol) in DCM (1.2 mL) was added aq. pH 7.0 
buffer (1 mL). The mixture was immersed in an ultrasonic bath and sonicated at +1 to + 3 °C 
for 5 min. To this mixture DDQ (69.1 mg, 0.305 mmol) was added and the reaction mixture 
was sonicated for 30 min at +1 to +3 °C (maintaining the temperature in the bath by adding 
ice). The reaction mixture was transferred into a separation funnel, saturated aq. Na2S2O3 (3 
mL) was added and the mixture was vigorously shaked for 20 sec. Saturated aq. NaHCO3 (30 
mL) was added and the mixture was vigorously shaked for 1 min. The mixture was extracted 
with EtOAc (2x30 mL), the organic phase was washed with saturated aq. NaHCO3 (30 mL). 
The combined water phases were extracted with EtOAc (4x30 mL). The combined organic 
phases were washed with brine (30 mL) and dried over MgSO4. Solvents were removed in 
vacuo below 30 °C. The crude mixture (ca. 0.15 mmol) was dissolved in THF (1.4 mL) and 
cooled to -78 °C. To this solution 2,6-di-tert-butylpyridine (115 mg, 129 µL, 0.60 mmol) was 
added and the mixture was stirred until a clear solution was obtained. Then TBSOTf (86 µL, 
99 mg, 0.375 mmol) was added dropwise and the mixture was stirred at -78 °C for 1h. The 
reaction was quenched by pouring into a vigorously stirred saturated aq. NaHCO3 (30 mL), 
stirred for 5 min and extracted with EtOAc (3x30 mL). The combined organic phases were 
washed with brine (20 mL) and dried over MgSO4. Volatiles were removed in vacuo and the 
residue was subjected to column chromatography (EtOAc/toluene) to obtain enone 6 in 89% 
(43.6 mg) over two steps.  
1H-NMR (400MHz, CDCl3): δ = 6.99 (ddd, J= 10.2, 6.1, 2.1 Hz, 1H), 6.09 (ddd J= 10.2, 2.7, 
1.0 Hz, 1H), 5.87 (ddd, J= 10.2, 4.8, 1.6 Hz, 1H), 5.64 (ddd J= 10.2, 4.8, 1.3 Hz, 1H), 4.37 
(bs, 1H), 3.33 (s, 3H), 3.31 (dd, J= 9.6, 5.1 Hz, 1H), 3.21 (dd, J= 9.6, 7.8 Hz, 1H), 2.87 - 2.72 
(m, 1H), 2.61 (ddd, J= 18.4, 11.3, 2.5 Hz, 1H), 2.47 (dd, J= 6.9, 2.6 Hz, 1H), 2.48 - 2.40 (m, 
1H), 2.38 (dddd, J= 18.3, 5.8, 5.8, 0.8 Hz, 1H), 0.79 (s, 9H), 0.01 (s, 3H), -0.01 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 201.9, 150.9, 130.5, 130.2, 125.3, 74.8, 71.7, 59.2, 46.8, 
45.0, 33.1, 31.5, 25.8, 17.9, -4.9, -5.2. 
IR (film): 3022, 2929, 2857, 2738, 1674, 1472, 1463, 1424, 1390, 1255, 1123, 1063, 1006, 
890, 834, 777, 745 cm-1. 
HRMS (ESI): calc. for C18H30NaO3Si [M+Na]+ 345.1862; found: 345.1862. 
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[α]D20  = -91.88 (c = 0.690, CHCl3). 
 
 
(1aR,2S,3R,3aS,7aR,7bS)-3-(tert-butyldimethylsilyloxy)-2-(methoxymethyl)-
1a,2,3,3a,7,7a-hexahydronaphtho[2,1-b]oxiren-4(7bH)-one (2). 
To a solution of 6 (700 mg, 2.17 mmol) in DCM (40 mL) at 0 °C was added mCPBA (77%, 
2.43 g, 10.8 mmol). The mixture was stirred for 2 h at 0 °C, washed with saturated aq. 
Na2S2O3 (20 mL) and saturated aq. NaHCO3 (2x20 mL). The combined water phases were 
extracted with DCM (5x50 mL). The combined organic phases were washed with brine, 
passed through a plug of cotton and concentrated in vacuo. The residue was subjected to 
column chromatography (EtOAc/hexane) to obtain starting 6 (281 mg) and epoxyketone 2 
(371 mg, 84% b.r.s.m.). 
1H-NMR (400 MHz, CDCl3): 7.00 (ddd, J= 10.2, 6.1, 1.6 Hz, 1H), 6.08 (bd, J=10.2 Hz, 1H), 
3.94 (bs, 1H), 3.50 (dd, J= 9.5, 7.1 1H), 3.16 (s, 3H), 3.34 - 3.28 (m, 2H), 3.25 (dd, J= 3.8, 1.0 
1H), 2.87 - 2.76 (m, 2H), 2.45-2.33 (m, 2H), 2.28 (dd, J= 5.6, 2.4 1H), 0.8 (s, 9H), 0.14 (s, 
3H), -0.14 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 200.8, 149.9, 131.0, 71.6, 69.5, 59.4, 55.4, 51.5, 43.9, 42.7, 
32.0, 28.5, 25.9, -5.0, -5.3. 
IR (film): 2928, 1733, 1674, 1557, 1388, 1326, 1253, 1212, 1067, 1035, 1006, 912, 828, 796, 
778 cm-1. 
HRMS (ESI): calc. for C18H30NaO4Si [M+Na]+ 361.1811; found: 361.1817. 
[α]D20  = -100.47 (c = 0.645, CHCl3). 
 
 
(5S,6S)-8,8-diisopropyl-6-(methoxymethyl)-9-methyl-5-((R)-pent-3-yn-2-yl)-2,4,7-trioxa-
8-siladecane (27). 
To a mixture of alcohol 26 (4.73 g, 14.4 mmol), iPr2NEt (7.0 g, 54.5 mmol) and DCM (2 mL) 
was added MOMCl (5.8 g, 72.0 mmol). The mixture was stirred at rt over 12 h. Reaction was 
quenched by stirring with aq. NaHCO3 (100 mL) over 30 min. The water phase was extracted 
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with Et2O (3x50 mL). The combined organic phases were washed with brine (50 mL) and 
dried over MgSO4. Volatiles were removed in vacuo and the residue was subjected to column 
chromatography (EtOAc/hexanes) to obtain 27 in 95% yield (5.10 g). 
1H-NMR (400MHz, CDCl3): δ = 4.73 (d, J = 6.5 Hz, 1H), 4.70 (d, J = 6.5 Hz, 1H), 4.30 (ddd, 
J = 6.1, 6.1, 3.0 Hz, 1H), 3.53 (dd, J = 9.3, 6.1 Hz, 1H), 3.49 (dd, J = 7.7, 3.0 Hz, 1H), 3.41 
(dd, J = 9.3, 6.1 Hz, 1H), 3.40 (s, 3H), 3.32 (s, 3H), 2.88-2.78 (m, 1H), 1.74 (d, J = 2.4 Hz 
3H), 1.20 (d, J = 7.0 Hz, 3H), 1.12-1.02 (m, 21H). 
13C-NMR (100 MHz, CDCl3): δ = 98.1, 82.9, 82.0, 77.2, 74.5, 72.5, 58.8, 56.1, 27.7, 18.4, 
18.3, 18.1, 13.0, 3.7. 
IR (film): 2943, 2881, 2867, 1464, 1417, 1384, 1344, 1152, 1079, 1037, 983, 974, 938, 921, 
902, 883, 836, 774, 714, 679, 419 cm-1. 
HRMS (ESI): calc. for C20H40NaO4Si [M+Na]+ 395.2594; found: 395,2597. 
[α]D20  = +8.68 (c = 2.50, CHCl3). 
 
 
(5S,6S)-5-((R,E)-4-iodopent-3-en-2-yl)-8,8-diisopropyl-6-(methoxymethyl)-9-methyl-
2,4,7-trioxa-8-siladecane (28). 
To a solution of Cp2ZrCl2 (5.0 g, 17.1 mmol) in THF (120 mL) at 0 °C was added DIBAL (1.0 
M in hexanes, 17.1 mL, 17.1 mmol). The reaction mixture was warmed to rt and the resulting 
slurry was stirred for 2 h. Then the stirring was stopped, and after 10 min the supernatant 
liquid was removed with a syringe. To the white precipitate a solution of 27 (2.20 g, 5.9 
mmol) in benzene (160 mL) was added, and the mixture was stirred at rt over 12 h. Then the 
reaction mixture was cooled to 0 °C, and a solution of I2 (5.0 g, 20 mmol) in benzene (100 
mL) was added over 5 min. The reaction was quenched by pouring into a vigorously stirred 
aq. 3M Na2S2O3 (100 mL). After both layers became colorless, the organic phase was 
separated, and the water phase was extracted with Et2O (4x50 mL). The combined organic 
phases were washed with brine (50 mL) and dried over MgSO4. Volatiles were removed in 
vacuo and the residue was subjected to column chromatography (EtOAc/hexanes) to obtain 28 
in 83% yield (2.45 g). 
1H-NMR (400MHz, CDCl3): δ = 6.23-6.18 (m, 1H), 4.74 (d, J = 6.8 Hz, 1H), 4.63 (d, J = 6.8 
Hz, 1H), 4.01-4.02 (m, 1H), 3.53 (dd, J = 9.6, 3.9 Hz, 1H), 3.44 (dd, J = 5.8, 4.8 Hz, 1H), 3.40 
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(s, 3H), 3.35 (dd, J = 9.6, 6.0 Hz, 1H), 3.32 (s, 3H), 2.77-2.66 (m, 1H), 2.38 (d, J = 1.5 Hz, 
1H), 1.10-1.06 (m, 21H), 1.00 (d, J = 6.9 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): δ = 144.7, 98.0, 92.7, 82.9, 74.9, 73.5, 58.9, 56.0, 36.4, 27.8, 
18.3, 16.4, 12.9. 
IR (film):  2943, 2906, 2866, 1465, 1112, 1076, 1039, 937, 919, 882, 766, 679, 415, 406 cm-1. 
HRMS (ESI): calc. for C20H41INaO4Si [M+Na]+ 523.1716; found: 523.1721. 
[α]D20  = +15.36 (c = 2.80, CHCl3). 
 
 
(2S,3S,4R,E)-6-iodo-1-methoxy-3-(methoxymethoxy)-4-methylhept-5-en-2-ol (29). 
To a solution of 28 (2.50 g, 5.00 mol) in THF (18 mL) at rt was added TBAF (1.0 M in THF, 
7 mL, 7 mmol) and the mixture was stirred for 1 h. Saturated aq. NH4Cl (5 mL) was added 
and volatiles were removed in vacuo. The residue was diluted with half-saturated NH4Cl (50 
mL) and extracted with EtOAc (5x30 mL). The combined organic phases were washed with 
brine (30 mL) and dried over MgSO4. Solvents were removed in vacuo and the residue was 
subjected to column chromatography (EtOAc/hexanes) to obtain 29 in 95% yield (1.63 g). 
1H-NMR (400MHz, CDCl3): δ = 6.08-6.03 (m, 1H), 4.65 (d, J = 6.6 Hz, 1H), 4.62 (d, J = 6.6 
Hz, 1H), 3.75-3.69 (m, 1H), 3.43-3.40 (m, 2H), 3.41 (s, 3H), 3.36 (dd, J = 6.1, 4.1 Hz, 1H), 
3.36 (s, 3H), 2.81-2.73 (m, 1H), 2.79 (d, J = 5.8 Hz, 1H, OH), 2.40 (d, J = 1.5 Hz, 3H), 1.00 
(d, J = 6.8 Hz). 
13C-NMR (100 MHz, CDCl3): δ = 143.6, 98.6, 94.8, 83.1, 74.1, 70.4, 59.2, 56.3, 37.4, 28.0, 
15.7. 
IR (film): 3460, 3165, 2931, 2363, 1457, 1326, 1126, 1070, 1029, 809, 671, 611, 590, 587, 
458, 452, 449, 434, 421, 410, 406, 403 cm-1. 
HRMS (ESI): calc. for C11H21INaO4 [M+Na]+ 367.0382; found: 367.0381. 
[α]D20  = +44.43 (c = 3.00, CHCl3). 
 
 
(5S,6S)-5-((R,E)-4-iodopent-3-en-2-yl)-6-(methoxymethyl)-8,8,9,9-tetramethyl-2,4,7-
trioxa-8-siladecane (8). 
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A mixture of 29 (1.5 g, 4.36 mmol), imidazole (1.20 g, 20 mmol), TBSCl (1.4 g, 9 mmol) and 
DMF (3.0 mL) was stirred over 12 h at rt. The reaction mixture was quenched with saturated 
aq. NaHCO3 (10 mL), stirred for 20 min, diluted with water (200 mL) and extracted with 
EtOAc (3x50 mL). The combined organic phases were washed with water (2x30 mL), brine 
(30 mL) and dried over MgSO4. Volatiles were removed in vacuo, and the residue was 
subjected to column chromatography (EtOAc/hexanes) to obtain 1.90 g of 8 (95%). 
1H-NMR (400MHz, CDCl3): δ = 6.22-6.17 (m, 1H), 4.73 (d, J = 6.8 Hz, 1H), 4.62 (d, J = 6.8 
Hz, 1H), 3.89-3.84 (m, 1H), 3.47 (dd, J = 9.9, 4.0 Hz, 1H), 3.41 (s, 3H), 3.39 (dd, J = 5.3, 5.3 
Hz, 1H), 3.33 (dd, J = 9.7, 5.8 Hz, 1H), 3.33 (s, 3H), 2.73-2.63 (m, 1H), 2.38 (d, J = 1.5 Hz, 
1H), 1.00 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 144.7, 98.1, 93.0, 82.5, 74.8, 73.2, 59.1, 56.1, 36.6, 27.8, 
26.1, 18.3, 16.1, -4.4, -4.5. 
IR (film): 2929, 2911, 2888, 2868, 2857, 2356, 1636, 1557, 1473, 1418, 1378, 1318, 1253, 
1229, 1196, 1182, 1105, 1069, 1037, 999, 980, 836, 818, 778, 665, 631 cm-1. 
HRMS (ESI): calc. for C17H35INaO4Si [M+Na]+ 481.1247; found: 481.1253. 
[α]D20  = -0.41 (c = 2.45, CHCl3). 
 
 
Alcohol (10). 
A solution of tBuLi (1.74 M in pentane, 1.13 mL, 1.96 mmol) was added within 10 min to 
THF (1.7 mL) cooled to -90 °C. The resulted yellow slurry was warmed to -80 °C, and a 
solution of 8 (451 mg, 0.98 mmol) in THF (1.2 mL) was added within 1.5 h. After stirring for 
additional 1 h, a solution of 2 (185 mg, 0.55 mmol) in THF (1.2 mL) was added within 5 min. 
The reaction mixture allowed to warm to rt overnight and stirred at rt for additional 3 h. 
Saturated aq. NH4Cl (5 mL) was added and the mixture was concentrated to half its volume in 
vacuo. The mixture was extracted with EtOAc (3x20 mL), the combined organic phases were 
washed with brine (20 mL), dried over MgSO4 and solvents were removed in vacuo. The 
residue was subjected to column chromatography (EtOAc/hexane) to obtain 282 mg of 10 
(82%). 
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1H-NMR (400 MHz, C6D6): δ = 6.12 (d, J=9.8 Hz, 1H), 5.96 (ddd, J= 9.3, 1.7, 1.8 Hz, 1H), 
5.51 (ddd, J= 9.3, 3.2, 3.2 Hz, 1H), 4.76 (d, J=6.5 Hz, 1H), 4.64 (d, J=6.5 Hz, 1H), 4.33 - 4.26 
(m, 2H), 4.18 - 4.09 (m, 2H), 3.72 - 3.66 (m, 2H), 3.62 (dd, J=5.4, 5.4 Hz, 1H), 3.57 (dd, J= 
9.7, 3.5 Hz, 1H), 3.43 (dd, J= 9.7, 6.6 Hz, 1H), 3.33 (dd, J= 9.3, 3.0 Hz, 1H), 3.31 (s, 3H), 
3.14 (s, 3H), 3.06 - 2.96 (m, 1H), 2.92 (s, 3H), 2.81 (d, J= 5.4 Hz, 1H), 2.78 - 2.71 (m, 1H), 
2.41 - 2.32 (m, 1H), 2.37 (d, J= 2.5 Hz, 1H), 2.09 (d, J= 18.3 Hz, 1H), 1.93 (s, 3H), 1.27 (d, 
J= 6.8 Hz, 1H), 1.06 (s, 9H), 0.99 (s, 3H), 0.22 (s, 3H), 0.21 (s, 3H), 0.08 (s, 3H), 0.04 (s, 3H). 
13C-NMR (100 MHz, C6D6): δ = 139.1, 133.6, 128.2, 127.9, 98.4, 85.5, 85.1, 83.4, 75.8, 74.2, 
73.8, 72.6, 72.2, 58.7, 58.4, 55.9, 49.6, 41.1, 38.0, 33.8, 33.6, 26.5, 26.4, 18.6, 18.5, 17.0, 
16.4, -3.1, -4.0, -4.3, -5.6. 
IR (film): 3468, 2930, 1473, 1423, 1388, 1349, 1253, 1223, 1103, 1083, 1039, 928, 898, 880, 
835, 797, 775, 722, 671, 649, 611, 419 cm-1. 
HRMS (ESI): calc. for C35H66NaO8Si2 [M+Na]+ 693.4194; found: 693.4200. 
[α]D20  = + 22.11 (c = 0.90, CHCl3). 
 
 
TBS-ether (11). 
A mixture of 10 (200 mg, 0.30 mmol), TBSCl (230 mg, 1.5 mmol), imidazole (200 mg, 3 
mmol) and DMF (0.3 mL) was stirred for 12 h at rt. Saturated aq. NaHCO3 (5 mL) was added 
and stirring was continued for 10 min. The mixture was diluted with water (30 mL) and the 
water phase was extracted with EtOAc (3x30 mL). The combined organic phases were washed 
with brine (20 mL), dried over MgSO4 and solvents were removed in vacuo. The residue was 
subjected to column chromatography (EtOAc/hexane) to obtain 11 in 95% yield (222 mg). 
1H-NMR (400 MHz, C6D6): δ = 6.20 (dd, J= 9.8, 1.1 Hz, 1H), 6.02 (ddd, J= 9.2, 1.8, 1.8 Hz, 
1H), 5.55 (ddd, J= 9.2, 3.1, 3.1 Hz, 1H), 4.76 (d, J= 6.5 Hz, 1H), 4.64 (d, J= 6.5 Hz, 1H), 4.26 
(dd, J= 4.5, 4.5 Hz, 1H), 4.19 - 4.14 (m, 2H), 3.79 (dd, J= 11.0, 2.7 Hz, 1H), 3.64 - 3.53 (m, 
4H), 3.44 (dd, J= 9.6, 6.8 Hz, 1H), 3.31 (s, 3H), 3.23 (s, 3H), 3.14 (s, 3H), 3.16 - 3.00 (m, 2H), 
2.70 (d, J= 5.4 Hz, 1H), 2.47 - 2.38 (m, 1H), 2.37 (d, J= 2.4 Hz, 1H), 2.10 (bd, J= 18.8 Hz, 
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1H), 1.96 (d, J= 1.1 Hz, 3H), 1.32 (d, J= 6.9 Hz, 3H), 1.06 (s, 9H), 1.00 (s, 9H), 0.96 (s, 9H), 
0.23 (s, 3H), 0.22 (s, 3H), 0.12 (s, 3H), 0.06 (s, 3H), 0.01 (s, 3H), 0.00 (s, 3H). 
13C-NMR (100 MHz, C6D6): δ = 139.4, 133.2, 128.5, 127.5, 98.4, 85.6, 85.3, 83.4, 75.9, 74.3, 
73.9, 71.0, 70.6, 58.7, 58.3, 55.9, 49.8, 41.2, 38.0, 33.9, 33.6, 26.5, 26.4, 26.2, 18.6, 18.5, 
18.4, 17.0, 16.3, -3.1, -3.9, -4.3, -4.6, -5.1, -5.3. 
IR (film): 2955, 2944, 2929, 2911, 2889, 2871, 1557, 1388, 1253, 1117, 1030, 874, 836, 776, 
705, 676, 619 cm-1. 
HRMS (ESI): calc. for C41H80NaO8Si3 [M+Na]+ 807.5059; found: 807.5067. 
[α]D20  = + 44.30 (c = 1.00, CHCl3). 
 
 
Ketone (12). 
To a suspension of CrO3 (1.02 g, 10.2 mmol, dried overnight over P2O5 ) in DCM (7.5 mL) at 
-20 °C was added at once 3,5-dimethylpyrazole (0.98 g, 10.2 mmol) and the mixture was 
stirred until all solids dissolved to give a dark cherry-red solution. To this solution of 
CrO3*3,5-dimethylpyrazole complex, a solution of 11 (0.200 g, 0.255 mmol) in DCM (2 mL) 
was added slowly and the mixture was stirred at -20 °C for 2h until TLC analysis showed full 
conversion of 11. The reaction mixture was diluted with hexanes (10 mL) and washed with 
portions of aq. NaOH (3M, 30 mL) until the water phase remained colorless. The combined 
water phases were extracted with EtOAc (3x30 mL). The combined organic phases were 
washed with aq. HCl (1M, 3x30 mL), saturated aq. NaHCO3 (30 mL), brine (30 mL) and dried 
over MgSO4. Concentration in vacuo and purification by column chromatography gave 204 
mg (67%) of 12 as a colorless oil. 
1H-NMR (400 MHz, C6D6): δ = 6.92 (d, J = 9.5 Hz, 1H), 6.26 (dd, J = 9.8, 1.3 Hz, 1H), 6.03 
(dd, J = 9.5, 1.4 Hz, 1H), 4.76 (d, J = 6.6 Hz, 1H), 4.60 (d, J = 6.6 Hz, 1H), 4.42 (dd, J = 4.6, 
4.6 Hz, 1H), 4.15 – 4.09 (m, 2H), 3.67 (s, 1H), 3.64 – 3.45 (m, 5H), 3.41 (dd, J = 9.7, 6.5 Hz, 
1H), 3.28 (s, 3H), 3.17 (s, 3H), 3.14 (s, 3H), 3.06 – 2.93 (m, 2H), 2.52 (d, J = 2.6 Hz, 1H), 
1.81 (d, J = 1.2 Hz, 3H), 1.27 (d, J = 6.8 Hz, 3H), 1.04 (s, 9H), 0.99 (s, 9H), 0.94 (s, 9H), 0.21 
(s, 3H), 0.20 (s, 3H), 0.07 (s, 3H), 0.03 (s, 3H), - 0.08 (s, 3H), - 0.10 (s, 3H). 
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13C-NMR (100 MHz, C6D6): δ = 198.0, 159.9, 130.5, 130.4, 130.0, 98.3, 86.9, 83.2, 78.3, 
75.7, 74.3, 72.0, 70.4, 70.1, 58.7, 58.4, 55.9, 55.5, 53.8, 41.5, 33.7, 26.3, 26.3, 26.1, 18.6, 
18.4, 18.4, 16.7, 16.0, -3.3, -4.1, -4.3, -4.5, -5.2, -5.6. 
IR (film): 2929, 2858, 1687, 1473, 1256, 1120, 1033, 838, 777, 674, 667, 515, 459, 438, 418, 
402 cm-1. 
HRMS (ESI): calc. for C41H78NaO9Si3 [M+Na]+ 821.4851; found: 821.4847. 
[α]D20  = + 79.1 (c = 0.22, CHCl3) 
 
 
Allylic alcohol (13). 
A solution of CeCl3*7H2O (746 mg, 2.00 mmol) in MeOH (20 mL) was added to ketone 12 
(800 mg, 1.00 mmol). The mixture was cooled to 0 °C, and NaBH4 (230 mg, 6 mmol) was 
added. The reaction was stirred at 0 °C for 12 h. Saturated aq. NH4Cl (20 mL) was added, the 
mixture was warmed to rt and stirred for 30 min. The water phase was extracted with EtOAc 
(5x50 mL), combined organic phases were washed with brine (50 mL) and dried over MgSO4. 
Volatiles were removed in vacuo, and the residue was repeatedly concentrated from MeOH 
(7x30 mL) in vacuo. The crude product was subjected to column chromatography 
(EtOAc/hexane) to obtain 13 in 97% yield (638 mg) as a mixture of diastereomers (dr 10:1). 
NMR data are given for the major diastereomer. 
1H-NMR (400 MHz, CDCl3): δ = 5.90 (dd, J = 9.3, 1.3 Hz, 1H), 5.73 (dd, J = 9.6, 1.2 Hz, 
1H), 5.67 - 5.62 (m, 1H), 4.73 (d, J = 6.4 Hz, 1H), 4.69 - 4.64 (m, 1H), 4.62 (d, J = 6.4 Hz, 
1H), 4.40 (d, J = 5.1 Hz, 1H), 4.09 (dd, J = 4.6, 4.6 Hz, 1H), 3.89 - 3.84 (m, 1H), 3.56 (dd, J = 
11.0, 2.6 Hz, 1H), 3.47 (dd, J = 9.7, 4.2 Hz, 1H), 3.40 - 3.29 (m, 4H), 3.38 (s, 3H), 3.30 (s, 
3H), 3.24 (s, 3H), 2.79 (d, J = 5.7 Hz, 1H), 2.79 - 2.68 (m, 2H), 2.32 (d, J = 2.4 Hz, 1H), 1.67 
(s, 3H), 1.58 (d, J = 7.2 Hz, 1H), 1.02 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 3H), 0.88 (s, 
3H), 0.07 (s, 3H), 0.06 (s, 6H), 0.055 (s, 3H), 0.05 (s, 3H), 0.01 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 141.6, 132.1, 129.7, 128.0, 98.3, 84.4, 83.2, 76.7, 75.3, 
73.3, 72.9, 70.7, 70.5, 69.4, 58.9, 58.4, 56.1, 51.9, 45.4, 41.2, 33.3, 26.3, 26.2, 26.1, 18.4, 
18.3, 18.2, 16.6, 15.8, -3.1, -4.2, -4.2, -4.4, -5.2, -5.3. 
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IR (film): 3470, 2932, 1471, 1422, 1387, 1349, 1253, 1223, 1103, 1083, 1039, 928, 898, 880, 
835, 797, 775, 722, 671, 649, 611, 419 cm-1. 
HRMS (ESI): calc. for C41H80NaO9Si3 [M+Na]+ 823.5008; found: 823.5014. 
Optical rotation for the mixture of diastereomers (10:1): [α]D20  = +66.63 (c = 2.05, CHCl3). 
 
 
Amide (15). 
A Biotage® microwave vial (for 2-5 mL reactions) was charged with a stirring bar and 4Å 
molecular sieves (powder, 1.20 g), sealed with a cap and a septa. The septa was pierced with a 
needle (0.8x80 mm), the vial together with the needle were placed in a flask (250 mL, joint 
29/42) and the system was subjected to evacuation-filling cycles with Ar. A solution of 13 
(100 mg, 0.125 mmol, dr 10 : 1) in DMF (dry, degassed, 1.4 mL) was added, followed by 
N,N-dimethylacetamide dimethyl acetal (1.2 mL, 8.2 mmol). The mixture was irradiated at 
220 °C for 2 min. Additional N,N-dimethylacetamide dimethyl acetal (0.3 mL, 2.05 mmol) 
was added and the mixture was irradiated for additional 2 min. All volatiles were removed in 
vacuo, the solid residue was suspended in EtOAc (10 mL) and passed through a plug of Celite. 
The filter cake was washed repeatedly with EtOAc (5x10 mL). The combined fractions were 
concentrated in vacuo and the residue was subjected to column chromatography 
(EtOAc/hexane) to yield 15 (64 mg, 64%) as a colorless oil. 
1H-NMR (400 MHz, C6D6): δ = 6.28 (dd, J = 10.1, 0.8 Hz, 1H), 6.12 (dd, J = 9.5, 2.4 Hz, 
1H), 6.00 - 5.95 (m, 1H), 6.12 (ddd, J = 9.2, 1.2, 3.0 Hz, 1H), 4.76 (d, J = 6.7 Hz, 1H), 4.62 
(d, J = 6.7 Hz, 1H), 4.34 (d, J = 4.8 Hz, 1H), 4.30 (dd, J = 4.6, 4.0 Hz, 1H), 4.15 - 4.10 (m, 
1H), 3.81 (dd, J = 10.9, 2.5 Hz, 1H), 3.74 - 3.69 (m, 1H), 3.60 - 3.55 (m, 3H), 3.52 (dd, J = 
9.7, 3.7 Hz, 1H), 3.41 (dd, J = 9.7, 6.6 Hz, 1H), 3.31 (s, 3H), 3.24 - 3.16 (m, 1H), 3.22 (s, 3H), 
3.09 (s, 3H), 3.08 - 3.01 (m, 1H), 2.85 (d, J = 6.5 Hz, 1H), 2.78 - 2.71 (m, 1H), 2.75 (s, 3H), 
2.63 (s, 3H), 2.57 - 2.51 (m, 2H), 1.91 (d, J = 0.9 Hz, 3H), 1.34 (d, J = 6.8 Hz, 3H), 1.05 (s, 
9H), 0.98 (s, 9H), 0.97 (s, 9H), 0.20 (s, 6H), 0.13 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H), 0.00 (s, 
3H). 
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13C-NMR (100 MHz, C6D6): δ = 170.7, 131.4, 131.1, 130.1, 127.6, 97.3, 89.4, 89.3, 85.2, 
83.0, 74.6, 73.4, 72.0, 69.9, 69.3, 57.6, 57.4, 54.7, 49.6, 42.3, 39.9, 39.0, 35.6, 34.2, 33.1, 
31.8, 25.5, 25.3, 25.1, 17.6, 17.5, 17.4, 15.9, 15.4, -4.1, -5.0, -5.4, -5.5, -6.1, -6.3. 
IR (film): 2931, 1662, 1474, 1422, 1387, 1349, 1253, 1223, 1103, 1083, 1039, 928, 898, 880, 
835, 797, 775, 722, 671, 649, 611, 419 cm-1. 
HRMS (ESI): calc. for C45H87NNaO9Si3 [M+Na]+ 892.5586; found: 892.5581. 
[α]D20  = +98.9 (c = 0.37, CHCl3). 
 
 
Alcohol (16). 
To a flask charged with amide 15 (179 mg, 0.206 mmol) under stirring was added dropwise 
Super-Hydride (1.0 M in THF, 3.2 mL, 3.2 mmol) at 0 °C, and the reaction was stirred for 5 h 
at 0 °C, 30 min at 5°C and 30 min at 10 °C.  Saturated aq. NH4Cl (5 mL) followed by MeOH 
(2 mL) were added carefully and the mixture was stirred for 10 min at rt. Most of organic 
solvents were removed in vacuo and the water phase was extracted with EtOAc (5x30 mL). 
Combined organic phases were diluted with toluene (40 mL), washed with brine (40 mL) and 
concentrated in vacuo. The residue was concentrated repeatedly from methanol (5x5 mL) and 
then subjected to column chromatography (EtOAc/hexane) to give 159 mg (93%) of 16. 
1H-NMR (400 MHz, CDCl3): δ = 5.92 (ddd, J = 9.2, 6.7, 2.1 Hz, 1H), 5.74 (dd, J = 10.0, 1.0 
Hz, 1H), 5.57 (dd, J = 9.5, 2.4 Hz, 1H), 4.74 (d, J = 6.7 Hz, 1H), 4.66 (d, J = 6.7 Hz, 1H), 4.05 
(d, J = 5.0 Hz, 1H), 3.97 (dd, J = 4.3, 4.3 Hz, 1H), 3.94 - 3.89 (m, 1H), 3.71-3.61 (m, 1H), 
3.62 (dd, J = 11.0, 2.5 Hz, 1H), 3.53 - 3.44 (m, 2H), 3.43 - 3.27 (m, 4H), 3.41 (s, 3H), 3.33 (s, 
3H), 3.23 (s, 3H), 2.84 - 2.73 (m, 2H), 2.73 - 2.68 (m, 1H), 2.68 - 2.63 (m, 2H), 2.30 (d, J = 
2.3 Hz, 1H), 1.75 - 1.66 (m, 1H), 1.68 (s, 3H), 1.55 - 1.45 (m, 1H), 1.04 (d, J = 6.7 Hz, 1H), 
0.90 (s, 9H), 0.90 (s, 9H), 0.89 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.04 (s, 3H), 
0.03 (s, 3H), 0.01 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 132.1, 130.1, 130.4, 129.0, 98.0, 90.1, 85.8, 83.0, 75.7, 
73.6, 72.5, 70.5, 69.4, 60.8, 58.9, 58.4, 56.0, 50.4, 43.1, 40.2, 39.3, 34.4, 32.4, 26.4, 26.1, 
26.0, 18.5, 18.4, 18.2, 17.1, 16.5, -3.1, -4.2, -4.3, -4.5, -5.2, -5.2. 
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IR (film): 3460, 1470, 1422, 1387, 1349, 1252, 1223, 1103, 1083, 1039, 921, 898, 880, 835, 
797, 775, 722, 671, 649, 611, 419 cm-1. 
HRMS (ESI): calc. for C43H84NaO9Si3 [M+Na]+ 851.5321; found: 851.5320. 
[α]D20  = +93.8 (c = 0.305, CHCl3). 
 
 
Diol (30). 
A flask was charged with magnesium turning (400 mg, 16.6 mmol) and diethyl ether (10 mL), 
equipped with a reflux condenser and immersed in an ultrasound bath (20 °C). Dibromoethane 
(0.65 mL, 7.6 mmol) was added and the mixture was sonicated at 20 to 40 °C for 1h. The 
sonication was stopped and the mixture was allowed to stay at rt for 20 min. The separated 
bottom layer was transferred into a Schlenk flask (10 mL) with a syringe. Most of the solvent 
was blown away with Ar-stream and finally dried in vacuo for 2-3min to obtain a white 
powder. Into this flask Me2S (2 mL) and a solution of substrate 16 (152 mg, 0.183 mmol) in 
1.5 mL were added. The flask was immersed in an oil bath (40 °C), heated to reflux  under Ar 
and the stop-cock to Ar-line was closed. The closed flask was heated at 40 °C for 12 h. 
Saturated aq. NaHCO3 (5 mL) was added and the organic solvents were removed in vacuo. 
The water phase was extracted with EtOAc (4x15 mL). The combined organic phases were 
washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was subjected to 
column chromatography (EtOAc/toluene) to obtain starting 16 (27 mg, 18%) and the desired 
diol 30 (83 mg, 70% b.r.s.m.) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 5.94 (ddd, J = 9.3, 6.7, 2.2 Hz, 1H), 5.57 (dd, J = 9.5, 2.3 
Hz, 1H), 5.53 (dd, J = 10.0, 0.9 Hz, 1H), 4.08 (d, J = 5.0 Hz, 1H), 4.00 (d, J = 4.3 Hz, 1H), 
3.88 (ddd, J = 7.0, 4.4, 1.2 Hz, 1H), 3.72-3.61 (m, 1H), 3.63 (dd, J = 10.9, 2.5 Hz, 1H), 3.54 - 
3.45 (m, 1H), 3.43 (dd, J = 9.8, 4.4 Hz, 1H), 3.37 (dd, J = 9.7, 7.1 Hz, 1H), 3.35 - 3.30 (m, 
2H), 3.32 (3H), 3.22 (s, 3H), 3.20 (dd, J = 9.4, 0.9 Hz, 1H), 2.82 (dd, J = 7.6, 5.3 Hz, 1H), 
2.84 - 2.74 (m, 1H), 2.74 - 2.68 (m, 1H), 2.69 (d, J = 6.6 Hz, 1H), 2.56 (d, J = 9.4 Hz, 1H), 
2.58 - 2.50 (m, 1H), 2.33 (d, J = 2.2 Hz, 1H), 1.79 (d, J = 0.90 Hz, 1H), 1.66 - 1.47 (m, 2H), 
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1.09 (d, J = 6.7 Hz, 1H), 0.91 (s, 9H), 0.90 (s, 9H), 0.88 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H), 
0.07 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), 0.01 (s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 133.4, 130.3, 129.9, 129.2, 90.3, 86.1, 76.5, 75.4, 72.4, 
72.2, 70.3, 69.2, 60.3, 58.9, 58.4, 50.5, 43.1, 40.2, 39.3, 37.1, 32.4, 26.4, 26.1, 26.0, 18.5, 
18.4, 18.2, 17.4, 17.0, -3.1, -3.7, -4.5, -4.6, -5.19, -5.22. 
IR (film): 3470, 1474, 1422, 1387, 1349, 1252, 1223, 1103, 1083, 1039, 921, 898, 880, 835, 
797, 775, 722, 671, 649, 611, 419 cm-1. 
HRMS (ESI): calc. for C41H80NaO8Si3 [M+Na]+ 807.5059; found: 807.5063. 
[α]D20  = + 105.4 (c = 0.280, CHCl3). 
 
 
Aldehyde (31). 
To diol 30 (46 mg, 0.060 mmol) at rt was added a solution of TEMPO (purified by 
sublimation in vacuo; 3.0 mg, 0.019 mmol) and PhI(OAc)2 (45 mg, 0.140 mmol) in DCM 
(0.45 mL) and the clear solution was stirred at rt for 2 h. Then a mixture EtOAc/hexane (1:1, 3 
mL) was added and the solution was passed through a short plug of silica gel (elution with 
EtOAc/hexanes 1:1) to remove PhI(OAc)2. The resulting solution was concentrated, the 
residue was dissolved in toluene (3 mL) and passed through a short silica gel column (1.5 g 
SiO2, elution with toluene; 2% EtOAc/toluene) to separate from most of TEMPO. (NOTE: 
slow column chromatography with oxidizing reagents cause partial oxidation of aldehyde 31 
to the corresponding acid 17; aq. saturated Na2S2O3 in our hands was not effective enough to 
reduce oxidizing PhI(OAc)2 and TEMPO). The fractions containing 31 were concentrated and 
subjected to column chromatography (EtOAc/toluene) to obtain aldehyde 31 (40 mg, 87%) as 
a colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 9.75 (d, J = 1.9 Hz, 1H), 5.96 (ddd, J = 9.4, 6.8, 2.2 Hz, 
1H), 5.62 (dd, J = 9.6, 0.8 Hz, 1H), 5.54 (dd, J = 9.4, 2.5 Hz, 1H), 4.05 (d, J = 5.0 Hz, 1H), 
4.00 (dd, J = 4.5, 4.5 Hz, 1H), 3.80 (ddd, J = 6.5, 4.9, 1.4 Hz, 1H), 3.63 (dd, J = 11.0, 2.5 Hz, 
1H), 3.41 (dd, J = 9.5, 4.9 Hz, 1H), 3.36 (dd, J = 9.5, 6.6 Hz, 1H), 3.33 - 3.25 (m, 3H), 3.32 (s, 
3H), 3.23 (s, 3H), 3.13 - 3.09 (m, 1H), 2.79 - 2.72 (m, 1H), 2.70 (d, J = 6.3 Hz, 1H), 2.58 - 
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2.50 (m, 1H), 2.48 - 2.43 (m, 2H), 2.40 (dd, J = 8.4, 2.5 Hz, 1H), 2.32 (d, J = 2.2 Hz, 1H), 
1.67 (d, J = 0.8 Hz, 1H), 1.09 (d, J= 6.9 Hz, 3H), 0.92 (s, 9H), 0.89 (s, 9H), 0.88 (s, 9H), 0.08 
(s, 3H), 0.08 (s, 3H), 0.04 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), 0.02(s, 3H). 
13C-NMR (100 MHz, CDCl3): δ = 202.1, 132.8, 130.3, 129.9, 129.5, 89.5, 86.1, 75.6, 75.3, 
72.2, 72.1, 70.2, 69.1, 58.9, 58.4, 50.2, 43.4, 41.1, 40.1, 39.1, 36.6, 26.3, 26.0, 25.9, 18.3, 
18.1, 16.9, 16.8, -3.3, 3.8, -4.6, -4.7, -5.3. 
IR (film): 3464, 1730, 1479, 1421, 1387, 1345, 1252, 1223, 1103, 1082, 1039, 921, 898, 885, 
835, 797, 770, 722, 671, 649, 611, 419 cm-1. 
HRMS (ESI): calc. for C41H78NaO8Si3 [M+Na]+ 805.4902; found: 805.4898. 
[α]D20  = + 92.0 (c = 0.275, CHCl3). 
 
 
Seco acid (17). 
To a solution of aldehyde 31 (25 mg, 0.032 mmol) in tBuOH (0.6 mL) was added 2-methyl-2-
butene (1.4 mL) and the mixture was cooled to 17 °C. A solution of NaClO2 (80%, 40 mg, 
0.356 mmol) and NaH2PO4*H2O (80mg, 0.580 mmol) in water (0.4 mL) was added and the 
mixture was stirred at 17 °C for 40 min. Chloroform (20 mL) was added and the organic phase 
was washed with water (2x5 mL). Combined aqueous phases were extracted with chloroform 
(4x15 mL) and the combined organic phases were washed with brine (20 mL), passed through 
a plug of cotton and concentrated in vacuo. The residue was subjected to column 
chromatography (EtOAc/hexane/1% iPrOH) to obtain acid 17 (21.9 mg, 85%).  
1H-NMR (400 MHz, CDCl3): δ = 5.97 (ddd, J = 9.4, 6.9, 2.0 Hz, 1H), 5.60 (dd, J = 9.6, 0.8 
Hz, 1H), 5.54 (dd, J = 9.4, 2.5 Hz, 1H), 4.11 (d, J = 5.0 Hz, 1H), 4.04 (dd, J = 4.5, 4.5 Hz, 
1H), 3.82 (dd, J = 6.1, 1.1 Hz, 1H), 3.46 - 3.36 (m, 2H), 3.34-3.27 (m, 3H), 3.33 (s, 3H), 3.23 
(s, 3H), 3.07 (m, 1H), 2.82 - 2.72 (m, 1H), 2.70 (d, J = 6.6 Hz, 1H), 2.60 - 2.49 (m, 2H), 2.32 
(d, J = 2.2 Hz, 1H), 2.21 (dd, J = 16.0, 6.8 Hz, 1H), 1.72 (bs, 3H), 1.08 (d, J = 6.7 Hz, 3H), 
0.92 (s, 9H), 0.82 (s, 9H), 0.78 (s, 3H), 0.08 (s, 3H), 0.04 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), 
0.02 (s, 3H). 
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13C-NMR (100 MHz, CDCl3): δ = 175.5, 133.0, 130.4, 130.2, 129.7, 89.8, 86.2, 75.3, 74.6, 
72.4, 71.9, 70.3, 69.2, 59.0, 58.5, 50.5, 42.4, 40.3, 39.0, 36.7, 34.2, 26.4, 26.1, 26.0, 18.42, 
18.39, 18.2, 17.3, 16.9, -3.1, -3.7, -4.5, -4.7, -5.20, -5.23. 
IR (film): 3460, 1710, 1479, 1421, 1387, 1345, 1252, 1223, 1103, 1082, 1039, 921, 898, 885, 
835, 797, 770, 722, 671, 649, 611, 419 cm-1. 
HRMS (ESI): calc. for C41H78NaO9Si3 [M+Na]+ 821.4851; found: 821.4857. 
[α]D20  = + 80.0 (c = 0.48, CHCl3). 
 
 
Macrolactone (18). 
To acid 17 (2.5 mg, 0.003 mmol) was added a solution of iPr2NEt (3.8 µL, 2.9 mg, 0.023 
mmol) and 2,4,6-trichlorobenzoyl chloride (2.2 µL, 3.4 mg, 0.014 mmol) in toluene (90 µL), 
and the mixture was stirred at rt for 6 h. The mixture was diluted with toluene (3.5 mL) and 
added via syringe pump to a solution of DMAP (17.0 mg, 0.14 mmol) in toluene (5.0 mL) at 
110 °C over 2 h. Saturated aq. NaHCO3 (10 mL) was added and the mixture was stirred for 15 
min until phases became clear. The mixture was extracted with EtOAc (3x20 mL). The 
combined organic phases were washed with saturated aq. NaHCO3 (20 mL), aq. NaH2PO4 
(2M, 30 mL), saturated aq. NaHCO3 (20 mL), brine (20 mL) and dried over MgSO4. The 
solvents were removed in vacuo and the residue was subjected to column chromatography 
(SiO2, EtOAc/hexanes) to obtain lactone 18 (1.2 mg, 50%). 
1H-NMR (600 MHz, CDCl3): δ = 5.91 (ddd, J = 9.2, 6.7, 2.3 Hz, 1H), 5.74 (dd, J = 8.9, 1.2 
Hz, 1H), 5.40 (dd, J = 9.5, 2.3 Hz, 1H), 4.94 (dd, J = 6.9, 6.9 Hz, 1H), 4.11 - 4.06 (m, 1H), 
4.02 – 3.96 (m, 2H), 3.67 (dd, J = 11.3, 2.1 Hz, 1H), 3.47 (dd, J = 9.9, 6.6 Hz, 1H), 3.43 (dd, J 
= 9.9, 6.2 Hz, 1H), 3.39 – 3.28 (m, 2H), 3.36 (s, 3H), 3.22 (s, 3H), 3.15 (md, J = 11.6 Hz, 1H), 
2.82 – 2.75 (m, 1H), 2.68 (d, J = 6.8 Hz, 1H), 2.57 – 2.49 (m, 2H), 2.33 (d, J = 1.8 Hz, 1H), 
2.01 (dd, J = 9.3, 1.0 Hz, 1H), 1.65 (d, J = 1.1 Hz, 3H), 1.17 (d, J = 7.0 Hz, 3H), 0.89 (s, 9H), 
0.89 (s, 9H), 0.88 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.05 (s, 3H), 0.03 (s, 3H), 0.03 (s, 3H), 
0.02 (s, 3H). 
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13C-NMR (150.9 MHz, CDCl3): δ = 175.2, 135.9, 134.9, 131.0, 128.9, 89.0, 84.7, 80.1, 75.6, 
72.4, 71.6, 70.2, 69.3, 68.3, 59.3, 58.2, 50.1, 49.7, 40.9, 40.1, 38.9, 36.6, 32.6, 30.5, 29.8, 
29.1, 26.4, 26.0, 26.0, 18.5, 18.5, 18.2, 17.1, 15.8, -3.4, -3.9, -4.4, -4.7, -5.0, -5.2. 
IR (film): 2928, 1729, 1577, 1464, 1388, 1258, 1116, 866, 836, 777, 671, 494, 448, 430, 411, 
404 cm-1. 
HRMS (ESI): calc. for C41H76NaO8Si3 [M+Na]+ 803.4746; found: 803.4742. 
[α]D20  = + 52.0 (c = 0.1, CHCl3). 
 
 
Diester (32). 
To a solution of Na (6 mg, 0.263 mmol) in MeOH (0.8 mL) was added dimethyl malonate ( 
0.18 mL, 1.579 mmol) at rt and the resulting mixture was stirred for 5 min. This mixture was 
then cooled to – 21 °C and a solution of enone 12 (140 mg, 0.175 mmol) in MeOH (0.8 mL) 
was added. The mixture was warmed to rt over night, then diluted with Et2O and quenched 
with aq. saturated NH4Cl. The water phase was extracted with Et2O (3x3 mL). The combined 
organic layers were washed with brine, dried (MgSO4) and concentrated in vacuo to give a 
residue, which was purified by flash chromatography (EtOAc/hexane) on silica gel to afford 
144 mg (88 %) of adduct 32 as an oil. 
1H-NMR (600 MHz, CDCl3): 5.88 (d, J = 10.0 Hz, 1H), 4.76 (d, J = 6.6 Hz, 1H), 4.69 (d, 
J = 6.6 Hz, 1H), 4.02 – 3.94 (m, 3H), 3.68 (s, 3H), 3.66 (s, 3H), 3.58 (d, J = 2.6 Hz, 1H), 3.56 
(dd, J = 11.2, 2.5 Hz, 1H), 3.51 (dd, J = 9.5, 4.7 Hz, 1H), 3.44 (dd, J = 4.6, 4.6 Hz, 1H), 3.42 
(s, 3H), 3.38 (dd, J = 9.5, 6.4 Hz, 1H), 3.34 (s, 3H), 3.32 – 3.26 (m, 2H), 3.22 (s, 3H), 3.10 
(dd, J = 17.4, 7.2 Hz, 1H), 3.04 (s, 1H), 2.94 – 2.87 (m, 2H), 2.87 – 2.80 (m, 1H), 2.56 (dd, J 
= 17.4, 8.7 Hz, 1H), 2.42 (d, J = 2.4 Hz, 1H), 1.71 (d, J = 1.1 Hz, 1H), 1.04 (d, J = 7.0 Hz, 
1H), 0.91 (s, 9H), 0.89 (s, 9H), 0.87 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H), 0.04 (s, 6H), 0.03 (s, 
3H), 0.00 (s, 3H). 
13C-NMR (150.9 MHz, CDCl3): 208.5169.6, 169.2, 133.0, 129.6, 100.1, 98.4, 89.8, 83.0, 
80.9, 75.0, 73.3, 71.4, 69.9, 68.8, 58.9, 58.6, 55.9, 53.4, 52.8, 52.0, 49.6, 49.4, 42.2, 41.1, 
37.1, 33.3, 26.3, 26.1, 26.0, 18.4, 18.3, 18.2, 16.7, 15.9, -3.2, -4.2, -4.4, -4.5, -5.3. 
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IR (film): 2928, 2851, 1792, 1735, 1539, 1473, 1307, 1254, 1177, 1118, 1060, 1028, 949, 
837, 794, 777, 676, 420, 418, 416, 403 cm-1. 
HRMS (ESI): calc. for C46H86O13Si3Na [M + Na]+: 953.5274; found: 953.5291. 
[α]D20  = + 42.4 (c = 0.55, CHCl3). 
 
 
Vinyltriflate (33). 
To a solution of N-Phenyltrifluoromethanesulfonimide (230 mg, 0.644 mmol) in THF (1.3 
mL) at – 78 °C was added KHMDS (0.5 M in toluene, 1.3 mL, 0.644 mmol) and the resulting 
mixture was stirred for 5 min. A solution of 32 (150 mg, 0.161 mmol) in THF (2 mL) was 
added dropwise and after further 10 min at – 78 °C the reaction mixture was warmed to rt and 
stirred for 30 min. The reaction was diluted with toluene and quenched with aq. saturated 
NH4Cl. The layers were separated and the organic phase was washed with H2O (2x3 mL) and 
brine. The solvents were removed under reduced pressure and the residue was subjected to 
column chromatography (EtOAc/hexane) to yield 159 mg (93 %) of vinyl triflate 33. 
1H-NMR (400 MHz, C6D6): 6.32 (s, 1H), 6.26 (d, J = 10.2 Hz, 1H), 4.79 (d, J = 6.6 Hz, 
1H), 4.71 (d, J = 6.6 Hz, 1H), 4.61 (d, J = 5.1 Hz, 1H), 4.34 – 4.28 (m, 1H), 4.20 (dd, J = 4.4, 
4.4 Hz, 1H), 4.07 (d, J = 2.7 Hz, 1H), 3.85 (dd, J = 11.1, 2.5 Hz, 1H), 3.77 (dd, J = 2.8, 2.8 
Hz, 1H), 3.67 – 3.61 (m, 2H), 3.59 (s, 3H), 3.52 – 3.45 (m, 3H), 3.30 (s, 3H), 3.27 (s, 3H), 
3.26 – 3.18 (m, 2H), 3.16 (s, 3H), 3.14 (s, 3H), 3.11 – 3.02 (m, 1H), 2.67 (d, J = 2.2 Hz, 1H), 
1.84 (d, J = 0.8 Hz, 3H), 1.31 (d, J = 6.9 Hz, 3H), 1.05 (s, 9H), 0.99 (s, 9H), 0.95 (s, 9H), 0.27 
(s, 3H), 0.22 (s, 3H), 0.06 (s, 3H), 0.03 (s, 3H), 0.01 (s, 3H), -0.02 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 169.5, 168.2, 149.4, 134.3, 123.8, 118.6, 99.0, 89.3, 85.5, 
84.1, 75.3, 74.3, 71.9, 70.2, 69.3, 58.6, 58.5, 55.7, 52.4, 51.9, 51.5, 50.0, 46.0, 44.1, 41.2, 
33.4, 26.4, 26.2, 26.1, 18.4, 18.2, 16.6, 16.2, -3.4, -3.8, -4.4, -4.5, -5.3, -5.4. 
IR (film): 3175, 2956, 2932, 2893, 2858, 1738, 1700, 1473, 1463, 1423, 1388, 1361, 1255, 
1212, 1143, 1120, 1045, 934, 868, 838, 778, 609 cm-1. 
HRMS (ESI): calc. for C47H85F3O15SSi3Na [M + Na]+: 1085.4767; found: 1085.4784. 
[α]D20  = + 80.0 (c = 0.53, CHCl3). 
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Diester (20). 
To a solution of vinyl triflate 33 (103 mg, 0.097 mmol) in degassed THF (2.2 mL) was added 
LiCl (32 mg, 0.776 mmol), tetrakis(triphenylphosphine)palladium(0) (22 mg, 0.0194 mmol) 
and 2,6-lutidine (0.068 mL, 0.582 mmol), followed by dropwise addition of n-tributyltin 
hydride (0.103 mL, 0.388 mmol) at 15 °C. The reaction mixture was allowed to warm to rt 
and stirred for 14 h, then diluted with toluene and quenched with aq. saturated NH4Cl. The 
layers were separated and the water phase was extracted with toluene (3x4 mL). The 
combined organic phases were washed with brine and the solvents were removed under 
reduced pressure. The residue was subjected to column chromatography (EtOAc/hexane) to 
obtain diester 20 (69 mg, 78 %) as a colorless oil. 
1H-NMR (400 MHz, C6D6): 6.27 (d, J = 10.1 Hz, 1H), 6.24 (dd, J = 9.6, 2.5 Hz, 1H), 6.07 
(ddd, J = 9.6, 6.9, 2.3 Hz, 1H), 4.79 (d, J = 6.5 Hz, 1H), 4.72 (d, J = 6.5 Hz, 1H), 4.37 – 4.31 
(m, 1H), 4.29 (d, J = 5.0 Hz, 1H), 4.21 (dd, J = 4.4, 4.4 Hz, 1H), 4.09 (d, J = 2.9 Hz, 1H), 3.86 
(dd, J = 5.1, 2.5 Hz, 1H), 3.79 (dd, J = 11.0, 2.6 Hz, 1H), 3.69 - 3.62 (m, 2H), 3.61 (s, 3H), 
3.56 – 3.49 (m, 3H), 3.38 (s, 3H), 3.30 (s, 3H), 3.31 – 3.22 (m, 1H), 3.20 (m, 3H), 3.17 – 3.08 
(m, 1H), 3.14 (s, 3H), 2.83 (d, J = 6.9 Hz, 1H), 2.52 (d, J = 2.5 Hz, 1H), 1.95 (d, J = 0.9 Hz, 
3H), 1.35 (d, J = 6.9 Hz, 3H), 1.07 (s, 9H), 0.98 (s, 9H), 0.95 (s, 9H), 0.28 (s, 3H), 0.24 (s, 
3H), 0.08 (s, 3H), 0.00 (s, 3H), - 0.01 (s, 3H), 0.03 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 170.3, 168.6, 133.0, 130.9, 129.3, 128.2, 98.9, 90.1, 86.5, 
84.2, 75.5, 74.2, 72.9, 70.7, 69.9, 58.6, 58.5, 52.1, 51.5, 51.3, 47.8, 41.0, 39.6, 33.5, 26.5, 
26.3, 26.1, 16.9, 16.5, - 3.2, - 3.8, - 4.5, - 5.2, - 5.3. 
IR (film): 2932, 2914, 2771, 2703, 1738, 1651, 1573, 1488, 1391, 1254, 1101, 1023, 837, 
781, 652, 543, 498, 475, 449, 419 cm-1. 
HRMS (ESI): calc. for C46H86O12Si3Na [M + Na]+: 937.5412; found: 937.5422. 
[α]D20  = + 104.9 (c = 0.47, CHCl3). 
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Diol (21). 
To a flask charged with diester 20 (60 mg, 0.066 mmol) was added dropwise under stirring 
Super-Hydride (1.0 M in THF, 2.0 mL, 2.00 mmol) at 0 °C. The resulting mixture was 
warmed to rt and stirred for 18 h. Pentaerythritol (540 mg, 4.00 mmol) was added carefully 
and the reaction mixture was stirred for 30 min. Aq. saturated NH4Cl (2 mL) followed by 
MeOH (2 mL) were added and the water phase was extracted with EtOAc (5x10 mL). The 
combined organic phases were diluted with toluene (20 mL), washed with brine (10 mL) and 
concentrated in vacuo. The residue was concentrated repeatedly from methanol (5x2 mL) and 
then purified by flash chromatography (EtOAc/hexane) to afford 48 mg (85 %) of diol 21 as 
an oil. 
1H-NMR (400 MHz, C6D6): 6.13 (dd, J = 10.1, 1.0 Hz, 1H), 5.93 (ddd, J = 9.4, 6.6, 2.5 
Hz, 1H), 5.55 (dd, J = 9.5, 2.4 Hz, 1H), 4.72 (d, J = 6.8 Hz, 1H), 4.64 (d, J = 6.8 Hz, 1H), 4.29 
(d, J = 5.1 Hz, 1H), 4.25 – 4.16 (m, 2H), 4.13 (ddd, J = 8.2, 4.5, 3.8 Hz, 1H), 3.83 – 3.63 (m, 
4H), 3.59 – 3.51 (m, 4H), 3.51 – 3.41 (m, 2H), 3.26 (s, 3H), 3.22 (s, 3H), 3.15 (s, 3H), 3.18 – 
3.05 (m, 2H), 2.90 (dd, J = 3.8, 2.2 Hz, 1H), 2.83 (d, J = 6.7 Hz, 1H), 2.49 (d, J = 2.3 Hz, 1H), 
2.36 – 2.19 (m, 2H), 1.91 (d, J = 1.0 Hz, 3H), 1.31 (d, J = 6.8 Hz, 3H), 1.07 (s, 9H), 0.99 (s, 
9H), 0.96 (s, 9H), 0.25 (s, 6H), 0.10 (s, 3H), 0.03 (s, 3H), - 0.01 (s, 3H), - 0.03 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 132.5, 131.6, 129.6, 128.4, 98.3, 91.5, 86.3, 83.5, 76.1, 
74.3, 72.8, 70.7, 69.8, 65.7, 62.7, 58.7, 58.4, 55.7, 51.3, 46.6, 43.2, 40.8, 39.8, 34.7, 26.5, 
26.3, 26.1, 18.7, 18.5, 18.3, 17.4, 16.5, - 3.1, - 4.0, - 4.1, - 4.5, - 5.2, - 5.3. 
IR (film): 3436, 2954, 2929, 2891, 2857, 1472, 1463, 1389, 1361, 1253, 1196, 1117, 1034, 
974, 914, 836, 802, 776, 668, 498, 436 cm-1. 
HRMS (ESI): calc. for C44H86O10Si3Na [M + Na]+: 881.5427; found: 881.5417. 
[α]D20  = + 70.9 (c = 0.55, CHCl3). 
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Alcohol (34). 
To a solution of diol 21 (47 mg, 0.055 mmol) in MeI (0.7 mL, 11.24 mmol) was added Ag2O 
(21.6 mg, 0.093 mmol) and the resulting mixture was refluxed for 24 h. The reaction mixture 
was diluted with DCM, filtrated through a pad of celite and the filtrate was concentrated in 
vacuo to give a residue which was flash chromatographed (EtOAc/hexane) to give 28.5 mg of 
diastereomers 34a/b (99% b.r.s.m., 60% conversion, d.r. = 1:1) as a colorless oil. 
IR (film): 3435, 2954, 2929, 2890, 2857, 1472, 1389, 1361, 1252, 1196, 1117, 1033, 974, 
914, 836, 802, 776, 677, 424, 407 cm-1. 
HRMS (ESI): calc. for C45H88O10Si3Na [M + Na]+: 895.5583; found: 895.5568. 
 
 
Diol (22a). 
To a flask charged with MgBr2*OEt2 (905 mg, 3.51 mmol) were added Me2S (2.9 mL) and a 
solution of alcohols 34a/b (51 mg, 0.058 mmol) in 1.9 mL DCM. The reaction mixture was 
heated at 40 °C for 6 h. Saturated aq. NaHCO3 (2 mL) was added and the water phase was 
extracted with EtOAc (4x5 mL). The combined organic phases were washed with brine, dried 
over MgSO4 and concentrated in vacuo. The crude product was subjected to column 
chromatography (EtOAc/hexane) to yield 25.5 mg of diols 22a/b (70% b.r.s.m., 75% 
conversion) as a colorless oil. 
1H-NMR (400 MHz, C6D6): 6.05 (dd, J = 9.8, 1.0 Hz, 1H), 5.97 (ddd, J = 9.5, 6.7, 2.5 Hz, 
1H), 5.67 (dd, J = 9.6, 2.4 Hz, 1H), 4.26 (d, J = 5.0 Hz, 1H), 4.21 (dd, J = 4.3, 4.3 Hz, 1H), 
4.12 (ddd, J = 6.7, 5.0, 1.2 Hz, 1H), 4.07 (dd, J = 9.4, 3.9 Hz, 1H), 3.96 (dd, J = 10.4, 5.9 Hz, 
1H), 3.80 (dd, J = 11.1, 2.6 Hz, 1H), 3.64 – 3.56 (m, 1H), 3.56 – 3.47 (m, 3H), 3.44 – 3.34 (m, 
3H), 3.23 – 3.17 (m, 1H), 3.20 (s, 3H), 3.14 (s, 3H), 3.03 (s, 3H), 2.97 – 2.93 (m, 1H), 2.93 – 
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2.87 (m, 1H), 2.84 (d, J = 6.7 Hz, 1H), 2.72 (d, J = 9.4 Hz, 1H), 2.48 (d, J = 2.3 Hz, 1H), 2.44 
– 2.31 (m, 2H), 1.97 (d, J = 0.9 Hz, 3H), 1.51 (d, J = 6.8 Hz, 3H), 0.99 (s, 9H), 0.98 (s, 9H), 
0.97 (s, 9H), 0.29 (s, 3H), 0.21 (s, 3H), 0.10 (s, 3H), 0.04 (s, 3H), 0.00 (s, 3H), - 0.03 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 134.0, 130.9, 129.7, 128.4, 91.7, 86.0, 76.2, 75.5, 73.7, 
73.0, 72.6, 70.7, 70.0, 65.6, 58.7, 58.5, 58.4, 51.5, 45.7, 40.7, 40.1, 39.9, 37.4, 26.5, 26.2, 
26.1, 18.6, 18.5, 18.4, 17.7, 17.6, - 3.2, - 3.7, - 4.3, - 4.5, - 5.2, - 5.3. 
IR (film): 3511, 2926, 2855, 1472, 1462, 1388, 1360, 1251, 1196, 1116, 1085, 1024, 965, 
911, 886, 836, 802, 776, 677, 595, 498, 436, 424, 420, 402 cm-1. 
HRMS (ESI): calc. for C43H84O9Si3Na [M + Na]+: 851.5321; found: 851.5311. 
[α]D20  = + 82.1 (c = 0.23, CHCl3). 
22b: 1H-NMR (400 MHz, C6D6): 6.03 – 5.96 (m, 2H), 5.66 (dd, J = 9.7, 2.1 Hz, 1H), 4.30 
(d, J = 5.0 Hz, 1H), 4.22 (ddd, J = 6.9, 5.9, 1.3 Hz, 1H), 4.16 (dd, J = 4.4, 4.4 Hz, 1H), 4.09 – 
3.94 (m, 2H), 3.79 (dd, J = 11.1, 2.5 Hz, 1H), 3.56 – 3.46 (m, 4H), 3.43 (d, J = 1.2 Hz, 1H), 
3.42 (s, 1H), 3.37 (dd, J = 9.1, 4.9 Hz, 1H), 3.32 (m, 1H), 3.20 (s, 3H), 3.20 (m, 1H), 3.10 (s, 
3H), 3.09 (s, 3H), 3.09 (m, 1H), 2.96 – 2.90 (m, 1H), 2.87 (d, J = 6.9 Hz, 1H), 2.78 (d, J = 9.3 
Hz, 1H), 2.59 (d, J = 2.2 Hz, 1H), 2.47 – 2.38 (m, 1H), 2.01 (d, J = 0.9 Hz, 3H), 1.52 (d, J = 
6.7 Hz, 3H), 1.00 (s, 9H), 0.96 (s, 9H), 0.95 (s, 9H), 0.29 (s, 3H), 0.25 (s, 3H), 0.08 (s, 3H), - 
0.01 (s, 3H), - 0.02 (s, 3H), - 0.08 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 133.4, 131.2, 129.8, 128.4, 91.8, 86.6, 76.2, 75.8, 73.5, 
72.9, 72.5, 70.6, 69.6, 61.3, 58.7, 58.6, 58.5, 51.7, 46.2, 41.7, 40.6, 40.2, 37.6, 26.4, 26.3, 
26.1, 18.6, 18.5, 18.3, 17.6, 17.3, - 3.3, - 3.8, - 4.6, - 4.7, - 5.2, - 5.3. 
 
 
Aldehyde (35a). 
To diol 22a (36 mg, 0.043 mmol) was added a solution of TEMPO (4.0 mg, 0.026 mmol) and 
PhI(OAc)2 (70 mg, 0.217 mmol) in DCM (0.7 mL) and the mixture was stirred at rt for 2 h. 
Then a mixture EtOAc/hexanes (1:1, 2.5 mL) was added and the solution was passed through 
a short plug of silica gel (elution with EtOAc/hexanes 1:1). The fractions containing 35a were 
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concentrated and subjected to column chromatography (EtOAc/toluene) to obtain aldehyde 
35a (33 mg, 92%) as a colorless oil. 
1H-NMR (400 MHz, C6D6): 10.09 (d, J = 2.3 Hz, 1H), 6.07 (d, J = 9.7 Hz, 1H), 5.97 (ddd, 
J = 9.3, 6.7, 2.3 Hz, 1H), 5.77 (dd, J = 9.6, 2.3 Hz, 1H), 4.24 (d, J = 5.0 Hz, 1H), 4.18 (dd, J = 
4.3, 4.3 Hz, 1H), 4.09 (ddd, J = 5.8, 5.8, 1.5 Hz, 1H), 3.79 (dd, J = 11.0, 2.5 Hz, 1H), 3.57 (dd, 
J = 9.4, 5.1 Hz, 1H), 3.54 – 3.42 (m, 4H), 3.37 (d, J = 5.8 Hz, 2H), 3.28 (dd, J = 4.5, 2.2 Hz, 
1H), 3.20 (s, 3H), 3.20 – 3.10 (m, 2H), 3.07 (s, 3H), 3.06 (s, 3H), 2.94 – 2.86 (m, 1H), 2.83 (d, 
J = 6.7 Hz, 1H), 2.70 (d, J = 8.9 Hz, 1H), 2.49 (d, J = 2.3 Hz, 1H), 1.95 (d, J = 0.8 Hz, 3H), 
1.51 (d, J = 6.7 Hz, 3H), 0.98 (s, 9H), 0.97 (s, 9H), 0.96 (s, 9H), 0.23 (s, 3H), 0.20 (s, 3H), 
0.09 (s, 3H), 0.01 (s, 3H), - 0.01 (s, 3H), - 0.06 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 202.1, 133.3, 131.7, 130.8, 127.2, 91.0, 87.0, 76.1, 75.6, 
72.8, 72.7, 70.6, 70.4, 69.7, 58.8, 58.6, 58.4, 51.2, 50.5, 46.6, 40.7, 39.9, 37.6, 26.4, 26.2, 
26.1, 18.6, 18.5, 18.3, 17.5, 17.2, - 3.3, - 3.8, - 4.5, - 4.7, - 5.2, - 5.3. 
IR (film): 3520, 2954, 2929, 2895, 2857, 1714, 1472, 1390, 1360, 1252, 1196, 1117, 1085, 
1026, 966, 888, 837, 778, 680, 664, 595, 508, 483, 439, 430, 422, 418, 411, 404 cm-1. 
HRMS (ESI): calc. for C43H82O9Si3Na [M + Na]+: 849.5164; found: 849.5179. 
[α]D20  = + 73.6 (c = 0.19, CHCl3). 
 
 
Aldehyde (35b). 
1H-NMR (400 MHz, C6D6): 10.00 (d, J = 0.5 Hz, 1H), 6.08 (dd, J = 9.7, 0.8 Hz, 1H), 5.92 
(ddd, J = 9.4, 6.7, 2.3 Hz, 1H), 5.53 (dd, J = 9.4, 2.3 Hz, 1H), 4.23 (d, J = 5.0 Hz, 1H), 4.20 – 
4.17 (m, 1H), 4.13 (dd, J = 9.3, 4.4 Hz, 1H), 4.02 (ddd, J = 6.1, 6.1, 1.5 Hz, 1H), 3.78 (dd, J = 
11.0, 2.5 Hz, 1H), 3.70 (dd, J = 9.2, 9.2 Hz, 1H), 3.58 – 3.49 (m, 4H), 3.36 (d, J = 6.0 Hz, 
2H), 3.18 (s, 3H), 3.17 – 3.07 (m, 1H), 3.14 (s, 3H), 3.03 (s, 3H), 3.03 – 2.98 (m, 1H), 2.91 – 
2.83 (m, 1H), 2.83 (d, J = 6.8 Hz, 1H), 2.61 (d, J = 9.3 Hz, 1H), 2.49 (d, J = 2.3 Hz, 1H), 1.92 
(d, J = 0.8 Hz, 3H), 1.49 (d, J = 6.7 Hz, 3H), 0.96 (s, 9H), 0.95 (s, 9H), 0.94 (s, 9H), 0.19 (s, 
3H), 0.17 (s, 3H), 0.09 (s, 3H), 0.01 (s, 3H), - 0.01 (s, 3H), - 0.04 (s, 3H). 
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13C-NMR (100.6 MHz, C6D6): 203.5, 133.6, 131.6, 130.3, 128.4, 91.2, 86.1, 75.7, 75.5, 
72.9, 72.5, 70.6, 70.2, 69.9, 58.8, 58.5, 58.4, 51.5, 51.0, 43.8, 40.7, 39.9, 37.1, 26.4, 26.2, 
26.1, 18.5, 18.5, 18.3, 17.4, 17.3, - 3.2, - 3.7, - 4.3, - 4.5, - 5.2, - 5.3. 
 
 
Seco acid (23a). 
To a solution of aldehyde 35a (26 mg, 0.031 mmol) in tBuOH (0.9 mL) was added 2-methyl-
2-butene (1.3 mL) and the mixture was cooled to 15 °C. A solution of NaClO2 (80%, 39 mg, 
0.35 mmol) and NaH2PO4*H2O (78 mg, 0.57 mmol) in water (0.7 mL) was added and the 
mixture was stirred at 15 °C for 30 min. Chloroform (20 mL) was added and the organic phase 
was washed with water (2x4 mL). The combined aqueous phases were extracted with 
chloroform (4x15 mL) and the combined organic phases were washed with brine (10 mL), 
passed through a plug of cotton and concentrated in vacuo. The residue was subjected to 
column chromatography (EtOAc/hexanes/iPrOH) to afford 23.9 mg of seco acid 23a (90%). 
1H-NMR (400 MHz, C6D6): 6.00 (dd, J = 9.8, 1.0 Hz, 1H), 5.86 (ddd, J = 9.4, 6.6, 2.5 Hz, 
1H), 5.70 (dd, J = 9.5, 2.3 Hz, 1H), 4.37 (d, J = 5.0 Hz, 1H), 4.11 (dd, J = 4.4, 4.4 Hz, 1H), 
4.00 – 3.95 (m, 1H), 3.94 (dd, J = 9.6, 4.4 Hz, 1H), 3.74 (dd, J = 11.1, 2.5 Hz, 1H), 3.56 – 
3.44 (m, 4H), 3.39 (dd, J = 2.2, 2.2 Hz, 1H), 3.36 – 3.30 (m, 2H), 3.27 (dd, J = 9.5, 6.5 Hz, 
1H), 3.17 (s, 3H), 3.10 (s, 3H), 3.08 (s, 3H), 3.10 – 3.02 (m, 1H), 2.92 – 2.82 (m, 1H), 2.83 (d, 
J = 6.6 Hz, 1H), 2.51 (d, J =2.3 Hz, 1H), 2.00 (d, J = 0.9 Hz, 3H), 1.50 (d, J = 6.7 Hz, 3H), 
0.96 (s, 9H), 0.94 (s, 9H), 0.92 (s, 9H), 0.20 (s, 3H), 0.16 (s, 3H), 0.05 (s, 3H), - 0.04 (s, 3H), - 
0.05 (s, 3H), - 0.10 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 170.9, 132.5, 130.4, 128.3, 126.9, 93.0, 87.1, 75.9, 75.1, 
72.7, 72.4, 71.5, 70.3, 68.8, 58.8, 58.7, 58.5, 51.2, 44.8, 44.5, 40.8, 39.7, 38.0, 26.4, 26.1, 
26.1, 18.5, 18.4, 18.2, 17.4, 16.9, - 3.3, - 4.0, - 4.6, - 5.0, - 5.3, - 5.4. 
IR (film): 3546, 2953, 2929, 2894, 2858, 1735, 1707, 1472, 1462, 1388, 1361, 1253, 1116, 
1085, 1027, 915, 862, 837, 776, 672, 495, 441, 424, 404 cm-1. 
HRMS (ESI): calc. for C43H82O10Si3Na [M + Na]+: 865.5114; found: 865.5110. 
[α]D20  = + 65.0 (c = 0.60, CHCl3). 
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23b: 1H-NMR (400 MHz, C6D6): 6.06 (d, J = 9.7 Hz, 1H), 5.95 (ddd, J = 9.1, 6.7, 2.1 Hz, 
1H), 5.80 (dd, J = 4.4, 4.4 Hz, 1H), 4.24 – 4.18 (m, 2H), 4.12 – 4.06 (m, 2H), 3.78 (dd, J = 
11.1, 2.4 Hz, 1H), 3.65 – 3.56 (m, 3H), 3.54 – 3.50 (m, 2H), 3.40 – 3.35 (m, 1H), 3.38 (dd, J = 
6.1, 0.8 Hz, 1H), 3.27 – 3.21 (m, 1H), 3.18 (s, 3H), 3.17 – 3.09 (m, 1H), 3.05 (s, 3H), 2.98 (s, 
3H), 2.96 – 2.86 (m, 1H), 2.82 (d, J = 6.9 Hz, 1H), 2.49 (d, J = 2.3 Hz, 1H), 1.99 (s, 3H), 1.49 
(d, J = 6.7 Hz, 3H), 0.98 (s, 9H), 0.96 (s, 9H), 0.95 (s, 9H), 0.27 (s, 3H), 0.19 (s, 3H), 0.09 (s, 
3H), 0.01 (s, 3H), - 0.01 (s, 3H), - 0.03 (s, 3H). 
13C-NMR (100.6 MHz, C6D6): 172.8, 133.7, 131.5, 128.7, 128.3, 91.2, 86.0, 75.5, 75.1, 
72.9, 72.3, 71.4, 70.6, 69.9,58.6, 58.4, 51.6, 44.3, 40.7, 39.7, 37.2, 30.2, 26.5, 26.2, 26.1, 18.5, 
18.5, 18.3, 17.5, 17.4, - 4.4, - 4.3, -4.5, - 5.2, -5.2, -5.3. 
 
 
Macrolactone (19). 
To seco acid 23a (6 mg, 0.007 mmol) was added a solution of 2,2´-dithiodipyridine (0.43M in 
toluene, 150 µL, 0.064 mmol) and a solution of PPh3 (0.43M in toluene, 150 µL, 0.064 
mmol), and the mixture was stirred at rt for 14 h. The resulting mixture was diluted by toluene 
(5 mL) and added via syringe pump to a solution of AgClO4 (44 mg, 0.214 mmol) in toluene 
(15 mL) at 85 °C over 2 h. The resulting mixture was filtrated through a pad of celite and the 
filtrate was concentrated in vacuo. The residue was subjected to column chromatography 
(EtOAc/hexanes) to obtain lactone 19 (2.4 mg, 40 %). 
1H-NMR (400 MHz, CDCl3): 5.98 (ddd, J = 9.2, 7.0, 2.0 Hz, 1H), 5.66 (dd, J = 7.5, 1.0 
Hz, 1H), 5.38 (dd, J = 9.8, 2.5 Hz, 1H), 4.95 (dd, J = 9.2, 6.2 Hz, 1H), 4.13 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 4.03 – 3.97 (m, 2H), 3.69 (dd, J = 11.2, 1.8 Hz, 1H), 3.58 – 3.51 (m, 2H), 3.46 
(dd, J = 8.6, 5.1 Hz, 1H), 3.41 – 3.33 (m, 2H), 3.33 – 3.25 (m, 1H), 3.31 (s, 3H), 3.29 (s, 3H), 
3.24 (s, 3H), 3.07 (dm, J = 9.5 Hz, 1H), 3.03 – 2.94 (m, 1H), 2.85 – 2.77 (m, 1H), 2.69 (d, J = 
7.0 Hz, 1H), 2.60 – 2.51 (m, 1H), 2.27 (s, 1H), 1.68 (s, 3H), 1.21 (d, J = 6.9 Hz, 3H), 0.90 (s, 
18H), 0.89 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H), 0.03 (s, 6H). 
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13C-NMR (150.9 MHz, CDCl3): 177.9, 138.5, 134.2, 131.2, 127.1, 89.1, 84.2, 80.7, 76.0, 
73.7, 72.5, 71.1, 70.3, 69.2, 59.2, 58.7, 58.4, 52.4, 50.0, 46.3, 41.1, 40.1, 32.3, 29.9, 26.4, 
26.3, 26.0, 18.6, 18.5, 18.2, 17.4, 15.8, -3.5, -3.6, -4.3, -4.9, -5.1, -5.2. 
IR (film): 2955, 2929, 2857, 1721, 1472, 1389, 1361, 1252, 1211, 1116, 1084, 1057, 1031, 
866, 837, 777, 668, 418, 404 cm-1. 
HRMS (ESI): calc. for C43H80O9Si3Na [M + Na]+: 847.5008; found: 847.5018. 
[α]D20  = + 173.3 (c = 0.05, CHCl3). 
24: 1H-NMR (400 MHz, CDCl3): 5.99 (ddd, J = 9.3, 6.8, 2.4 Hz, 1H), 5.74 (dd, J = 9.6, 
1.0 Hz, 1H), 5.46 (dd, J = 9.4, 2.4 Hz, 1H), 4.98 (dd, J = 7.2, 5.1 Hz, 1H), 4.15 (dd, J = 10.1, 
5.3 Hz, 1H), 4.06 – 3.98 (m, 2H), 3.95 (dd, J = 4.8, 3.9 Hz, 1H), 3.64 (dd, J = 11.3, 2.1 Hz, 
1H), 3.50 – 3.47 (m, 2H), 3.44 (dd, J = 10.1, 2.0 Hz, 1H), 3.39 – 3.28 (m, 3H), 3.35 (s, 3H), 
3.31 (s, 3H), 3.20 (s, 3H), 2.97 – 2.87 (m, 1H), 2.65 (d, J = 6.8 Hz, 1H), 2.62 – 2.56 (m, 1H), 
2.55 – 2.46 (m, 1H), 2.30 (d, J = 2.0 Hz, 1H), 1.68 (d, J = 1.0 Hz, 3H), 1.19 (d, J = 7.0 Hz, 
3H), 0.92 (s, 9H), 0.90 (s, 9H), 0.88 (s, 9H), 0.1 (s, 3H), 0.09 (s, 3H), 0.06 (s, 6H), 0.05 (s, 
3H), 0.01 (s, 3H). 
13C-NMR (100.6 MHz, CDCl3): 174.6, 135.6, 134.3, 131.1, 130.8, 90.7, 85.2, 79.1, 75.8, 
72.3, 71.9, 70.1, 69.4, 68.8, 59.2, 58.6, 58.2, 52.8, 51.3, 50.5, 40.7, 39.9, 32.6, 26.5, 26.2, 
26.0, 18.5, 18.5, 18.2, 17.3, 15.5, -3.4, -3.7, -4.3, -5.0, -5.2. 
 
 
Branimycin (1). 
To a stirred solution of lactone 19 (1.6 mg, 0.002 mmol) in THF (0.15 mL) was added TBAF 
(1M in THF, 35µL) dropwise. The reaction mixture was then stirred for 14 h. The resulting 
mixture was diluted with THF and the reaction was quenched by addition of aq. saturated 
NH4Cl. The water phase was extracted with EtOAc (4x1 mL), the combined organic phases 
were washed with brine, dried over MgSO4 and concentrated in vacuo. The crude product was 
subjected to column chromatography (CCl4/iPrOH) to yield Branimycin (1) (0.8 mg, 85%) as 
a colorless oil. 
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1H-NMR (600 MHz, CDCl3): 6.05 (ddd, J = 9.6, 7.2, 2.0 Hz, 1H), 5.68 (dd, J = 8.0, 1.2 
Hz, 1H), 5.39 (dd, J = 9.7, 2.2 Hz, 1H), 5.04 (dd, J = 10.0, 6.7 Hz, 1H), 4.12 – 4.04 (m, 3H), 
4.02 (ddd, J = 11.1, 5.3, 2.9 Hz, 1H), 3.78 (dd, J = 9.6, 4.6 Hz, 1H), 3.64 (dd, J = 9.6, 5.2 Hz, 
1H), 3.59 – 3.54 (m, 2H), 3.48 (dd, J = 8.5, 4.8 Hz, 1H), 3.42 – 3.39 (m, 1H), 3.40 (s, 3H), 
3.36 (s, 3H), 3.32 (s, 3H), 3.06 – 3.03 (m, 2H), 2.99 (d, J = 2.6 Hz, 1H), 2.91 – 2.84 (m, 1H), 
2.72 (d, J = 7.2 Hz, 1H), 2.49 (d, J = 4.3 Hz, 1H), 2.48 (d, J = 2.5 Hz, 1H), 2.32 – 2.27 (m, 
1H), 2.09 (d, J = 5.5 Hz, 1H), 1.69 (d, J = 0.9 Hz, 3H), 1.27 (d, J = 7.0 Hz, 3H). 
13C-NMR (150.9 MHz, CDCl3): 177.6, 138.7, 133.8, 131.5, 126.8, 88.7, 84.0, 79.4, 74.6, 
73.7, 73.3, 72.0, 71.9, 68.1, 59.4, 59.3, 59.3, 51.8, 48.3, 46.2, 40.4, 38.6, 32.5, 17.0, 15.4. 
IR (film): 3455, 2930, 1725, 1651, 1540, 1375, 1224, 1118, 944, 886, 874, 793, 685, 672, 
668, 425, 421, 413 cm-1. 
HRMS (ESI): calc. for C25H38O9Na [M + Na]+: 505.2414; found: 505.2420. 
[α]D25 = + 88.0 (c = 0.04, CHCl3). 
Rf = 0.27 (CHCl3/5% MeOH), 0.22 (CCl4/12.5% iPrOH), 0.35 (DCM/10% iPrOH). 
25: 1H-NMR (400 MHz, CDCl3): 6.08 (ddd, J = 9.5, 6.8, 2.2 Hz, 1H), 5.66 (dd, J = 9.8, 
1.1 Hz, 1H), 5.49 (dd, J = 9.6, 2.2 Hz, 1H), 5.04 (dd, J = 8.4, 2.8 Hz, 1H), 4.17 – 4.10 (m, 
2H), 4.08 – 3.97 (m, 3H), 3.75 (dd, J = 9.6, 4.6 Hz, 1H), 3.63 (dd, J = 9.6, 5.2 Hz, 1H), 3.50 – 
3.41 (m, 3H), 3.41 – 3.37 (m, 1H), 3.40 (s, 3H), 3.35 (s, 3H), 3.32 (s, 3H), 3.06 – 2.97 (m, 
1H), 2.92 (d, J = 2.7 Hz, 1H), 2.71 (d, J = 7.0 Hz, 1H), 2.67 (dm, J = 10.4 Hz, 1H), 2.54 (d, J 
= 2.7 Hz, 1H), 2.27 – 2.20 (m, 1H), 2.18 – 2.12 (m, 1H), 2.08 (d, J = 5.5 Hz, 1H), 1.72 (d, J = 
0.8 Hz, 3H), 1.29 (d, J = 7.0 Hz, 3H). 
13C-NMR (100.6 MHz, CDCl3): 177.6, 137.9, 136.8, 134.9, 130.0, 88.8, 82.9, 79.0, 74.9, 
73.7, 73.4, 72.1, 71.9, 70.0, 59.5, 59.3, 58.8, 52.2, 48.9, 45.4, 40.6, 38.5, 33.0, 17.1, 15.6. 
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Comparison of the 1H- and 13C-NMR Data of Natural and Synthetic Branimycin. 
1H-NMR (600 MHz, CDCl3) 13C-NMR (150.9 MHz, CDCl3) 
Synthetic Natural Synthetic Natural 
6.05 (ddd, J = 9.6, 7.2, 2.0 Hz, 5-H) 6.05 (ddd, J = 9.5, 7.1, 2.0 Hz, 5-H) 177.6 (C-1) 177.6 (C-1) 
5.68 (dd, J = 8.0, 1.2 Hz, 14-H) 5.68 (d, J = 8.1 Hz, 14-H) 138.7 (C-14) 138.7 (C-14) 
5.39 (dd, J = 9.7, 2.2 Hz, 4-H) 5.38 (dd, J = 9.9, 2.3 Hz, 4-H) 133.8 (C-13) 133.7 (C-13) 
5.04 (dd, J = 10.0, 6.7 Hz, 16-H) 5.04 (dd, J = 9.9, 6.8 Hz, 16-H) 131.5 (C-5) 131.5 (C-5) 
4.12 – 4.04 (m, 7-H, 8-H, 17-H) 4.12 – 3.99 (m, 7-H, 8-H, 17-H, 10-H) 126.8 (C-4) 126.8 (C-4) 
4.02 (ddd, J = 11.1, 5.3, 2.9 Hz, 10-H)  88.7 (C-12) 88.7 (C-12) 
3.78 (dd, J = 9.6, 4.6 Hz, 9-CHa) 3.78 (dd, J = 9.7, 4.7 Hz, 9-CHa) 84.0 (C-7) 84.0 (C-7) 
3.64 (dd, J = 9.6, 5.2 Hz, 9-CHb) 3.64 (dd, J = 9.5, 5.1 Hz, 9-CHb) 79.4 (C-16) 79.5 (C-16) 
3.59 – 3.54 (m, 18-CHa, 2-CHa) 3.58 – 3.54 (m, 18-CHa, 2-CHa) 74.6 (C-18) 74.6 (C-18) 
3.48 (dd, J = 8.5, 4.8 Hz, 2-CHb) 3.48 (dd, J = 8.4, 4.6 Hz, 2-CHb) 73.7 (2-CH2) 73.7 (2-CH2) 
3.42 – 3.39 (m, 18-CHb) 3.43 – 3.38 (m, 18-CHb) 73.3 (9-CH2) 73.3 (9-CH2) 
3.40 (s, 18-OCH3) 3.40 (s, 18-OCH3) 72.0 (C-10) 72.1 (C-10) 
3.36 (s, 9-OCH3) 3.36 (s, 9-OCH3) 71.9 (C-8) 71.9 (C-8) 
3.32 (s, 2-OCH3) 3.32 (s, 2-OCH3) 68.1 (C-17) 68.1 (C-17) 
3.06 – 3.03 (m, 2-H, 3-H) 3.06 – 3.02 (m, 2-H, 3-H) 59.4 (9-OCH3) 59.4 (9-OCH3) 
2.99 (d, J = 2.6 Hz, 8-OH) 3.00 (d, J = 2.1 Hz, 8-OH) 59.3(18-OCH3) 59.3(18-OCH3) 
2.91 – 2.84 (m, 15-H) 2.91 – 2.84 (m, 15-H) 59.3 (2-OCH3) 59.3 (2-OCH3) 
2.72 (d, J = 7.2 Hz, 6-H) 2.72 (d, J = 7.0 Hz, 6-H) 51.8 (C-3) 51.7 (C-3) 
2.49 (d, J = 4.3 Hz, 17-OH) 2.50 (d, J = 4.0 Hz, 17-OH) 48.3 (C-11) 48.3 (C-11) 
2.48 (d, J = 2.5 Hz, 11-H) 2.48 (d, J = 2.7 Hz, 11-H) 46.2 (C-2) 46.2 (C-2) 
2.32 – 2.27 (m, 9-H) 2.32 – 2.26 (m, 9-H) 40.4 (C-9) 40.5 (C-9) 
2.09 (d, J = 5.5 Hz, 10-OH) 2.09 (d, J = 5.5 Hz, 10-OH) 38.6 (C-6) 38.6 (C-6) 
1.69 (d, J = 0.9 Hz, 13-CH3) 1.69 (d, J = 0.8 Hz, 13-CH3) 32.5 (C-15) 32.5 (C-15) 
1.27 (d, J = 7.0 Hz, 15-CH3) 1.27 (d, J = 7.0 Hz, 15-CH3) 17.0 (13-CH3) 17.0 (13-CH3) 
  15.4 (15-CH3) 15.4 (15-CH3) 
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Total Synthesis of the Antibiotic Branimycin 
 
 
 
 
Supporting Information (1H and 13C NMR) 
 
 
 
 
Stefan Marchart*, Alexey Gromov and Johann Mulzer* 
 
Institute of Organic Chemistry, University of Vienna, 
Waehringerstr. 38, A-1090 Vienna, Austria 
 
113
HH
OTBS
OMe
O
6
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
6.
16
9.
36
3.
09
1.
05
1.
01
5.
17
1.
00
1.
02
1.
02
0.
99
1.
01
-
5.
17
-
4.
88
17
.
89
25
.
84
31
.
54
33
.
13
44
.
98
46
.
78
59
.
22
7
1.
66
7
4.
84
7
6.
84
7
7.
16
7
7.
47
12
5.
30
13
0.
19
13
0.
45
15
0.
91
20
1.
94
200 180 160 140 120 100 80 60 40 20 0 ppm
114
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
2.
95
2.
98
9.
21
0.
99
2.
05
2.
03
1.
01
2.
08
2.
98
1.
06
1.
00
0.
99
1.
02
-
5.
25
-
4.
98
17
.8
5
25
.8
9
28
.5
4
32
.0
5
42
.7
0
43
.8
9
51
.5
4
55
.4
0
59
.3
6
69
.5
4
71
.5
8
76
.8
4
77
.1
6
77
.4
8
13
1.
05
14
9.
93
20
0.
80
200 180 160 140 120 100 80 60 40 20 0 ppm
115
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
21
.6
9
3.
23
3.
04
1.
02
3.
07
4.
13
2.
10
1.
00
2.
06
3.
69
12
.7
3
13
.0
3
13
.3
2
18
.0
5
18
.3
1
18
.3
5
27
.6
8
56
.1
4
58
.7
9
72
.5
2
74
.5
2
76
.8
4
77
.1
6
77
.2
1
77
.4
8
82
.0
1
82
.9
5
98
.1
3MOMO
OTIPSMeO
27
200 180 160 140 120 100 80 60 40 20 0 ppm
116
MOMO
OTIPSMeO
I
28
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
3.
40
23
.4
8
3.
00
1.
04
4.
42
2.
99
1.
09
1.
01
1.
00
1.
01
1.
03
1.
00
-
4.
53
-
4.
36
16
.0
6
18
.3
1
26
.1
2
27
.8
4
36
.5
8
56
.1
3
59
.1
1
73
.2
3
74
.8
2
76
.8
4
77
.1
5
77
.4
7
82
.5
3
92
.9
5
98
.1
1
14
4.
71
200 180 160 140 120 100 80 60 40 20 0 ppm
117
MOMO
I
OHMeO
29
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
3.
00
2.
87
1.
96
9.
01
1.
00
2.
02
0.
93
15
.7
0
27
.9
6
37
.3
8
56
.3
4
59
.2
4
70
.4
1
74
.0
9
76
.8
4
77
.1
6
77
.4
8
83
.1
1
94
.8
0
98
.5
8
14
3.
56
200 180 160 140 120 100 80 60 40 20 0 ppm
118
MOMO
I
OTBSMeO
8
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
6.
05
9.
27
3.
06
3.
03
1.
01
4.
00
3.
97
1.
01
1.
00
1.
01
1.
00
0.
99
-
4.
53
-
4.
36
16
.0
6
18
.3
1
26
.1
2
27
.8
4
36
.5
8
56
.1
3
59
.1
1
73
.2
3
74
.8
2
76
.8
4
77
.1
5
77
.4
7
82
.5
3
92
.9
5
98
.1
1
14
4.
71MOMO
I
OTBSMeO
8
200 180 160 140 120 100 80 60 40 20 0 ppm
119
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
5.
98
6.
08
18
.9
6
3.
08
3.
06
1.
07
2.
03
2.
08
3.
05
1.
10
3.
27
4.
09
1.
12
2.
14
1.
99
2.
04
2.
03
1.
00
1.
01
1.
00
1.
03
1.
01
-
5.
59
-
4.
32
-
3.
98
-
3.
10
16
.3
8
16
.9
9
18
.5
5
18
.6
0
26
.3
6
26
.5
2
33
.6
2
33
.7
7
38
.0
0
41
.1
1
49
.5
6
55
.9
0
58
.4
1
58
.6
5
72
.2
0
72
.5
6
73
.8
0
74
.2
0
75
.7
6
83
.3
8
85
.0
9
85
.4
9
98
.3
8
12
7.
82
12
7.
95
12
8.
06
12
8.
20
12
8.
30
13
3.
56
13
9.
12
200 180 160 140 120 100 80 60 40 20 0 ppm
120
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
6.
12
3.
18
3.
15
6.
14
9.
31
9.
39
9.
27
3.
15
3.
01
1.
02
1.
00
1.
02
0.
99
5.
25
3.
05
3.
05
1.
03
4.
10
1.
01
2.
03
1.
01
0.
99
1.
00
1.
00
1.
00
1.
00
-
5.
28
-
5.
06
-
4.
56
-
4.
31
-
3.
98
-
3.
08
16
.2
9
16
.9
9
18
.3
7
18
.5
0
18
.6
1
26
.1
7
26
.3
8
26
.4
6
33
.5
6
33
.8
6
37
.9
6
41
.1
5
49
.8
2
55
.8
8
58
.3
0
58
.6
4
70
.5
9
70
.9
8
73
.8
7
74
.3
1
75
.8
6
83
.4
0
85
.2
5
85
.5
9
98
.3
6
12
7.
54
12
7.
82
12
8.
06
12
8.
30
12
8.
41
12
8.
54
12
8.
59
13
3.
19
13
9.
44
200 180 160 140 120 100 80 60 40 20 0 ppm
121
O
OTBS
O
H
H
OTBS
MOMO
OMe
12
OMe
OTBS
7 6 5 4 3 2 1 ppm
222118360075712808032920252409831805080009010300
6.
2
3.
2
3.
1
6.
3
11
.09.
7
9.
7
3.
2
3.
0
1.
0
2.
2
3.
2
3.
2
3.
2
1.
0
5.
8
1.
1
2.
0
1.
0
1.
0
1.
0
1.
0
1.
0
1.
0
-
4.
48
-
4.
33
-
4.
05
-
3.
30
16
.0
1
16
.6
6
18
.3
6
18
.5
5
26
.1
4
26
.3
2
33
.7
2
41
.4
6
53
.7
6
55
.5
0
55
.8
7
58
.3
6
58
.7
3
70
.0
9
70
.4
5
72
.0
4
74
.3
4
75
.6
7
78
.3
5
83
.2
2
86
.8
9
98
.3
4
12
7.
94
12
8.
41
13
0.
02
13
0.
39
13
0.
50
15
9.
93
19
7.
97
----11112234555557777778891111111
200 180 160 140 120 100 80 60 40 20 ppm
122
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
20
.6
6
31
.2
9
3.
52
1.
02
3.
29
1.
00
0.
11
2.
29
1.
06
3.
43
11
.4
7
1.
21
1.
17
1.
23
1.
12
0.
11
1.
02
2.
16
1.
12
1.
02
1.
21
1.
00
0.
11
-
5.
18
-
4.
46
-
4.
38
-
4.
24
-
4.
18
-
3.
11
15
.7
8
15
.8
9
16
.6
0
18
.2
4
18
.3
1
18
.3
9
26
.0
6
26
.0
9
26
.1
7
26
.2
6
33
.2
9
40
.9
8
41
.2
3
45
.3
3
45
.3
8
45
.5
9
51
.9
0
56
.1
4
58
.3
8
58
.9
0
69
.4
2
69
.7
6
70
.1
6
70
.4
7
70
.7
2
72
.9
3
73
.1
1
73
.3
4
75
.3
0
76
.7
3
76
.8
4
77
.1
6
77
.4
8
79
.1
6
83
.2
2
84
.3
9
84
.9
6
98
.2
8
12
8.
03
12
9.
18
12
9.
72
13
2.
13
13
2.
25
14
1.
62
14
1.
96
200 180 160 140 120 100 80 60 40 20 0 ppm
123
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
9.
05
3.
30
5.
96
27
.1
4
2.
90
2.
94
2.
13
2.
93
4.
05
0.
98
4.
10
4.
12
2.
92
1.
07
4.
00
1.
03
1.
00
1.
00
2.
00
0.
98
0.
98
0.
98
0.
99
0.
98
-
5.
28
-
5.
09
-
4.
52
-
4.
36
-
4.
01
-
3.
09
16
.4
2
16
.9
0
16
.9
3
18
.3
6
18
.5
2
18
.5
5
26
.1
4
26
.2
8
26
.5
1
32
.8
2
34
.0
9
35
.1
7
36
.5
8
39
.9
8
40
.8
8
43
.3
0
50
.6
5
55
.7
0
58
.4
4
58
.6
1
70
.2
9
70
.8
9
73
.0
0
74
.4
1
75
.5
9
83
.9
6
86
.2
0
90
.3
3
90
.3
6
98
.2
7
12
7.
82
12
8.
06
12
8.
30
12
8.
56
13
1.
06
13
2.
07
13
2.
44
17
1.
74
200 180 160 140 120 100 80 60 40 20 0 ppm
124
7 5 7 0 6 5 6 0 5 5 5 0 4 5 4 0 3 5 3 0 2 5 2 0 1 5 1 0 0 5 0 0. . . . . . . . . . . . . . . . ppm
18
.3
6
27
.6
0
3.
14
1.
10
3.
99
0.
98
3.
01
2.
04
3.
01
10
.0
9
2.
04
2.
02
2.
04
1.
00
1.
01
1.
00
0.
98
1.
01
0.
99
-
5.
22
-
5.
19
-
4.
46
-
4.
27
-
4.
15
-
3.
06
16
.5
2
17
.1
0
18
.2
3
18
.4
2
18
.4
5
26
.0
3
26
.1
3
26
.4
1
32
.3
5
34
.4
0
39
.2
7
40
.2
2
43
.1
0
50
.4
1
56
.0
2
58
.4
3
58
.9
2
60
.7
9
69
.3
9
70
.4
5
72
.4
6
73
.5
9
75
.6
5
76
.8
4
77
.1
6
77
.4
8
83
.0
1
85
.8
3
90
.1
1
98
.0
3
12
8.
96
13
0.
39
13
0.
69
13
2.
16
200 180 160 140 120 100 80 60 40 20 0 ppm
125
HO
OTBS
OMe
HO H
OTBS
OTBS
HO
30
OMe
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
9.
30
3.
37
6.
06
27
.7
0
3.
01
1.
09
0.
95
2.
98
0.
99
1.
51
2.
02
2.
06
4.
13
7.
23
1.
01
2.
03
0.
99
1.
01
0.
98
1.
01
1.
01
1.
00
-
5.
22
-
5.
19
-
4.
60
-
4.
47
-
3.
72
-
3.
09
16
.9
9
17
.4
4
18
.2
2
18
.4
2
18
.5
0
26
.0
3
26
.1
0
26
.3
6
32
.4
4
37
.1
4
39
.3
3
40
.1
7
43
.0
8
50
.4
6
58
.4
2
58
.9
7
60
.3
3
69
.2
4
70
.3
4
72
.2
3
72
.4
1
75
.3
7
76
.4
9
76
.8
4
77
.1
6
77
.4
8
86
.0
9
90
.3
1
12
9.
23
12
9.
88
13
0.
26
13
3.
39
200 180 160 140 120 100 80 60 40 20 0 ppm
126
HH
O
OTBS
OMe
O
OTBS
OM
OTBS
HO
31
e
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
12
.8
8
6.
37
29
.7
9
2.
94
2.
71
0.
95
1.
15
1.
83
1.
08
1.
01
1.
05
1.
00
10
.8
1
1.
05
0.
96
0.
92
0.
97
1.
00
0.
94
0.
98
0.
95
0.
99
-
5.
28
-
4.
65
-
4.
57
-
3.
81
-
3.
26
16
.8
1
16
.9
0
18
.1
2
18
.3
6
25
.9
3
26
.0
0
26
.2
7
36
.5
8
39
.1
6
40
.1
2
41
.0
9
43
.4
2
50
.2
0
58
.4
2
58
.8
8
69
.1
3
70
.2
1
72
.0
8
72
.2
3
75
.3
0
75
.6
5
76
.9
5
77
.1
6
77
.3
7
77
.6
5
86
.0
8
89
.4
7
12
9.
49
12
9.
95
13
0.
30
13
2.
80
20
2.
13
H
O
OTBS
OMe
O H
OTBS
OTBS
HO
31
OMe
200 180 160 140 120 100 80 60 40 20 0 ppm
127
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
17
.5
4
26
.7
5
3.
41
3.
10
1.
21
1.
02
2.
11
1.
00
1.
05
1.
00
2.
90
5.
77
2.
11
1.
04
1.
00
1.
04
0.
95
0.
94
0.
95
0.
93
-
5.
23
-
5.
20
-
4.
73
-
4.
49
-
3.
74
-
3.
12
16
.9
1
17
.3
1
18
.2
1
18
.3
9
18
.4
2
26
.0
1
26
.0
6
26
.3
7
34
.1
9
36
.7
3
39
.0
0
40
.2
6
42
.4
4
50
.5
2
58
.5
0
59
.0
1
69
.2
0
70
.3
2
71
.8
5
72
.3
6
74
.5
5
75
.2
5
76
.8
4
77
.1
6
77
.4
8
86
.1
9
89
.7
6
12
9.
74
13
0.
19
13
0.
40
13
2.
95
17
5.
49
200 180 160 140 120 100 80 60 40 20 0 ppm
128
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
53007753650939066293
13
.7
5
21
.4
3
2.
60
2.
40
1.
31
1.
07
0.
57
1.
95
0.
93
1.
16
1.
05
2.
20
4.
39
0.
93
0.
89
1.
00
1.
91
1.
06
1.
06
1.
02
1.
09
1.
13
-
5.
24
-
4.
97
-
4.
71
-
4.
38
-
3.
45
15
.7
7
17
.0
7
18
.1
8
18
.4
6
18
.4
9
26
.0
0
26
.0
5
26
.0
7
26
.4
3
29
.0
6
29
.8
4
30
.4
9
32
.6
2
36
.6
2
38
.8
6
40
.0
6
40
.8
7
49
.7
3
50
.1
4
58
.2
3
59
.2
7
68
.2
9
69
.3
4
70
.2
2
71
.6
4
72
.3
7
75
.6
0
80
.0
7
84
.7
4
88
.9
9
12
8.
95
13
1.
03
13
4.
93
13
5.
87
17
5.
22
-----11111222222333344455566777788811111
180 160 140 120 100 80 60 40 20 0 ppm
129
7 6 5 4 3 2 1 ppm
023284396570826490
18
.5
0
27
.8
2
2.
83
2.
82
0.
98
1.
04
1.
13
1.
99
1.
06
1.
05
3.
07
2.
20
3.
01
5.
08
3.
12
5.
81
2.
96
1.
04
0.
99
1.
00
-
5.
29
-
4.
49
-
4.
37
-
4.
12
-
3.
21
15
.9
4
16
.7
3
18
.1
7
18
.3
4
18
.4
1
25
.9
9
26
.0
5
26
.3
2
29
.8
5
33
.2
8
37
.1
4
41
.0
5
42
.1
5
49
.4
0
49
.5
8
52
.0
3
52
.8
1
53
.4
2
55
.9
5
58
.6
1
58
.8
6
68
.8
4
69
.9
0
71
.3
8
73
.3
4
74
.9
7
80
.9
4
83
.0
5
89
.7
8
98
.3
8
10
0.
13
12
8.
37
12
9.
62
13
3.
00
16
9.
20
16
9.
62
20
8.
55
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
130
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
3.
34
3.
18
3.
10
3.
02
3.
19
3.
15
10
.3
5
9.
54
9.
63
3.
77
3.
13
1.
02
1.
24
6.
30
0.
90
1.
55
2.
98
3.
05
3.
11
3.
07
2.
08
1.
02
1.
02
1.
01
1.
01
1.
03
1.
00
1.
01
0.
99
1.
03
1.
00
-
4.
47
-
4.
35
-
3.
79
-
3.
41
16
.2
1
16
.6
4
18
.2
0
18
.4
4
26
.0
8
26
.2
4
26
.4
0
33
.4
4
41
.1
5
44
.0
8
46
.0
4
49
.9
8
51
.5
2
51
.9
3
52
.3
6
55
.6
6
58
.4
8
58
.5
9
69
.2
7
70
.2
2
71
.9
3
74
.2
6
75
.3
2
84
.1
4
85
.4
9
89
.3
3
98
.9
6
11
8.
58
12
3.
84
12
7.
27
12
7.
94
12
8.
36
12
8.
40
12
9.
30
12
9.
48
13
4.
29
14
9.
38
16
8.
16
16
9.
50
----111122234444555555677778889111111111111
160 140 120 100 80 60 40 20 ppm
131
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
2865690825243542042797040
12
.7
2
6.
78
19
.4
6
9.
41
3.
55
2.
96
0.
99
1.
00
4.
48
3.
22
4.
35
3.
02
3.
14
3.
03
0.
65
1.
44
1.
02
1.
00
1.
04
1.
02
1.
07
0.
99
1.
07
1.
00
1.
04
2.
10
16
8.
62
17
0.
26
-
4.
50
-
3.
20
16
.4
5
16
.9
0
18
.5
2
26
.1
1
26
.2
8
26
.4
7
33
.5
1
39
.6
0
41
.0
2
47
.8
2
50
.4
7
51
.2
8
51
.5
1
52
.1
0
55
.6
5
58
.4
8
58
.5
5
69
.9
3
7
0.
7
4
7
2.
86
7
4.
25
7
5.
49
84
.2
2
86
.5
4
90
.0
9
98
.9
2
12
7.
94
12
8.
41
12
8.
7
3
12
9.
29
13
0.
82
13
3.
00
180 160 140 120 100 80 60 40 20 0 ppm
132
7 6 5 4 3 2 1 ppm
2867084323400486233390
12
.7
2
6.
08
19
.1
6
9.
37
3.
90
2.
98
1.
04
1.
03
1.
02
1.
03
1.
04
5.
40
6.
30
2.
24
4.
08
4.
16
3.
12
1.
03
1.
03
1.
03
0.
99
1.
01
1.
00
-
5.
32
-
5.
17
-
4.
51
-
4.
14
-
3.
96
-
3.
07
16
.5
5
17
.3
7
18
.3
2
18
.5
1
18
.6
5
26
.1
3
26
.3
3
26
.5
0
34
.7
4
39
.7
9
40
.8
4
43
.2
4
46
.6
0
51
.2
9
55
.6
9
58
.4
2
58
.7
4
62
.7
4
65
.6
6
69
.8
1
70
.7
1
72
.8
5
74
.2
7
76
.0
9
83
.5
1
86
.2
9
91
.4
9
98
.2
9
12
8.
36
12
8.
41
12
9.
57
13
1.
64
13
2.
52
140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
133
7 6 5 4 3 2 1 ppm
073460642948389873606855405390
10
.6
0
3.
07
3.
13
3.
74
31
.4
6
3.
30
3.
06
2.
04
1.
12
0.
99
1.
24
0.
98
1.
33
3.
08
3.
59
4.
88
3.
37
3.
43
3.
56
1.
30
1.
16
1.
08
1.
15
1.
05
1.
14
1.
10
0.
05
1.
03
1.
19
1.
00
-
5.
27
-
5.
16
-
4.
52
-
4.
35
-
3.
69
-
3.
18
17
.5
7
17
.6
5
18
.5
4
18
.5
8
26
.1
4
26
.2
1
26
.4
6
37
.4
2
39
.8
9
40
.1
5
40
.6
7
45
.7
4
51
.5
1
58
.4
0
58
.5
2
58
.7
0
65
.6
5
69
.9
6
70
.6
9
72
.6
1
73
.0
2
73
.6
9
75
.5
4
76
.2
1
86
.0
2
91
.7
1
12
7.
82
12
8.
06
12
8.
30
12
8.
36
12
8.
41
12
8.
45
12
8.
72
12
9.
74
13
0.
91
13
4.
00
140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
134
HO
OTBS
OMe
MeO
H
OTBS
OTBS
HO
O
H
35a
OMe
10 9 8 7 6 5 4 3 2 1 ppm
74231086605394357711490206
19
.0
7
28
.6
4
3.
12
3.
03
1.
01
1.
00
1.
08
1.
06
6.
16
5.
30
1.
05
0.
93
0.
89
2.
04
1.
93
2.
15
1.
07
5.
17
1.
01
1.
01
1.
04
0.
99
1.
00
1.
02
1.
00
0.
96
-
5.
29
-
5.
19
-
4.
72
-
4.
50
-
3.
76
-
3.
26
17
.1
6
17
.5
3
18
.3
1
18
.5
2
18
.5
9
26
.1
3
26
.2
3
26
.4
1
37
.5
7
39
.8
6
40
.7
3
46
.5
8
50
.5
5
51
.1
5
58
.4
4
58
.6
2
58
.7
7
69
.7
4
70
.3
8
70
.5
9
72
.7
5
72
.8
4
75
.6
4
76
.0
9
86
.9
7
91
.0
1
12
7.
22
12
8.
36
12
8.
41
13
0.
81
13
1.
67
13
3.
30
20
2.
06
------111112223344555556777777891111112
H
O
OTBS
OMe
MeO
H
OTBS
OTBS
HO
O
H
35a
OMe
200 180 160 140 120 100 80 60 40 20 0 ppm
135
7 6 5 4 3 2 1 ppm
25432115631277513910120
18
.9
2
28
.8
5
3.
24
3.
13
1.
02
1.
41
1.
01
0.
65
3.
46
3.
13
3.
11
1.
12
3.
27
1.
07
0.
75
4.
11
1.
03
2.
09
1.
01
1.
00
1.
01
1.
02
1.
00
-
5.
37
-
5.
28
-
4.
96
-
4.
57
-
3.
98
-
3.
28
16
.9
4
17
.4
3
18
.2
3
18
.4
6
18
.4
9
26
.0
5
26
.1
5
26
.3
7
37
.9
6
39
.7
3
40
.7
7
44
.4
8
44
.8
1
51
.2
2
58
.4
7
58
.7
1
58
.7
6
68
.8
4
70
.2
6
71
.4
7
72
.4
0
72
.7
3
75
.0
6
75
.8
7
87
.1
2
92
.9
6
12
6.
87
12
7.
94
12
8.
36
12
8.
40
12
8.
72
13
0.
40
13
1.
90
13
2.
53
17
0.
89
------11111222334445555677777789111111111
160 140 120 100 80 60 40 20 0 ppm
136
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
72707082639450076200
13
.1
7
5.
52
28
.2
7
3.
10
3.
01
1.
17
1.
00
1.
18
1.
12
1.
06
2.
73
4.
09
2.
64
1.
45
1.
11
1.
10
2.
00
1.
07
1.
96
1.
11
1.
11
1.
02
1.
00
1.
10
-
5.
25
-
5.
12
-
4.
88
-
4.
31
-
3.
62
-
3.
47
15
.8
4
17
.4
3
18
.1
8
18
.5
2
18
.5
7
26
.0
0
26
.2
8
26
.4
2
29
.8
5
32
.3
1
40
.1
0
41
.0
8
46
.3
1
49
.9
8
52
.4
2
58
.4
5
58
.6
7
59
.2
0
69
.2
2
70
.3
3
71
.0
9
72
.5
4
73
.7
3
76
.0
0
80
.7
0
84
.2
3
89
.1
3
12
7.
14
13
1.
24
13
4.
17
13
8.
48
17
7.
85
180 160 140 120 100 80 60 40 20 0 ppm
137
1.52.02.53.03.54.04.55.05.56.06.57.0 ppm
4.
39
2.
36
0.
94
1.
09
1.
71
0.
92
1.
15
0.
83
1.
73
2.
42
2.
31
3.
26
0.
96
1.
76
1.
03
1.
00
1.
06
2.
72
1.
02
1.
00
0.
96
1.
00
15
.4
5
16
.9
6
32
.5
2
38
.6
0
40
.4
6
46
.1
8
48
.2
9
51
.7
6
59
.2
8
59
.3
3
59
.3
8
68
.1
5
71
.9
1
72
.0
5
73
.3
0
73
.7
2
74
.6
2
79
.4
2
84
.0
1
88
.7
3
12
6.
81
13
1.
47
13
3.
76
13
8.
70
17
7.
61
1133444555567777778811111
20406080100120140160180 ppm
138
Natural Branimycin, 600 MHz, CDCl3
1.52.02.53.03.54.04.55.05.56.06.57.0 ppm
602806239458096361800
13
.7
6
2.
20
0.
92
1.
38
1.
00
1.
96
1.
02
1.
33
0.
89
1.
64
10
.2
5
1.
08
2.
20
1.
29
0.
86
1.
13
3.
96
1.
11
0.
98
1.
00
1.
10
79
.4
6
15
.4
5
16
.9
6
29
.8
5
32
.5
2
38
.5
9
40
.4
5
46
.1
8
48
.2
8
51
.7
5
59
.2
8
59
.3
3
59
.3
8
68
.1
5
71
.9
1
72
.0
5
73
.2
9
73
.7
2
74
.6
2
77
.6
5
84
.0
1
12
6.
81
12
7.
79
12
7.
96
12
8.
12
13
1.
47
13
3.
76
13
8.
70
17
7.
61
Natural Branimycin, 150.9 MHz, CDCl3
102030405060708090100110120130140150160170180 ppm
139
Results and Discussion 
 
140 
 
7.1 Additional remarks48 
7.1.1 Synthesis of decalin ketone 2 
Decalin ketone 2 was also successively synthesized via the intermolecular quinone based 
Diels-Alder route (Scheme 39). Incorporation of the C9-methoxy methyl substituent from the 
convex face was accomplished by mesylation of the allylic hydroxyl group of 86 at -78 °C 
 
Scheme 42: Preparation of decalin ketone 6. 
followed by SN2´ displacement of this unstable mesylate via addition of a silylmethyl copper 
boron trifluoride etherate complex (derived from Me2PhSiCH2MgCl) and subsequent warming 
to room temperature according to the method of Yamamoto.49 The resulting diene ketal 155 
was unstable upon concentration in the presence of traces of BF3.OEt2. Work up with 
concentrated aqueous ammonia solution and repeated extraction of the reaction mixture with 
brine alleviated this problem (Scheme 42). Interestingly, by using CuCl or CuCN in a catalytic 
amount and in the absence of BF3.OEt2 mainly the corresponding SN2 regioisomer 154 was 
formed (154:155 = 4:1, 81% yield). Oxidative cleavage of the C-Si bond50  followed by 
                                                   
48 Numbering remains the same as in the publication for compounds which have been presented therein. 
49 Yamamoto, Y.; Maruyama, K. J. Am. Chem. Soc. 1978, 100, 3240. 
50 Tamao, K.; Akita, M.; Kumada, M. J. Organomet. Chem. 1983, 254, 13-22. 
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methylation of the corresponding primary alcohol gave ketal 156 in high yields. Cleavage of 
acetal 156 in aqueous HCl and THF was followed by allylic oxidation with manganese 
dioxide in DCM. The resulting -hydroxy ketone was protected as TBS ether. Initial attempts 
using TBSCl/imidazole in DMF at 22 °C resulted in nearly exclusive formation of side 
products of intramolecular 1,4-addition. Applying TBSOTf at -78 °C gave the desired enone 6 
in excellent yield. 
 
Scheme 43: Regio- and stereoselective epoxidation of 6. 
 Epoxidation of 6 from the -face was accomplished with high stereoselectivity by mCPBA 
(Scheme 43). The stereoselectivity is strongly influenced by the protecting group on C10. The 
PMB-ether affords a diastereomeric ratio of 3:1 whereas TBS-protection of the hydroxyl 
group increased the diastereomeric ratio to 10:1. The best yields were obtained at 60% 
conversion, whereas full conversion resulted in a decrease of isolable product (77%), mostly 
due to a competitive Bayer-Villiger oxidation yielding lactone 2´. While facing scale-up 
problems when applying the reported enantioselective route to 8645a we decided to work with 
the racemic mixture. Racemic 2 could be separated by chiral HPLC, being available in 
multigram quantities via this sequence. The racemates were unambiguously distinguished 
after addition of 3, comparing 1H and 13C spectra of the resulting products with 10 derived 
from the recently published desymmetrization route.43  
7.1.2 Modification of the C13-C18 side chain 
Optimization studies of the preparation of the side chain became necessary because of the 
large quantities needed and also because of the rather high price of starting (S)-glycidol. 
Methylation of (S)-glycidol with MeI/Ag2O required up to 48 h and never resulted in full 
conversion. Addition of molecular sieves51 gave full conversion after only 2 h yielding 135 
(see chapter 3.2.6) in decent 78% isolated yield. To our delight, also the addition of 138 to 137 
could be optimized. Upon increasing the amount of TiCl4 up to 1.7 mol eq. and performing the 
reaction at lower temperatures (-95 to -78 °C) the desired product 139 was obtained in 89% 
                                                   
51 Reymond, S.; Cossy, J. Tetrahedron 2007, 63, 5918-5929. 
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yield. 139 was protected as its MOM-ether (Scheme 44). To avoid 1,2-migration of the TIPS-
group, iPr2EtN was used as a base. After regioselective hydrozirconation, followed by 
iodination, the hydroxyl functionality was converted to the TBS-ether instead of the TIPS-
ether (because of the possibility to cleave the protecting group under milder conditions), to 
yield 8 in 69% over 4 steps. 
 
Scheme 44: Modification of the C13-C18 side chain. 
7.1.3 Introduction of the C5-oxygen functionality 
Allylic oxidation of tricycle 11 by selenium dioxide52 was unsuccessful. Unfortunately, only 
decomposition was observed upon treatment of 11 with PhIO2/(PhSe)2. Oxidation with 
Mn(OAc)3*2H2O/tBuOOH gave 12 in only 30% yield. Further improvement was achieved by 
employing an excess of CrO3*3,5-dimethylpyrazole in DCM, providing enone 12 in 67% 
yield. Performing the reaction in AcCN, EtOAc or PhCl gave the same result with respect to 
DCM, whereas no reaction was observed in THF or DMF. No product formation was 
observed when the reaction was performed at lower temperatures (-78 °C) even if the reaction 
mixture was subsequently warmed to -20 °C, most probably as too low temperatures result in 
precipitation of the complex and subsequent polymerization. On the other hand, if the 
complex is stored at 0 °C or room temperature, it also rapidly loses its activity due to 
polymerization. 
7.1.4 C2-C3 bond formation via conjugate addition and completion of the synthesis of 
branimycin (1) 53 
1,4-Addition of dimethyl malonate occurred exclusively at the concave face of enone 1254 
presumably due to steric hinderance of the opposing face by the C13-C18 side chain and by 
directing effects imposed by the ether bridge. We then intended to pave the way for 
stereoinduction via regio- and stereoselective hydrogenation of a double bond at C2-C2´ 
(Scheme 45). Unfortunately, treating 157 with Tf2O/KHMDS to obtain 2,2´- and 4,5-bis-vinyl 
                                                   
52 Umbreit, M. A.; Sharpless, K. B. J. Am. Chem. Soc. 1977, 99, 5526. 
53 For a detailed discussion of sequence 12 -> 18 see: Gromov, A. Dissertation, Universität Wien, 2009.  
54  The relative configuration at C3 was corroborated by NOE experiments, showing clear crosspeaks 
between H3 and H11. 
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triflates mainly caused decomposition of the molecule whereas PhNTf2/KHMDS only gave 
mono-vinyl triflate 158 in excellent yield. Treatment of 158 with Tf2O/KHMDS also caused 
decomposition. 
 
Scheme 45: Vinyl triflate formation. 
 Pd-catalyzed reduction of vinyl triflate 158 failed using both Et3SiH and formic acid/DIPEA 
respectively, where only starting material could be recovered. Reduction with Bu3SnH gave 
desired diester 20 in good yield, the presence of LiCl and 2,6-lutidine turned out to be crucial 
for the outcome of the reaction. 20 was reduced to diol 21 by treatment with superhydride. 
The presence of pentaerythritol in the course of work up for re-complexation of boron from 
the product was important for obtaining high yields. Applying DIBAL or LiAlH4 always 
caused partial cleavage of the TBS group located on the C13-C18 side chain whereas LiBH4 
gave no reaction. Enzyme mediated stereodifferentiation at the stage of diol 21 also failed. 
Using vinyl acetate and Pseudomonas fluorescens lipase, Pseudomonas cepacia, candida 
Antarctica lipase and pig pancreatic lipase respectively resulted only in the recovery of 
starting material. Exclusive mono O-methylation of 21 was achieved applying Ag2O and MeI. 
The presence of molecular sieves or an excess of Ag2O also gave the corresponding diether in 
up to 20% yield, applying HgO in place of Ag2O gave no reaction. 
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 Employing the Corey-Nicolaou double activation protocol55 for the construction of the nine-
membered lactone in 19/24 failed. The corresponding 2-thiopyridyl esters of 23a and b were 
generated smoothly by treatment with 2,2´-dipyridyldisulfide and triphenylphosphine56 but 
slow addition of the thiopyridyl esters to refluxing xylene and toluene respectively gave no 
further reaction, only starting material (23a/b) and the corresponding thiopyridyl esters could 
be recovered. A substantial increase in the rate of cyclization in the presence of metal ions has 
been described by several groups. 57  Applying Gerlach´s modification with an excess of 
AgClO4 did afford the nine-membered macrolactones 19 and 24 in good yields. The reaction 
could be optimized from initial 20% to 40% yield. Decreasing temperature from 110 °C to 85 
°C and a concomitant decrease in addition time of the 2-thiopyridyl ester from 8 h to only 2 h 
resulted in the substantial improvement to up to 40% yield. 
 The global deprotection of the three secondary hydroxyl groups of 19 and 24 with a 70% 
solution of HF.pyridine in either MeCN or THF gave no reaction. Eventually, the global 
deprotection step was smoothly effected with an excess of TBAF in THF to provide 
branimycin (1) in 85% yield. The relative configuration at C2 of 1, 19, 24 and 25 was 
unambiguously assigned by NOE experiments. 1 and 19 showed clear crosspeaks between H2 
and H14, whereas C2 methylene protons did not interact with H14. On the other hand C2 
methylene protons of 24 and 25 showed clear crosspeaks with H14, H2 did not.  
 
                                                   
55 Corey, E. J.; Nicolaou, K. C. J. Am. Chem. Soc. 1974, 96, 5614. 
56 Mukaiyama, T.; Matsueda, R.; Suzuki, M. Tetrahedron Lett. 1970, 1901. 
57 a) Wollenberg, R. H.; Nimitz, J. S.; Gokcek, D. Y. Tetrahedron Lett. 1980, 21, 2791. b) Gerlach H.; 
Thalmann, A. Helv. Chim. Acta 1974, 57, 2661. c) Masamune, S.; Hayase, Y.; Schilling, W.; Chan, W. K.; 
Bates, G. S. J. Am. Chem. Soc. 1977, 99, 6756. d) Kim, S.; Lee, J. I. J. Org. Chem. 1984, 49, 1712. e) 
Palomo, C.; Oiarbide, M.; Garcia, J. M.; Gonzalez, A.; Pazos, R.; Odriozola, J. M.; Banuelos, P.; Tello, M.; 
Linden, A. J. Org. Chem. 2004, 69, 4126. 
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7.2 Additional experimental procedures 
 
Ketal (155). 
To a slurry of CuI (8.90 g, 46.85 mmol) in 67 mL of THF at 0 °C was added dimethyl-phenyl-
silyl-methyl-magnesium chloride (9.04 g, 43.24 mmol). The suspension was stirred for 10 min 
and then cooled to -78 °C. Boron trifluoride etherate (5.66 mL, 45.05 mmol) was added and 
the resulting mixture was stirred for 20 min. 
A solution of ketal 86 (4.00 g, 18.02 mmol) in 30 mL of THF was cooled to – 78 °C and n-
butyllithium (1.6 M in hexanes, 12.95 mL, 20.72 mmol) was added. After 5 min 
methanesulfonyl chloride (1.68 mL, 21.62 mmol) was added slowly, and the solution was 
stirred for 5 min and then transferred via cannula into the cuprate suspension at – 78 °C, 
stirred for 40 min and then warmed to room temperature for 3.5 h. The reaction was quenched 
at 0 °C via addition of NEt3 and after 5 min an ammonia solution (ca. 25% NH3) was added. 
After warming to ambient temperature the mixture was filtered, the layers were separated and 
the aqueous layer was extracted with DCM. The combined organic layers were washed three 
times with NaClsat, dried (MgSO4) and concentrated. The residue was subjected to column 
chromatography (EtOAc/hexane) to yield 155 (5.75 g, 90%). 
1H-NMR (400 MHz, CDCl3): 7.54 – 7.48 (m, 3H), 7.37 – 7.32 (m, 3H), 6.30 (ddd, J = 9.6, 
6.7, 2.8 Hz, 1H), 6.08 (ddd, J = 8.8, 5.8, 2.7 Hz, 1H), 5.72 (ddd, J = 9.6, 5.6, 2.3 Hz, 1H), 5.51 
(dd, J = 10.0, 2.3 Hz, 1H), 4.46 (dd, J = 5.3, 5.3 Hz, 1H), 3.88 (dd, J = 3.3, 3.3 Hz, 1H), 2.38 
(m, 1H), 2.29 – 2.13 (m, 2H), 2.07 (m, 1H), 1.96 (m, 1H), 1.40 (s, 3H), 1.29 (s, 3H), 0.90 (dd, 
J = 14.5, 5.7 Hz, 1H), 0.78 (dd, J = 14.5, 9.8 Hz, 1H), 0.35 (s, 3H), 0.31 (s, 3H). 
13C-NMR (100.6 MHz, CDCl3): 139.6, 136.5, 133.7, 133.5, 129.9, 129.4, 129.1, 128.0, 
97.8, 71.6, 65.1, 36.8, 31.0, 30.9, 30.1, 29.7, 20.3, 19.9, -1.6, -2.4. 
IR (film): 3069, 3045, 2991, 2954, 2905, 1773, 1487, 1378, 1301, 1250, 1170, 1113, 1045, 
958, 834, 790, 728, 699, 467 cm-1. 
HRMS: calc. for C21H27O2Si [M – CH3]+: 339.1780; found: 339.1776. 
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Alcohol (155a). 
Potassium hydride (35 wt % suspension in mineral oil, 10.08 g, 88.14 mmol) was transferred 
in a dried flask under Ar and the mineral oil was removed by washing three times with dry 
pentane. N-Methyl-2-pyrrolidone (NMP, 54 mL) was added and the flask was cooled to 0 °C. 
tBuOOH (5-6 M in decane, 17.63 mL) was added dropwise, followed 10 min later by addition 
of a solution of 155 (5.20 g, 14.69 mmol) in NMP (97 mL). After another 10 min the mixture 
was warmed to rt, TBAF (1 M in THF, 33.80 mL, 33.80 mmol) was added and the stirring 
was continued for 3 h. The reaction was quenched with aqueous Na2S2O3 (5 M, 200 mL) and 
stirred for 30 min. The mixture was diluted with water, the aqueous phase was extracted with 
EtOAc (4 x 100 mL) and the combined organic phases were dried (MgSO4). Solvents were 
removed in vacuo (5 torr at ~ 100 °C to remove NMP) and the residue was subjected to 
column chromatography (EtOAc/hexane) to yield alcohol 155a (2.78 g, 78 %). 
1H-NMR (400 MHz, CDCl3): (m, 1H), 6.00 (ddd, J = 9.5, 4.4, 1.5 Hz, 1H), 5.72 (d, J 
= 10.0 Hz, 1H), 5.60 (ddd, J = 10.1, 4.2, 2.0 Hz, 1H), 4.60 (dd, J = 5.2, 5.2 Hz, 1H), 4.23 (dd, 
J = 4.8, 4.8 Hz, 1H), 3.73 (d, J = 10.3 Hz, 1H), 3.60 (dd, J = 10.6, 7.4 Hz, 1H), 2.65 – 2.58 
(m, 1H), 2.42 – 2.32 (m, 3H), 2.28 – 2.19 (m, 1H), 2.13 – 2.05 (m, 1H), 1.51 (s, 3H), 1.40 (s, 
3H). 
13C-NMR(100.6 MHz,CDCl3): 

IR (film): 3417, 2990, 2910, 1681, 1613, 1482, 1379, 1204, 1085, 1024, 745, 713, 611 cm-1. 
HRMS: calc. for C13H17O3 [M – CH3]+: 221.1178; found: 221.1177. 
 
 
Ketal (156). 
To a suspension of NaH (60 wt % in mineral oil, 1.38 g, 34.32 mmol) in THF (36 mL) at 0 °C 
was added a solution of 155a (2.70 g, 11.44 mmol) in THF (18 mL), and the mixture was 
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stirred for 30 min. DMF (54 mL) and MeI (10.70 mL, 171.61 mmol) were added and after 10 
min the reaction mixture was warmed to ambient temperature. After 2 h the reaction was 
diluted with toluene and NH4Clsat was added carefully. The organic phase was washed with 
water (2 x 30 mL) and brine (40 mL) and the solvents were removed under reduced pressure. 
The crude product was purified by column chromatography (EtOAc/hexane) to yield 156 
(2.60 g, 91%) as a colorless oil. 
1H-NMR (400 MHz, CDCl3): (ddd, J = 9.8, 6.3, 3.8 Hz, 1H), 6.03 (ddd, J = 9.6, 4.9, 
2.2 Hz, 1H), 5.73 – 5.65 (m, 2H), 4.61 (dd, J = 5.5, 5.5 Hz, 1H), 4.23 (dd, J = 4.5, 4.5 Hz, 
1H), 3.40 – 3.31 (m, 5H), 2.69 – 2.60 (m, 1H), 2.37 – 2.14 (m, 4H), 2.13 – 2.04 (m, 1H), 1.49 
(s, 3H), 1.37 (s, 3H). 
13C-NMR (100.6 MHz, CDCl3):

IR (film): 3025, 2987, 2909, 2690, 1597, 1523, 1461, 1377, 1198, 1084, 961, 942, 865, 713, 
523, 422, 418, 403 cm-1. 
HRMS: calc. for C14H19O3 [M – CH3]+: 235.1334; found: 235.1331. 
 
 
Diol (156a). 
Ketal 156 (2.10 g, 8.40 mmol) in THF (18 mL) was cooled to 0 °C, 1N aqueous HCl (8.4 mL) 
was added and the reaction mixture was stirred for 30 min. The reaction was quenched at 0 °C 
by addition of pyridine (8 mL), the solvents were removed under reduced pressure and the 
residue was subjected to column chromatography (EtOAc/hexane) to obtain diol 156a (1.59 g, 
90 %). 
1H-NMR (400 MHz, CDCl3): (t, J = 11.6 Hz, 2H), 5.68 (ddd, J = 10.0, 2.6, 2.6 Hz, 
1H), 5.55 (ddd, J = 10.0, 3.2, 2.8 Hz, 1H), 4.54 – 4.46 (m, 1H), 4.22 (dd, J = 10.0, 4.4 Hz, 
1H), 3.53 (dd, J = 8.9, 4.8 Hz, 1H), 3.39 (s, 3H), 3.33 (dd, J = 8.7, 8.7 Hz, 1H), 2.83 – 2.75 
(m, 1H), 2.75 (d, J = 4.2 Hz, 1H), 2.56 – 2.48 (m, 1H), 2.32 (ddd, J = 6.7, 4.8, 4.8 Hz, 1H), 
2.25 (ddd, J = 18.2, 6.9, 1.8 Hz, 1H), 2.20 – 2.11 (dm, J = 18.2 Hz, 1H), 2.05 (d, J = 7.8 Hz, 
1H).  
13C-NMR (100.6 MHz, CDCl3): 133.4, 129.8, 128.1, 127.3, 76.9, 72.7, 65.4, 59.3, 44.9, 
40.3, 30.8, 30.6. 
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IR (film): 3423, 3018, 2891, 1685, 1475, 1452, 1418, 1384, 1193, 1119, 1044, 996, 938, 757, 
739, 669, 408 cm-1. 
HRMS: calc. for C12H16O2 [M – H2O]+: 192.1150; found: 192.1145. 
 
 
Enone (156b). 
Diol 156a (1.6 g, 7.62 mmol) was dissolved in DCM (76 mL), and activated MnO2 (2.52 g, 
28.95 mmol) was added. After stirring for 26 h at rt, the reaction mixture was filtered through 
a pad of celite, concentrated in vacuo and the residue was subjected to column 
chromatography (EtOAc/hexane) to yield 1.49 g (94%) of enone 156b as a colorless oil. 
1H-NMR (400 MHz, C6D6): (dddd, J = 9.9, 5.8, 2.3, 1.0 Hz, 1H), 5.81 – 5.74 (m, 
2H), 5.03 (d, J = 9.9 Hz, 1H), 4.34 (d, J = 11.2 Hz, 1H), 3.77 (ddd, J = 11.2, 9.4, 4.1 Hz, 1H), 
3.56 – 3.52 (m, 2H), 3.11 (s, 3H), 2.67 – 2.59 (m, 1H), 2.48 (dd, J = 4.5, 4.5 Hz, 1H), 2.38 – 
2.31 (m, 1H), 1.82 – 1.73 (dm, J = 19.0 Hz, 1H), 1.62 – 1.53 (dm, J = 19.0 Hz, 1H). 
13C-NMR (100.6 MHz, C6D6): 147.1, 131.9, 130.0, 129.7, 73.4, 71.0, 58.7, 49.5, 
43.6, 35.8, 31.1. 
IR (film): 3481, 3051, 2999, 2886, 1652, 1423, 1393, 1312, 1258, 1116, 1076, 1029, 846, 
741, 675, 588, 564, 460, 445, 419, 411, 403 cm-1. 
HRMS: calc. for [C12H16O3]+: 208.1099; found: 208.1097. 
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8. Summary 
In summary, we have accomplished the first total synthesis of (+)–branimycin, an antibiotic 
isolated from Actinomycete GW 60/1571. This synthesis confirms the relative stereochemistry 
assigned by the Laatsch group. Additionally, the absolute configuration of branimycin has 
been established.  
In accordance with our synthetic plan, we efficiently incorporated the oxa-bridged cis-decalin 
core of branimycin via an intramolecular epoxide opening. The C13-C18 side chain and the 
C7-C12 ether bridge of the nucleus were incorporated in one high yielding synthetic step. 
Improvement and modification of the side chain synthesis paved the way for the completion of 
the total synthesis of branimycin. The C3 appendage could be introduced exclusively at the 
concave face of the branimycin framework via 1,4-addition. The highly challenging 
construction of the strained nine-membered lactone of branimycin was successively achieved 
employing Gerlach´s modification of Corey-Nicolaou´s double activation protocol. This is a 
very rare, if not the first example of macrolactonization to provide such a nine-membered 
lactone containing a trans-double bond.  
In this dissertation two approaches toward the cis-fused decalin nucleus of branimycin are 
presented. Starting from (-)–quinic acid a very flexible and stereoselective synthesis of the 
highly functionalized cis-decalin core was accomplished. Key-annulation of the A ring was 
conducted via a high yielding Claisen-Ireland rearrangement – RCM protocol. 
Following an intermolecular quinone based Diels-Alder cycloaddition strategy the desired 
functional group pattern was established by a regio- and stereoselective introduction of a 
masked C9-methoxy methyl group and a regioselective allylic oxidation at C12. In both 
approaches epoxidation occurred nearly exclusively from the exo-face.  
The longest linear sequence required only 20 steps from known easily accessible compounds 
(23 steps from commercially available p-benzoquinone). This route allows the preparation of 
sufficient material and it is very flexible with respect to the substituents and configurations of 
the individual stereogenic centers which should enhance the diversity for biological testing. 
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9. Abbreviations 
Ac acetyl 
AIBN 2,2’-azobisisobutyronitrile 
aq. aqueous 
Ar aryl, aromatic 
Bn benzyl 
Bu butyl 
cat. catalyst, catalytic amount 
DBU 1,8-diazabicyclo[5.4.0]undec-7-en 
DDQ 2,3-dichloro-5,6-dicyano-p-quinone 
DIBAL diisobutylaluminum hydride 
DMAP 4-dimethylaminopyridine 
DMF N,N-dimethylaminopyridine 
EE 1-ethoxyethyl 
eq. equivalent 
Et ethyl 
er enantiomeric ratio 
et al. latin: “et alii”, meaning “and others” 
EtOAc ethyl acetate 
Imid. imidazole 
INOC intramolecular nitrile oxide cyclization 
IR infra red 
J coupling constant 
KHMDS potassium hexamethyldisilazide 
LDA lithium diisopropylamide 
LHMDS lithium hexamethyldisilazide 
mCPBA meta-chloro peroxybenzoic acid 
Me methyl 
min minute 
MOM methoxymethyl 
mp melting point 
MS mass spectroscopy 
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4Å MS or 3Å MS molecular sieves with pores of 4 or 3 Angstrom 
NBS N-bromosuccinimide 
NMR nuclear magnetic resonance spectroscopy 
P or PG unspecified protecting group 
ppm part per million 
R, R’, R’’, R1, R2, R3 unspecified substituents 
RCM ring closing metathesis 
TBAF tetrabutylammonium fluoride 
THF tetrahydrofuran 
TBS dimethyl-tert-butylsilyl 
TBDPS tert-butyldiphenylsilyl 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TMS trimethylsilyl 
Ts tosyl 
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